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Abstract
Major depression is a common psychiatric disorder with considerable associated 
morbidity and mortality. Investigations to understand the causes of depression and how it 
can be more effectively treated are high priority. The serotonergic system has been 
implicated in the aetiology and treatment of depression by a wealth of preclinical and 
clinical evidence. This includes findings that drugs increasing serotonin 
neurotransmission have antidepressant action and inhibition of serotonin synthesis (via 
tryptophan depletion) can induce relapse of symptoms in depressed patients.
Neuroendocrine challenges are an established method of indirectly examining brain 
serotonergic function, utilising changes in the secretion of pituitary hormones influenced 
by tonic serotonergic activity at the level of the hypothalamus. This thesis describes the 
development of two such neuroendocrine challenge tests, using the selective serotonergic 
probes, zolmitriptan and citalopram.
Orally administered zolmitriptan, licensed for the treatment of migraine, clearly elevated 
plasma growth hormone in healthy subjects. This growth hormone response was 
antagonised by ketanserin suggesting mediation by postsynaptic 5-HTm receptors. The 
response to zolmitriptan was attenuated in melancholic depressed subjects, and further 
reduced following antidepressant treatment. This implies a dysfunction of postsynaptic 
5 -H T id  receptor function in melancholia, and further 5 -H T id functional downregulation 
following antidepressant treatment.
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Citalopram, a selective serotonin reuptake inhibitor, administered at low dose 
intravenously was associated with an increase in plasma prolactin and cortisol in healthy 
subjects. The postsynaptic serotonin receptor subtype mediating these responses was not 
clearly elucidated from experiments using available 5 -HT2 and 5-HTiA ligands. 
Depressed subjects demonstrated an attenuated prolactin response to citalopram 
suggesting impaired presynaptic 5-HT neuronal function.
These findings confirm impaired brain 5-HT function in depressed patients and assist in 
more clearly defining the nature of this impairment.
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INTRODUCTION
Depressive disorders are increasingly recognised as a major public health issue in current 
society (Scott and Dickey 2000) with around 16% of the population affected at some time 
in their lives (Kessler et al. 2003). The incidence of depressive disorders appears to be 
increasing, particularly in younger age groups (Klerman and Weissman, 1989). Up to 
15% of more severely depressed subjects commit suicide (reviewed by K^eitman 1993). 
There is an obvious need to understand the aetiology of depressive disorders and develop 
effective identification and treatments.
The involvement of serotonin (5-hydroxytryptamine, 5-HT) in depressive disorders was 
first suggested in 1957 when the mood altering effects of imipramine and iproniazid, 
which modify serotonergic function, were reported (Ayuso-Gutierrez 2002). Following 
much investigation, 5-HT has been shown to have a critical role in the aetiology of 
depression and its treatment, which will be discussed in this thesis. The exact nature of 
this role of 5-HT, however, remains unclear.
This chapter will examine depressive disorders, known aetiological factors and 
treatments. The nature and function of 5-HT and the experiments that have been 
undertaken to elucidate its role in depressive disorders are then discussed.
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DEPRESSIVE DISORDERS
CLINICAL FEATURES
Experiencing a range of emotions is part of normal human experience, and unhappiness is 
common. A more persistent or severe lowering of mood, however, may reach the clinical 
characteristics of a depressive disorder. Depression is known to occur secondarily to other 
disorders such as psychiatric (e.g. schizophrenia) (Foulds et al. 1975) or physical illnesses 
(e.g. substance misuse or hypothyroidism) (Lishman 1997). As depression in these 
situations appears to have a different aetiology and management to prima .y depression, 
the exclusion of such a cause is necessary.
Depressive disorder is a syndrome with cognitive and somatic features. Individuals may 
vary in which particular features are most manifest; classification of symptom groups 
using diagnostic guidelines such as the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV 1994) can be useful to predict the most beneficial treatments and 
predict prognosis. Validated scales, such as the Hamilton Rating Scale for Depression 
(HAM-D) are widely used to quantify depressive symptoms (Hamilton 1967). The 
following clinical description of depression is derived from Hamilton* s account of this 
disorder (Hamilton 1980).
All depressed individuals experience low mood. This is often described subjectively as 
being depressed, sad, hopeless or helpless. Concurrent anxiety or irritability is common.
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Complaints of physical aches and pains may often be the superficial presentation of such 
mood changes. It is however important to distinguish between hypochondriasis as a 
personality trait and as a symptom of depressive disorder. Diurnal vai iation of mood 
often occurs, classically with depressed mood being worse on wakening but improving 
during the day, although its significance has been debated (Haug and Wirz-Justice 1993). 
Loss of interest or pleasure (anhedonia) in activities they would usually enjoy and 
diminution of working capacity are pervasive features of depressive disorders. Patients 
reject ‘hobbies’ and avoid social encounters. They often describe reduced libido.
Appetite is often reduced but rarely in some ‘atypical’ depressive disorders this may be 
increased. Associated weight changes may be present. In severe disorders, life threatening 
starvation and weight loss may be present.
Sleep is commonly disturbed in depression, classically associated with early morning 
wakening, but also associated with difficulty getting off to sleep (particularly if anxiety 
features are present) and waking throughout the night. Excessive sleep 
(hypersomnolence) is again associated with ‘atypical’ depressive disorders.
Psychomotor changes associated with depression include agitation, with restlessness, or 
retardation, with slowed speech, thinking and movements. If severe, retardation can be 
manifest as speechlessness and catatonia with no observable movements by the patient. 
Reduced energy and becoming easily fatigued are common. Self neglect may be 
associated with this.
Depressed patients describe an inability to concentrate on everyday tasks and may 
complain of memory disturbances (most likely associated with impairment of memory 
formation through concentration disturbance).
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Cognitive biases of depressive disorder are always present to some degree, and may 
include hopelessness, helplessness, worthlessness, guilt, negative appraisal of oneself and 
others, and negative misinterpretation of events (Beck 1967). Other disturbances of 
thought such as suicidal ideas become more common with increasing severity of illness, 
and at an extreme, mood congruent delusions may arise. Similarly, insight may diminish 
with increasing severity of illness.
CLASSIFICATION AND HISTORICAL PERSPECTIVE
Current thinking about depression can be traced back to Hippocrates’ (460-337BC) 
descriptions of melancholia, with features of ‘aversion to food, sleeplessness, irritability 
and restlessness’. Hippocrates suggested that melancholia was caused by Saturn’s 
influence on the spleen resulting in secretion of black bile, hence blackening the mood 
through effect on the brain (Hippokrates 1897). Later, the Romans (Aurelianus, translated 
in 1950) added further symptoms to this syndrome, such as aggression, suicide and 
delusions. In 1621 Robert Burton published his influential work, ‘Anatomy of 
Melancholy* (reprinted 1850), and attempted to subgroup melancholic disorders and 
postulate a rational aetiology relating to environmental factors (diet, alcohol, biological 
rhythms, and intense emotions). Esquirol (1838) postulated that melancholia was due to a 
primary mood disturbance (not a form of insanity), influencing other European 
psychiatrists to propose the existence of milder states of melancholia without delusions.
Kraepelin’s careful longitudinal observations gave rise to his concept of manic depressive
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insanity, classifying all affective disorders within this heading whether having only 
depressive features or both manic and depressive features (Kraepelin 1913). This related 
to his identification of the cyclical nature of both manic and depressive states, and 
believing that they had common heredity. The flaws in this ‘unitary affective disorder’ 
hypothesis were primarily that depressive states, identical to the descriptions of 
Kraepelin, could arise in response to stress (and not be of hereditary or endogenous 
origin), and other depressive states not reaching the criteria of melancholia showed no 
clear boundary from melancholia, needing to be classified separately.
Kraepelin’s concepts were successfully challenged by Angst (1966) and Perris (1966), 
demonstrating different features of recurrent manic disorders (e.g. age of onset, duration 
of episode, and incidence of illness in relatives) to recurrent depressive disorders through 
studies of patient groups. Leonhard’s concept of unipolar and bipolar disorders 
subsequently developed (Leonhard 1957). Bipolar disorder described disorders with 
features of both mania and depression whilst unipolar described disorders of only 
recurrent mania or recurrent depression. This unipolar-bipolar distinction is further 
supported by a greater concordance of unipolar-unipolar and bipolar-bipolar features 
reported in a study of Kraepelinian manic depressive twins (Bertelsen et al. 1977).
In the 20th century, many dichotomous subcategories of unipolar depression were 
proposed including: endogenous-exogenous, neurotic-psychotic, autonomous-reactive 
and acute-chronic, however these have been largely unhelpful and have not been clarified 
as groups with different aetiological characteristics or been consistently useful predictors
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of best treatment (Kendell 1993). Statistical methods such as multiple regression analysis, 
factor analysis and clustering have been adopted to attempt to subgroup clinical features 
but there have been few replicable outcomes. The strongest finding appears to be a cluster 
representing melancholic (endogenous) features (see appendix); however an opposing 
cluster (such as ‘reactive’) has not been shown (Kendell 1993). It should be noted that the 
term ‘melancholic’ refers to a particular symptom profile, with no assumption about 
causation, although there seem to be biological differences that distinguish this group 
which will be explored later in this thesis. Melancholic patients have been shown in some 
studies to have a greater response rate to antidepressant medication than non melancholic 
patients (eg. Heiligenstein et al. 1994), but more robustly, melancholic subjects have a 
lower response rate to placebo than patients without these features (Peselow et al. 1992). 
Atypical depression as described above, particularly with features of hypersomnia and 
hyperphagia, also appears to be a discrete subgroup with some differing demographics 
and clinical features from non atypical depression (Matza et al. 2003; Postemak and 
Zimmerman 2002), and is more likely to respond to monoamine oxidase inhibitors 
(MAOIs) than other antidepressant treatments (Postemak and Zimmerman 2002).
Seasonal affective disorder (SAD), characterised by cyclical depression during winter 
months and subsequent remission, may represent a further subgroup (Magnusson and 
Boivin 2003). This disorder classically responds to bright light therapy but many patients 
also require antidepressant medication, which has established efficacy in SAD. Several 
studies have investigated the biological substrates of SAD, with particular focus on 
circadian rhythms, but findings have largely been inconsistent. Whether SAD is a valid 
depressive disorder subtype remains to be clarified.
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The principal challenge that has arisen in later years is the categorical distinction of 
depressive disorders from other psychiatric disorders and the development of clinically 
useful diagnostic systems. DSM-IV retains the concept of unipolar and bipolar disorders, 
distinguishes between single episodes of illness, and terms recurrent illness episodes as 
recurrent depressive disorders. ‘Major depressive disorder’ appears with a clear 
categorical definition, and can occur with or without melancholic features (see appendix). 
Melancholic features are retained for reasons as described above. DSM-IV has been 
widely adopted amongst international researchers, standardising groups of patients 
examined, and will be used throughout this thesis.
EPIDEMIOLOGY OF DEPRESSIVE DISORDERS
The lifetime prevalence for DSM-III major depressive disorder from the first large 
community based epidemiological case finding study using fully structured interviews 
(NIMH Epidemiological Catchment Area studies for major depressive disorder, Robins 
and Reiger eds. 1991) was 3.0 to 5.9%. The latest such study identifying DSM-IV major 
depressive disorder found a lifetime prevalence of 16.2% (Kessler et al. 2003). From 
these findings and others (Klerman and Weissman, 1989), the incidence of depression 
appears to be increasing over time; however the influence of subjects being more willing 
to admit psychiatric disturbance and the effect of changing diagnostic systems cannot be 
excluded. A consistent gender difference is observed amongst such studies, with women 
having a greater prevalence. There is no clear biological or psychosocial cause for this
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difference but it may be linked to a greater chronicity of illness in women (Bracke 1998). 
Depression commonly has an early age of onset and an increase in prevalence in younger 
groups has been observed (Kessler et al. 2003), possibly relating to psychosocial factors.
Urban communities and working class status have a greater association with depression 
than rural and middle class groups respectively (Brown and Harris 1978). There appears 
to be no racial variation in lifetime prevalence of depression (Jablensky et al. 1981) but 
the way in which depressive disorders present does vary. Chinese and Asian depressed 
subjects (for example) present with more somatic symptoms than subjective mood 
changes.
Depressive disorders have a high rate of comorbidity with other DSM-IV disorders, 
reported as 78.5% of cases by Kessler et al. (2003).
AETIOLOGY
The cause of depression remains obscure; however several factors have been shown to be 
important, from both biological and environmental viewpoints.
Biological aetiology 
Genetic influence
It is clear that (Kraepelinian defined) affective disorders have a familial component. From
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both Angst’s and Perris’ family studies in 1966, the distinction between unipolar and 
bipolar affective disorder was clarified. Both found a high risk of unipolar illness in first 
degree relatives of unipolar (depressed) patients and no increased risk (above population 
rates) of bipolar illness. Perris found that bipolar illness similarly ‘bred true’, however 
Angst found an increase of both bipolar and unipolar illness in relatives of bipolar 
patients.
Studies have reported a wide variation of rates of unipolar illness in first degree relatives 
of unipolar depressed subjects, probably due to varied diagnostic criteria, but the pooled 
risk from studies examined by McGuffin and Katz (1986) was 9.1% (range 6 to 40%), 
compared with general population rates of 3%.
Twin studies are similarly affected by diagnostic problems. A review of previous studies 
by Allen (1976) found a monozygotic concordance of unipolar depressive disorder of 
40% and dizygotic of 11%. In comparison, for bipolar disorder the monozygotic to 
dizygotic ratio was 72% to 14%, demonstrating a relatively greater genetic influence in 
these disorders.
There are few adoption studies of unipolar depression. Cadoret and Gath (1978), 
however, found a higher rate of unipolar illness in adopted away children of biological 
parents with unipolar disorder than children of parents without such a disorder.
The association between genetic traits, such as human erythrocyte blood groups and
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human leukocyte antigen, and depressive disorder has been investigated with no positive 
replicated findings (Propert et al 1981). A small association has been noted with 
depressive disorder and two different sites on the 5-HT transporter (5-HTT) gene 
(Furlong et al. 1998).
Particular interest has arisen with the identification of polymorphic areas within the 
genome that code for specific proteins or enzymes involved with the activity of amines 
implicated in the process of depressive illness. One of the most important findings has 
been a common 44 base pair insertion/deletion polymorphism in the promotor region of 
the 5-HTT gene, with long and short variants (Heils et al. 1995), which alter 5-HTT gene 
transcription. The short variant is associated with less cellular 5-HTT expression, more 
anxiety related traits (Lesch et al.1996) and a greater depressogenic effect to tryptophan 
depletion (Moreno et al. 2002; Neumeister et al. 2002). The long variant is associated 
with a greater plasma prolactin (PRL) response to acute clomipramine in healthy subjects 
(Whale et al. 2000) and a greater reduction in hippocampal volume in depressed subjects 
(Frodl et al. 2004). A recently reported large prospective cohort study indicated that 
subjects with the long variant were significantly less likely to report symptoms of 
depression or suicidality following life events, or be formally diagnosed with depression 
following such events (Caspi et al. 2003). Childhood maltreatment of subjects in this 
study also predicted adult depression only in those carrying the short allele. This study 
therefore displays a potential mediating effect of genes in the development of depressive 
disorders following environmental stressors. A 5-HTT knockout mouse has been 
developed which has overall reduced brain 5-HT and reduced 5-HT neurone firing, but
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increased 5-HT synthesis and synaptic 5-HT (Gobbi et al. 2001; Murphy et al. 2004). 
Together, these findings indicate that the reduced expression (short allele) variant 
subjects have a greater vulnerability to depression, although the hippocampal findings 
described above (Frodl et al. 2004) do not appear consistent with this, and clearly 
neurotransmission is modulated by many other factors including autoreceptor function. 
These different concepts and experimental paradigms will be discussed later in this thesis.
Functional anatomy
Functional and structural imaging studies in recent years have attempted to localise brain 
structures and circuits involved with mood. Both patients and healthy subjects have been 
involved, with novel experimental designs including scanning during illness episodes and 
following treatment (Bench et al. 1995), and during psychological induction of depressive 
states (Schneider et al. 1997). Most studies have implicated several cortical and 
subcortical structures, such as orbitofrontal cortex, cingulate cortex and basal ganglia. A 
depressive state abnormality of over activity in amygdala, hippocampus and parts of the 
temporal lobes has also been found (Schneider et al. 1997). The findings from MRI 
volumetric studies have varied but reduction in hippocampal volume has been reported 
(Shah et al. 1998; Sheline et al. 1996).
Neuropathology findings
Findings from structural imaging studies have driven neuropathological investigations 
into mood disorders and there are now preliminary reports of cytoarchitectural alterations 
in anterior cingulate and prefrontal cortices. These alterations are characterised by a
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decrease in the number or density of glia. Reductions in the size and density of neuronal 
populations have also been reported, which is postulated to be caused by abnormal 
neurodevelopment or impaired neuronal plasticity (reviewed by Harrison 2002). Drug 
treatment does not appear to be a causative factor.
The amine hypothesis
Since the 1960’s, the ‘amine hypothesis’ of depressive disorders has been the primary 
proposed aetiology (Schildkraut 1965). It has been clear from this time that drugs 
enhancing amine systems can have antidepressant effects. Tricyclic antidepressants 
(TCAs) inhibit amine reuptake from the synaptic cleft into presynaptic terminals 
(increasing available monoamines for binding at postsynaptic receptor sites), and MAOIs 
block the breakdown of amines in presynaptic terminals (increasing the amount of amines 
available for release into the synapse). Both drug groups therefore enhance amine 
neurotransmission. Reserpine and tetrabenazine deplete presynaptic stores of 
monoamines and have been shown to be depressogenic (Muller et al. 1955). The three 
amines implicated in this theory are 5-HT, dopamine (DA) and noradrenaline (NA). The 
importance of 5-HT in depressive disorders will be dealt with in more detail in the 
dedicated section below.
DA has been implicated in depression for the following reasons. L-dopa, a precursor of 
DA, was shown to reverse the psychological effects induced by reserpine (Degkwitz et al. 
1960). Bupropion, a drug reported to have dopaminergic properties, has antidepressant
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effects and may be a useful addition to selective 5-HT reuptake inhibitor (SSRT) treatment 
in depressed partial responders (Bodkin et al. 1997). In Piarkinson’s disease (a disorder 
characterised by a primary dysfunction of dopaminergic function) there is a high rate of 
comorbid depression (of around 40%), and comparison studies have shown this rate in 
Parkinson’s disease to be greater than in healthy controls, spouses and other physically 
disabled groups (as reviewed by Cummings 1992). Interestingly electroconvulsive 
therapy (ECT), which enhances DA transmission in rat striatum (McGarvey et al. 1993) 
and DA mediated neuroendocrine responses in humans (Costain et al. 1982), improves 
both depression and the motor symptoms of Parkinson’s disease (Mann et al. 1995).
Cerebrospinal fluid (CSF) concentrations of DA’s primary metabolite, hottiovanillic acid 
(HVA) are generally lower in depressed patients in comparison to healthy controls (eg. 
Kasa et al. 1982). A reduced CSF HVA has been associated specifically with 
psychomotor retardation (Wolfe et al. 1990) and suicidali ty (Engstrom et al. 1999). The 
rate at which CSF HVA accumulates after probenecid blockade (see later) is also reduced 
in depression, implying reduced DA turnover.
A limited number of imaging studies have examined DA function in depression. Agren 
and Reibring (1994) found a decreased uptake of [(11)C]L-DOPA over the blood brain 
barrier in depressed subjects, possibly implying reduced overall dopaminergic brain 
function. Two single photon emission computerised tomo»graphy (SPECT) studies of 
striatal D2 receptor binding found no difference in mean ligand binding between 
unmedicated depressed and control subjects but reduced D 2 binding in treatment
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responders in comparison to pretreatment and controls (Ebert et al. 1996 and Klimke et 
al. 1999). Striatal DA transporter binding affinity has also been shown to be increased in 
drug free depressed subjects in comparison to controls using SPECT (Brunswick et al. 
2003). These findings go some way to support an abnormality of DA function in 
depressive disorders and a role of DA in treatment.
Clinically, the most significant evidence for specific involvement of NA in depression is 
the antidepressant efficacy of selective NA reuptake inhibitors, such as reboxetine with 
apparent equal efficacy to TCAs and SSRIs (Holm and Spencer 1999). The major 
metabolite of NA, 3-methoxy-4-hydroxyphenylglycol (MHPG), measured in urine, 
plasma and CSF has been shown to vary widely in depressed subjects, with studies 
reporting both increases and decreases (Delgado 2000). Patients with low urinary MHPG 
may be more responsive to TCAs than those with high MHPG levels (Maas et al. 1984). 
It is also claimed that the enzyme responsible for the breakdown of neuronally released 
NA, catechol-O-methyltransferase (COMT), has reduced activity in erythrocytes of 
depressed patients and their first degree relatives (Gershon and Jonas 1975); however, 
how far this correlates with central COMT activity is unknown.
Using a ligand that binds to the NA presynaptic transport mechanism, [3H] nisoxetine, 
Klimek et al. (1997) found reduced transport sites in the midcaudal portion of the locus 
coeruleus in postmortem brains from subjects with major depression compared with 
healthy control subjects. Several groups have examined the numbers and functions of 
specific noradrenergic receptors in depression, particularly the presynaptic <X2
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autoreceptor. The density and affinity of 012 adrenoreceptors appear increased in the 
frontal cortex, hypothalamus, amygdala and hippocampus of depressed suicide victims 
(Meana et al. 1992), which theoretically could be linked with reduced NA release from 
presynaptic areas, and therefore a reduced overall noradrenergic function. An increase in 
density and affinity of platelet 012 receptors in depressed subjects (Piletz 1990) and a 
decrease following antidepressant treatment have been reported (Garcia-Sevilla 1990) 
although not replicated. Studies of p-adrenoreceptor density and affinity in depressed 
subjects have varied (as reviewed by Leonard 1997).
Neuroendocrine studies (see Chapter 2) have examined the hypothalamic (X2 receptor 
mediated growth hormone (GH) response to clonidine, which is blunted in most studies 
of depressed patients compared with controls (eg. Checkley et al. 1981; Checkley et al. 
1984). This blunted GH response persisted in one study of recovered depressed subjects, 
and may therefore represent a trait marker of depression and persistent <X2 receptor 
dysfunction (Mitchell et al. 1988). Miller et al. (1996) examined the effects of 
catecholamine depletion in groups of depressed patients in remission including depressed 
unmedicated patients, patients medicated with a noradrenergic antidepressant 
(desipramine) and patients medicated with a serotonergic antidepressant (fluoxetine).
This method depletes central NA and DA by inhibiting the rate limiting enzyme in NA 
production using a-methyl-p-tyrosine (AMPT). They found no effect on mood in 
unmedicated patients or in patients on fluoxetine, but a significant relapse of mood 
symptoms in patients on desipramine. Understandably, this implies a need for central NA 
to maintain recovery in patients on a noradrenergic antidepressant. The fact that
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unmedicated patients were not made worse by AMPT suggests that dysfunction of NA 
systems does not correlate with the severity of depression. However, AMPT did cause 
pronounced, temporary, depressive relapse in unmedicated patients who had recovered 
from depression and were clinically well. This suggests that in those vulnerable to 
depression, depletion of NA and /or DA can be sufficient to cause clinical 
symptomatology.
There are several findings that appear inconsistent with the amine hypothesis. Firstly, 
antidepressant efficacy in depressed patients is only apparent after several weeks of 
treatment. The expected immediate increase in monoaminergic function from blockade of 
amine reuptake, for example, should cause a rapid antidepressant effect under the amine 
hypothesis. The immediate increase in extracellular monoamines is actually likely to be 
diminished by the activity of presynaptic autoreceptors. Several studies have shown 
downregulation of postsynaptic (particularly 5-HT) receptors (see Chapter 2), which 
again would go against enhanced overall aminergic function. Tianeptine, a 5-HT uptake 
enhancer, reduces 5-HT induced behaviour in rats but has clear antidepressant effects in 
humans (reviewed by Wilde and Benfield 1995). Some drugs which alter monoamine 
levels, such as cocaine and amphetamine are not antidepressant. Similarly, some drugs 
that have minimal or no apparent effect on aminergic function have antidepressant 
properties, such as iprindole (Zis and Goodwin 1979) or MK 869 (Argyropoulos and Nutt 
2000).
5-HT, DA and NA have been dealt with separately; however there is a well documented
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interaction between these amines. For example: stimulation of a i receptors on 
serotonergic neurone cell bodies causes an increased firing of these neurones, stimulation 
of ct2 receptors on serotonergic terminal areas reduces 5-HT release, and in animal 
models, 5-HT2C receptor stimulation causes a reduction in activity of mesocortical 
dopaminergic and adrenergic transmission (Gobert et al. 2000). Many other studies have 
detailed such interactions (see discussion of individual 5-HT receptor types in this 
Chapter). There is also evidence of interaction between neurotransmitter systems at an 
intracellular level, so that binding to one receptor influences activity at another (Manji
1992). These findings may explain why selectively blocking the reuptake of a single 
amine has the same antidepressant efficacy as using a non selective amine reuptake 
blocker.
In conclusion, monoamines clearly play a part in depressive disorders but the exact nature 
of disturbances in monoamine function, and how this can lead to such a clinical 
syndrome, remains unclear.
Endocrine abnormalities
Cortisol (CORT) output is increased in depressive disorders, but despite this being known 
since the 1960’s, the functional significance remains unclear. Theories exist of CORT 
having both antidepressant qualities and being a causative factor in depression (Dinan
1994). The dexamethasone suppression test (DST) has been widely used as an index of 
this hypercortisolaemia. Dexamethasone potently inhibits the secretion of
31
adrenocorticotrophic hormone (ACTH), which in turn suppresses CORT secretion for 24 
hours in normal subjects. Plasma CORT levels remain high after dexamethasone 
challenge (non suppression) in subjects with hypercortisolaemia. Carrol et al. (1981) 
claimed that DST non suppression was a specific test for melancholic depression. Other 
authors suggested this test predicts response to biological antidepressant treatments, such 
as TCAs or ECT. These findings have not been consistently replicated, but confounding 
factors for the DST, such as weight loss and insomnia, have been more clearly identified 
(Mullen et al. 1986). In association with raised CORT, adrenal gland hypertrophy, 
reversed on recovery from depression (Rubin et al. 1995), and decreased bone density in 
elderly depressed women have been observed (Michelson et al.1996). CORT has also 
been shown to be toxic to hippocampal neurones. The hippocampus has an inhibitory 
influence over the hypothalamic pituitary adrenal axis (HPA), so a link with depression 
and HPA overactivity may therefore by perpetuated by CORT induced hippocampal 
damage.
Thyroid dysfunction has been implicated as a potential cause of depressive disorder due 
to the common co-occurrence of depressive symptoms with hypothyroidism and the 
beneficial use of tri-iodothyronine as a useful adjunct to antidepressant treatment in 
euthyroid depressed patients (Aronson et al. 1996). The thyroid stimulating hormone 
(TSH) response to thyrotrophin releasing hormone (TRH) is abnormal in some depressed 
subjects (Duval et al. 1999), but the clinical significance of this is uncl ear. Other 
endocrine disorders, such as Cushing’s syndrome, hyper and hypoparathyroidism, are 
associated with depression. Normalisation of the hormonal and metabolic abnormalities is
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largely followed by resolution of the depressive state suggesting a cause and effect 
relationship (Kelly et al. 1983; Sonino et al. 1993).
Physical illness and change in physiological state
Many physical disorders and state changes are associated with depressive disorder, and 
some of these that have been specifically investigated are detailed below. The 
psychosocial stress of physical illness is an important aetiological factor in itself but the 
illness process may have a direct biological aetiological effect too.
Childbirth is significantly associated with depressive states. ‘Postnatal blues’ occurs in at 
least 50% of women within 10 days of childbirth, with features of crying, low mood and 
emotional lability. This state usually rapidly resolves but a higher rate of more severe 
depression is recorded in these subjects at a later postnatal stage. Some biochemical 
associations have been found with postnatal blues such as increased urinary cyclicAMP 
and reduced plasma concentrations of free tryptophan (TRP). Neurotic tyoe personality 
features appear to be higher in this group. Approximately 13% of postnatal women 
experience a major depressive episode, with onset typically between 2 and 12 weeks 
postpartum. No consistent associations with depressive states and sex hormones have 
been observed (Harris et al. 1996).
An association between hysterectomy and depression has been reported, with 36% of 
postoperative women being treated for depression in one study, four times the rate of 
matched controls (Richards 1973). Gath et al. (1982), however, found that women who
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undergo hysterectomy have higher rates of psychopathology pre and post operation than 
controls, suggesting that those who undergo surgery are more at risk of illness than the 
general population.
Many investigators have examined depression following stroke, demonstrating that it is a 
common consequence and is associated with excess disability, cognitive impairment and 
mortality (Whyte and Mulsant 2002). Studies have focussed on whether lesions in 
specific brain areas, particularly left anterior regions, are more associated with depression 
but this hypothesis has been discounted by a systematic review of 48 such reports (Carson 
et al. 2000).
Viral infections are often linked with depressive disorders, particularly during physical 
recovery. Few studies have systematically investigated this association. Depression is 
common in HIV positive subjects, with clear psychosocial reasons (Fenton 1987). Such 
groups respond as well to antidepressant medications as other physically healthy groups 
(Wagner et al. 1996). The organic changes associated with AIDS similarly can clearly be 
linked with psychiatric changes (Fenton 1987).
The mediator between physical pathology, stress and mood states may be cytokines 
(including the interleukins and interferons) which are a diverse group of proteins that 
regulate the immune response and also act as neuromodulators in the central nervous 
system (CNS). Cytokines are released following physical and psychological stress and 
have a stimulatory influence on the HPA, which could thereby alter mood via enhanced
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CORT release as described above (reviewed by Kronfol and Remick 2000). Maes et al. 
(1993; 1995) have reported an increase in the plasma levels of acute phase proteins and 
the proinflammatoy cytokines interleukin-1, interleukin-6 and their respective receptors in 
patients with major depression, which correlated with severity of depression and 
measures of HPA hyperactivity. This has not been consistently replicated however 
(Weizman et al. 1994). Treatment of depressed subjects with clomipramine has been 
associated with an apparent paradoxical increase in the synthesis of interleukin-1 and 
interleukin-3-like activity in lymphocytes (Weizman et al. 1994). Treatment with 
interferon also has been reported to be associated with depression (Kronfol and Remick 
2000).
Sleep
Disturbances of diurnal rhythms maybe a causal factor for depressive disorders for 
several reasons. Disturbances of sleep, particularly early morning wakening, are a 
common feature of depressive disorders, particularly severe or melancholic types (DSM- 
IV 1994). A reasonably consistent finding on electroencephalogram (EEG) recording in 
this group is shortened rapid eye movement (REM) sleep latency and a reduction in total 
slow wave sleep (reviewed by Kendell 1993). Therapeutically, sleep deprivation has been 
shown to have antidepressant qualities in 50 to 70% of depressed subjects, and the brief 
duration of this effect may be extended by restricting sleep at critical times of the day 
(Riemann et al. 1996).
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Environmental aetiology
Environmental factors are clearly involved in the aetiology of depression, as shown by the 
incomplete evidence of a genetic basis, as detailed above. Studies are beginning to show 
gene-environment interactions, such as a variant of a 5-HTT gene promotor region 
polymorphism being associated with adult depression following early life adversity 
(Caspi et al. 2003) (see above). Three focal areas of environmental stress have been 
particularly studied: early parental loss, life events and social support.
Parental loss
Parental loss has been investigated since the original proposals of Freud (1917) and 
Abraham (1924), that melancholia was a reaction to the loss of a ‘love object’ in 
childhood. Many studies have attempted to clarify this with inconsistent results. 
Methodological problems include matching control groups, and studies using known 
depressed subjects rather than all depressed subjects in a population (personality features 
being the confounding factor). In a large community study of women, Harris et al. (1986) 
found a relationship between loss of a mother (not father) before the age of 17 years and 
depression in the previous 12 months. ‘Lack of care’ appeared more important than the 
loss event itself in this group. The association was also not specific to depression hence 
early parental loss is likely to be commoner in all subjects with psychiatric illness.
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Life events
Life events clearly have a role in the aetiology of depression; however investigations have 
been similarly marred by methodological problems. Studies before the mid 1980’s had 
been retrospective, with the associated problem of depressed subjects attributing past 
events more negatively due to their current mood, and remembering more negative than 
positive events. Identifying events that occurred independently of a depressive illness 
(rather than as a result of it, for example losing a job due to depressive cognitive 
impairment) was also difficult. Paykel et al. (1969) found a three times gieater number of 
life events (unpleasant, mainly social loss events) in referred depressed subjects than 
matched controls. Brown and Harris (1978) found an increased rate of events of all types 
(mostly threatening) in the 3 weeks preceding depressive illness. This group also 
identified vulnerability factors, which increase the likelihood of depressive illness only in 
combination with provoking (threatening) events. These vulnerability factors were: loss 
of mother before the age of 11 years, having three or more children at home below the 
age of 14 years, the lack of a confiding intimate relationship, and unemployment. They 
also point out a higher prevalence of depression in lower social classes (IV and V). 
Studies have attempted to replicate these findings, agreeing only with the social class and 
lack of confiding intimate relationship attributes (eg. Campbell et al. 1993). Two studies 
have prospectively examined the influence of vulnerability and life events, Brown et al. 
1986, and Surtees et al. 1986. Brown found the most important vulnerability factor to be 
low self esteem, and highlighted the importance of a confiding relationship at the time of 
a stressful event. Surtees failed to replicate the importance of such vulnerability factors, 
and only found an increase of life events prior to illness episode that could be seen as
37
related to the illness. Surtees did however identify chronic stress (major difficulties) as an 
important aetiological factor. Several authors have more recently examined the influence 
of parental care on later depression and low maternal care (rated with the Parental 
Bonding Instrument) has been replicated as an important factor (Parker et al. 1995). Both 
childhood physical and sexual abuse are also associated with a greater risk of depression 
in later life (Bifulco et al. 1994; Vize and Cooper 1995).
Social support
As indicated above, Brown and Harris (1978) reported an importance of social support 
(presence of a confiding intimate relationship) as a vulnerability factor for depression. 
Methodological problems arise in investigating this area as depressive disorders, and 
possible associated personality attributes will influence social networks. Harris et al.
(1999) investigated the effects of volunteers befriending patients with chronic depression 
(in a randomised manner). Although difficulties arose with a control group and 50% of 
potential subjects not being interested, a significant effect on remission rates was 
observed. Living with an over involved and critical family (measured as expressed 
emotion) has also been shown to increase illness relapse in depression (Vaughan and Leff 
1976), as shown in schizophrenia.
Conclusion
A unitary theory of major depressive disorder aetiology needs to include the predisposing 
factors of genetic susceptibility and early life adversity, and the precipitating influence of 
acute and chronic stresses and some drugs. Psychosocial support appears to have a
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protective influence. These combine to create a disorder with significant clinical 
heterogeneity, characterised by low mood and anhedonia, with biological features such as 
sleep and appetite disturbance, hypercortisolaemia, monoamine neurotransmitter 
dysfunction, and focal disturbance of brain function. This disorder responds in a 
significant proportion of people to manipulation of monoaminergic neurotransmission, 
and in milder disorders to psychological treatment alone.
Kendler et al. (1993) clarified the diverse importance of such factors, showing that 50% 
of the variance in liability to suffer major depression at follow up was accounted for by 
stressful life events, genetic factors, a previous depressive episode and neuroticism as a 
personality trait. The aetiology of depression is therefore complex with a variety of 
factors that interact with each other both directly and indirectly. In view of this 
complexity and probable biochemical heterogeneity it is perhaps rather remarkable that 
fairly simple neurotransmitter manipulations such as potentiation of 5-HT function can 
have antidepressant effects in a sizeable proportion of depressed subjects (see below).
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TREATMENT OF DEPRESSIVE DISORDERS
The treatment of depressive disorders has both biological and psychosocial components, 
with efficacy studies showing significant benefits for specific treatments from both areas
Biological Treatments
The first widely used specific antidepressant, imipramine, was introduced in 1957 by 
Roland Kuhn who published an open trial of its use in depressed subjects (reviewed by 
Ayuso-Gutierrez 2002). This tricyclic drug was discovered following the adaptation of 
the phenothiazine antipsychotic drug, promazine. Isoniazid, a treatment for tuberculosis, 
was also shown to have antidepressant properties by Nathan Kline in 1957, and was 
identified as an MAOI, but was not taken on for the treatment of depression due to liver 
toxic properties. Following this era, many variations of antidepressant have been 
discovered, and will be discussed by group.
TCAs, for example amitriptyline, imipramine and dothiepin, have been the most widely 
used antidepressants until recent years. They block the presynaptic reuptake of the 
monoamines, 5-HT and NA (Stahl 1998). This theoretically enhances the availability of 
monoamines to bind at postsynaptic receptor sites and thereby increases monoaminergic 
neurotransmission. The antidepressant effect, as with other antidepressant drugs, starts 
after about 2 to 3 weeks continuous administration (Blier et al. 1994). This time course
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coincides with the onset of a variety of neuroadaptive effects, such as postsynaptic 
receptor downregulation (Stahl 1998). The side effects of TCAs are predicted by their 
effects at cholinergic, adrenergic and histaminergic receptors. The most dangerous side 
effect is their arrhythmogenic properties, leading to toxicity in overdose (Henry et al.
1995). This has been one of the driving forces to discover less toxic antidepressants.
SSRIs, such as fluoxetine, fluvoxamine, paroxetine, sertraline and citalopram, have been 
available for use as antidepressants from the late 1980s/early 1990s. Due to their greater 
tolerability than TCAs, and much lower toxicity in overdose (with the possible exception 
of citalopram), their popularity has risen dramatically. Their efficacy appears equal to 
TCAs (see below) but their cost initially limited their use. Their mechanism of action is 
the selective blockade of 5-HT reuptake into presynaptic terminals. More detailed 
receptor effects will be discussed below. Side effects are associated with increased 
serotonergic function, including nausea, decreased appetite, diarrhoea, anxiety, dizziness, 
headache and sexual dysfunction. The reported increased suicidality with SSRIs is 
discussed later in this chapter. There appear to be few differences between SSRIs in terms 
of efficacy, but tolerance may vary between subjects. Fluoxetine may be associated with 
greater agitation, a slightly longer time to onset of effect, but fewer withdrawal effects, 
citalopram has more associated deaths in overdose and paroxetine has the most 
troublesome withdrawal syndrome (Edwards and Anderson 1999). Escitalopram, the 
active S-isomer of citalopram, has been recently introduced (Owens et al. 2001) with 
claims of greater efficacy than citalopram (Gorman et al. 2002), but this will need to be 
examined in further studies.
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The antidepressant efficacy of TCAs and SSRIs, in comparison to placebo, was examined 
in a meta analysis of 49 RCTs by Joffe et al. published in 1996. A clear benefit of drug 
treatment was observed, with 69% of patients taking placebo doing worse than the 
average person on drug treatment (effect size 0.50). Subsequently, several authors have 
questioned whether antidepressants have any benefit over placebo. Kirsch et al. (2002) 
undertook a systematic review of all trials submitted to the US Food and Drug 
Administration of antidepressants approved between 1987 and 1999 (fluoxetine, 
paroxetine, sertraline, venlafaxine, nefazodone and citalopram). This included many 
previously unpublished trials, so represents the most complete potential dataset. They 
found that approximately 80% of the response to medication was duplicated by placebo 
and the mean difference between drug and placebo was 2 points on the HAM-D scale, 
with no difference between high and low doses. They argued that this represents a 
negligible difference between these antidepressants and placebo in such trials and that 
different trial designs are necessary to clearly examine the placebo effect in depression. 
The 2 point HAM-D scale difference was a highly statistically significant benefit however 
and this may be an under estimation of the actual effect of these drugs in usual clinical 
practice for many reasons, including sample selection biases and the studies being set up 
to measure efficacy as opposed to effectiveness.
Several systematic reviews have examined the relative antidepressant efficacy of SSRIs 
as opposed to TCAs. The reviews by Geddes et al. (2000), Hotopf et al. (1997), and Song 
et al. (1993) revealed no significant difference between these drug groups. The
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tolerability of SSRIs was significantly better than TCAs, demonstrated by a lower trial 
dropout rate of patients on SSRIs. Within the limits of these reviews, no difference was 
shown between the efficacy of SSRIs and TCAs in severe depressive disorders. Anderson
(2000) also examined this comparison with a slightly larger number of pooled studies 
than Geddes et al. (2000) agreeing that there is no overall difference between efficacy of 
SSRIs and TCAs but found that TCAs had a greater effect in inpatients and that 
amitriptyline was more effective than SSRI comparators. Barbui and Hotupf (2001) also 
found that amitriptyline had a greater efficacy than SSRIs and reported that amitriptyline 
had a greater effect than other TCAs.
Other drugs which block the reuptake of monoamines more selectively than TCAs have 
been developed. Venlafaxine selectively blocks 5-HT and NA reuptake, and has been 
reported to have a greater efficacy than SSRIs (Smith et al. 2002), particularly in more 
severe depressive disorders (Hirschfeld 1999). Duloxetine has recently become available 
and is also a reuptake blocker of 5-HT and NA. It has an efficacy in depressive disorders 
greater than placebo and an apparent equivalence to paroxetine in acute and chronic 
treatment (Detke et al. 2004) but does not appear to have any greater efficacy in 
melancholic than non melancholic subjects (Mallinckrodt et al. 2005). Duloxetine has 
also has been shown to reduce reports of physical pain associated with depression 
(Brannan et al. 2005) but this could be a class property of all antidepressants. Reboxetine, 
which only blocks NA reuptake has been shown to have equal efficacy to SSRIs and may 
also improve social functioning rather more (Holm and Spencer 1999).
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Monoamine oxidase inhibitors have been available since the 1950’s, and those without 
hepatotoxic effects, such as phenelzine, isocarboxazid and tranylcypromine are still used 
clinically. Their mechanism of action is to block both forms (A and B) of the enzyme 
monoamine oxidase (MAO) which breaks down monoamines presynaptically. They 
thereby increase the availability of monoamines for release into the synapse. As this 
blockade is irreversible, dietary tyramine is not broken down hence a potentially 
dangerous hypertensive effect can be experienced if tyramine is ingested. Patients on 
irreversible, non selective, MAOIs therefore need to avoid tyramine containing foods 
such as: cheese, meat extracts, Chianti, pickles, game, offal and avocado. This side effect 
and perceived limited clinical efficacy have inhibited the widespread use of MAOIs.
In the Clinical Trial of the Treatment of Depressive Illness (Medical Research Council 
Clinical Psychiatry Committee 1965), phenelzine was shown to offer no benefit over 
placebo, and indeed was worse than placebo in female subjects. A systematic review 
(Thase et al. 1995) compared MAOIs with TCAs, confirming clinical opinion that 
MAOIs are less effective in severe depressive disorders, but may be more effective in 
atypical depressive syndromes (with hypersomnia, increased appetite, mood reactivity 
and rejection sensitivity).
A reversible inhibitor of MAO A, moclobemide, was recently introduced, which at 
therapeutic doses does not have the tyramine pressor effect. The clinical efficacy data of 
moclobemide relative to other antidepressants is uncertain, perhaps explaining why it has 
had limited impact on clinical practice (Lotufo-Neto et al. 1999).
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Several other drugs have been developed with more selective receptor action than TCAs, 
in an attempt to produce a better tolerated drug with equal efficacy to TCAs. Mirtazepine 
and nefazodone are two such drugs, with particular action on the 5 -HT2 receptor, a site 
implicated as important in antidepressant action (see below).
Other antidepressants worthy of mention include L-TRP. This is a precursor to 5-HT, 
which has some evidence supporting a benefit in the treatment of mild to moderate 
depression (Meyers 2000). Theoretically, loading the system with more precursor would 
boost the amount of presynaptically available 5-HT. L-TRP was withdrawn from regular 
clinical use due to the association with eosinophilia myalgia syndrome, but has returned 
on a named patient prescription basis. It is probably used most currently as an augmentor 
of antidepressant treatment in resistant disorders (Meyers 2000). The use of 
L-TRP in neuroendocrine challenges will be discussed in Chapter 2.
In the pharmacological management of depressive disorders, there has been much debate 
as to which drug group should be considered first line. TCAs have the disadvantage of 
toxicity in overdose and are less well tolerated than SSRIs. SSRIs have been felt to be 
less effective in severe disorders and have been expensive. SSRIs are now widely 
recommended as first line, particularly those off patent, and reasonably priced. In subjects 
not responding to initial drug treatment there is reasonable evidence to change to another 
drug. Patients are usually given 6 weeks on a medication without improvement before 
lack of response is accepted. Other monotherapy options at this stage may include 
venlafaxine, mirtazepine, or an MAOI. In depressive disorders not responding to
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monotherapy, there is good evidence for the augmenting effect of lithium and some that 
tri-iodothyronine can augment TCAs (Joffe et al. 1993). Controlled evidence for the 
efficacy of other combinations of drugs (SSRI - TCA or MAOI - TCA) or augmentors 
(amphetamine, bupropion, pindolol, typical and atypical neuroleptic) are sparse. The 
National Institute for Clinical Excellence for England and Wales, has reviewed available 
data in depth and published guidelines for antidepressant use, available at 
www.nice.org.uk.
Case reports that pindolol augmentation of SSRIs reduced the time to onset and enhanced 
antidepressant effect, along with a convincing mechanism of action (Artigas 1994) has set 
off a flurry of research in recent years. Pindolol has been shown to have an affinity for 
5-HTia receptors (alongside P-adrenergic receptor antagonism) and in theory might 
antagonise the presynaptic 5-HTiA autoreceptor on the 5-HT cell body. 5-HTiA 
autoreceptors would normally mediate the inhibition of 5-HT cell firing that follows the 
increase of extracellular 5-HT caused by an SSRI. Hence concomitant 5-HTiA 
autoreceptor blockade might persistently enhance serotonergic neurotranr inission, and 
may reduce the time to onset of clinical effect. Several randomised controlled trials 
(RCTs) have been undertaken to examine this effect of pindolol, and a great heterogeneity 
of response is observed. Taking these studies together, a positive overall antidepressant 
enhancing effect is observed up to 4 weeks of treatment (the number needed to treat 
statistic (NNT) at 2 weeks is 7), with a possible reduced time to onset of effect (Whale et 
al., The Cochrane Library, in preparation). This line of augmentation strategy, using 
presynaptic antagonists, appears hopeful in improving future antidepressant treatment.
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Other apparently non aminergic antidepressant agents are being investigated, such as 
Substance P receptor antagonists. The substance P antagonist, MK-869, has been shown 
to have antidepressant properties in a placebo controlled trial in patients with moderate to 
severe major depression (Kramer et al. 1998) and to be of equivalent efficacy to 
paroxetine treatment (Nutt et al. 1998). Haddjeri and Blier (2000) recently demonstrated 
that such agents alter central NA and 5-HT activity in rats, possibly suggesting that while 
they are primarily non aminergic agents, Substance P antagonists may nevertheless act by 
modifying monoamine neurotransmission.
ECT has been the treatment of choice for severe, life threatening depressive illness for 
some time, with proven efficacy since the 1960’s (The UK ECT Review Group 2003). 
The first recorded association between seizures (induced by oral camphor) and relief of 
melancholic symptoms was in 1785. Troublesome associated side effects, such as 
temporary memory impairment, and social stigma have limited its use. The efficacy of 
ECT as a rapid onset antidepressant treatment, and its benefit in resistant disorders, mean 
that it retains an important place in clinical management. The mode of action of ECT is 
unclear. Animal studies have shown that ECT down regulates P noradrenergic receptors 
(as with antidepressants) but up regulates 5 -HT2 receptors (opposite to antidepressants) 
(Leonard 1991). Further elucidation of the mechanism of action may lead to the discovery 
of more effective antidepressant treatments.
Repetitive transcranial magnetic stimulation (rTMS) is a technique in which small 
electrical currents are induced in brain tissue by placing a magnetic coil over the cortex.
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This was originally used as a tool to map brain functions, but has recently been used 
experimentally as a treatment for psychiatric disorders. rTMS appears to improve the 
mood of depressed patients when applied over the dorsolateral prefrontal cortex. 
Controlled studies have demonstrated a clinically useful antidepressant effect (George et 
al. 1997; Pascual-Leone et al. 1996), although the optimal dosing schedule is unclear. As 
rTMS is well tolerated (in patients without a history of fits) and does not require 
concurrent anaesthesia, the potential for widespread use as an antidepressant and for 
insights into the aetiology of depression are evident.
Several authors have attempted to identify predictors of response to specific treatments. 
The clinical impression that response to physical treatments (drugs and ECT) is more 
likely in melancholic depressed subjects is not consistent in well controlled trials, but 
these subjects do appear less likely to respond to placebo than non melancholic subjects 
(Peselow et al. 1992). Patients with atypical depression have a greater response rate to 
MAOIs than non atypical depressed patients (Postemak and Zimmerman 2002). The 
presence of depressive delusions also appears to predict response to ECT (Johnstone et al. 
1980). Genetic influences may affect response. Replicated studies of the 
insertion/deletion polymorphism in the promotor region of the 5-HTT gene, referred to 
above, have demonstrated poorer therapeutic response and greater side effects during 
SSRI treatment for the short variant homozygote (reviewed by Murphy et al. 2004), 
consistent with the neuroendocrine and tryptophan depletion findings described above.
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Psychosocial Treatments
Many psychological treatments have been claimed to be effective in the treatment of 
depressive disorders, although few have undergone rigorous trials. Most psychological 
treatments compare favourably with placebo (or waiting list) but a limited number of 
trials have compared them directly with drug treatments. This will be briefly discussed for 
the most effective treatments. The effects of a supportive partner are discussed in the 
social support section above.
Psychoanalysis does not lend itself to studies of effectiveness of treatment of acute 
depression. Treatment goals are usually associated with change in underlying conflicts or 
deficits that may change the subject's vulnerability to depression. Therapeutic techniques 
used would be difficult to standardise for a meaningful trial. Although brief 
psychodynamic psychotherapy for major depressive disorder is more effective than 
waiting list control, it does not appear to be as effective as cognitive behevioural therapy 
(CBT) or interpersonal therapy (IPT) (meta-analysis finding, Depression guideline panel,
1993).
CBT is based on Beck’s theory that depressive symptoms may arise from dysfunctional 
patterns of thinking and behaviour, which may be a result of early life experiences (Beck 
et al. 1979). The process of treatment involves identification of such abnormal patterns of 
thinking and behaviour, and underlying attitudes that may influence these. The therapist 
assists in challenging irrational thinking and dysfunctional assumptions, and behavioural
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modification. Twenty RCTs were included in a systematic review comparing cognitive 
therapy with waiting list or placebo (Gloaguen et al. 1998). Significantly, 79% of patients 
in the placebo group were more symptomatic than the average patient treated with 
cognitive therapy. Seventeen studies were included in this review comparing drug 
treatment with cognitive therapy. 65% of patients receiving cognitive therapy were less 
symptomatic than the average patient receiving drug treatment. The subjects in these 
studies were from primary care settings, likely to have mild to moderate depression and 
drug dosages varied, possibly explaining the more favourable response to psychological 
than drug treatment. A recent ‘mega analysis’, including four selected RCTs of CBT vs 
antidepressant medication in severe depression, however, reported an equal efficacy of 
both treatments (DeRubeis et al. 1999).
The focus of IPT is current social context and relationships, and how interpersonal 
problems maybe linked with depression. The areas of loss, role disputes, role transitions 
and interpersonal skill deficits are examined and tackled using practical problem solving 
techniques (Klerman et al. 1984). A large RCT of 16 weeks duration, including mild to 
moderate depressive disorders, compared IPT with placebo and imipramine treatment. 
The recovery rates were favourable for IPT: 21% recovery in the placebo group, 43% in 
the IPT group and 42% in the imipramine group.
Several small RCTs have examined the effect of problem solving therapy, in which the 
focus of therapy is the identification and practical management of specific life stresses 
(detailed in Hawton et al. 1989). Problem solving was shown to be as effective as drug
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treatment in major depressive disorders (in a primary care setting), with no further benefit 
gained from adding drug to psychological treatment (Mynors-Wallis et al. 2000).
The addition of drug treatment to psychological treatments is more effective than 
psychological treatment alone in severe depressive disorders, but addition of drug 
treatment does not appear to add any significant benefit in milder depressive states (Thase 
et al. 1997).
PROGNOSIS
Less is known of the prognosis of depressive disorders than other severe psychiatric 
disorders as few long term follow up studies have been carried out, and many cases do 
not reach medical attention.
The short term prognosis is relatively good, but variable, with a mean duration of 16 
weeks reported by Kessler et al. (2003). 20% of patients have symptoms which persist 
beyond 2 years (Keller et al. 1992). Depressive disorder is highly recurrent with 30% of 
patients experiencing a relapse within 3 months of recovery and 50% (in the absence of 
ongoing treatment) experience relapse within 2 years. In Lee and Murray’s (1988) follow 
up of inpatients, 18 years after initial admission, only 11 of 89 patients h£ d good outcome 
with no further depressive episodes, and those with severe (melancholic or psychotic) 
index episodes had by far the worst eventual outcome. Very low rates of adequate
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community treatment of depressive disorder of 22% are observed (Kessler et al. 2003).
Suicide rates are relatively easy to measure and globally the annual incidence of suicide 
among depressed patients has been found to be 1%. About 15% of depressed patients 
treated as inpatients eventually die by suicide. History of depression is associated with a 
30 fold increase in suicide risk (reviewed by Kreitman 1993). Elderly depressed patients 
(over 50 years old) and younger men appear to be at greater risk (Lejoyeux et al. 1994). 
Although there is ample evidence that available treatments significantly improve acute 
depressive disorders, and some reduce the likelihood of further episodes, there appears to 
be little impact on the general suicide rate (Kreitman 1993).
There have been many recent reports of SSRIs increasing suicidality in adults but more 
rigorous investigation has not confirmed this (eg. Khan et al. 2003). In 2003, the 
Committee on Safety of Medicines in the UK reviewed the safety and efficacy of SSRIs 
in the treatment of major depressive disorder in the under 18s, recommending that 
paroxetine, venlafaxine, sertraline, citalopram and escitalopram are contraindicated due 
to risks outweighing any benefits of treatment, particularly increased suicidality,. 
Fluoxetine was the only SSRI deemed to have a favourable balance of risks. In 2004 the 
Committee on Safety of Medicines concluded that there is no clear evidence of an 
increased risk of self harm and suicidal thoughts in young adults over 18 years, but as in 
all age groups, anyone treated with SSRIs should be closely monitored for the 
development of suicidal ideas, particularly at the time of initiation and dose changes. 
These reports are available at http://medicines.mhra.gov.uk.
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If the above findings are valid, then a major public health problem will exist in the future. 
The World Health Organisation has predicted that by 2020, major unipolar depression 
will one of the leading causes of ill health related disability (Murray and Lopez 1997).
THE DISCOVERY AND BIOCHEMISTRY OF 5-HT
Scientists in the nineteenth century were aware of a component of human serum that 
caused contraction of smooth muscle. It was not until the years 1948 to 1953, however, 
that this substance was isolated, identified as 5-HT and synthesised. This work was 
carried out by Rapport, Green and Page. As 5-HT was a serum vasoconstrictor, released 
from platelets during blood clotting, they called it ‘serotonin’ (serum tonic factor) (Page 
1976). Concurrently, Erspamer had been studying a smooth muscle contracting substance, 
that he called ‘enteramine’ (due to its extraction from gut enterochromaffin cells), which 
was later found to be identical to 5-HT (Erspamer 1963). In 1953 Twarong and Page 
detected 5-HT in extracts of brain (Twarong 1988), which has led to the investigation of 
its involvement in brain disorders.
5-HT is formed in the body by hydroxylation and decarboxylation of the essential amino 
acid TRP (figure 1.1). TRP is found in foods such as cheese, peanuts, chocolate and fruits 
such as banana and avocado. TRP is highly bound to plasma protein, with less than 20% 
being free in plasma. Normally TRP hydroxylase (the rate limiting step to 5-HT
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formation) is not saturated, so an increase of available TRP in the brain will increase 
brain 5-HT concentration. The amount of available brain TRP is dependent on total serum 
TRP, unbound serum TRP and the concentration of other amino acids (tyrosine, valine, 
phenylalanine, isoleucine and leucine) competing for the same brain uptake mechanism. 
5-HT synthesis occurs in nerve terminals. It is stored in vesicles in the presynaptic areas, 
and released into the synaptic cleft on nerve firing via a Ca2+ dependant mechanism (Stahl 
1998).
Following release from serotonergic neurones, available 5-HT is taken back into the 
presynaptic neurone via an active transport mechanism, the 5-HTT. At this stage it is 
broken down by monoamine oxidase to the inactive, 5-hydoxyindoleacetic acid 
(5-HIAA). 5-HIAA can be measured in CSF (and urine), and may be helpful in estimating 
total serotonergic activity. In the pineal gland, 5-HT is converted to melatonin (N-acetyl- 
5-methoxytryptamine), which has diurnal control functions including sleep regulation 
(Forsling 2000).
54
Figure 1.1 5-HT synthesis and metabolism
C X T '
COOH
CH— NH, Tryptophan HO
Hydroxylase
Tryptophan
Amino add decarboxylase
XKT
5-hydroxytryptophan
(jiOOH 
.— CH— NH,
Amino acid decarboxylase
"°COr■ CH,— CH/—-NH;
Tryptamine 5-HT
5-HT N-acetylase Monoamine oxidase 
+ aldehyde dehydrogenase
"Our”'-'n-"T‘"1 “CO
N-Acetyl 5-HT
5-hydoxy indole O-methyl transferase
C H - O - ^ j ^ j j — CH,— CH,— N —  C —  CH,
O
■CH,— H — OH
5-hydroxy indole acetic add
Melatonin
55
BRAIN DISTRIBUTION OF 5-HT NEURONES
Serotonergic neurone cell bodies are located primarily in the midline raphe of the 
midbrain, pons and medulla oblongata. They have extensive projections throughout the 
brain and spinal cord.
Most ascending serotonergic pathways originate from raphe nuclei in the medulla, give 
branches to the substantia nigra and interpeduncular nucleus and supply the posterior and 
lateral hypothalamic nuclei and the neostriatum. The largest distribution of the ascending 
fibres is to the limbic system and neocortex.
Descending serotonergic pathways arise from the raphe nuclei of the pons and medulla 
and enter the dorsolateral spinal tract. These pathways synapse with other 
neurotransmitter associated neurones in the spinal tract, and may be in/olved with pain 
modulation. 5-HT neurones therefore have a very widespread distribution in the CNS.
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5-HT RECEPTORS AND THEIR FUNCTIONAL SIGNIFICANCE
Over the last 20 years the identification of distinct 5-HT receptors has progressed 
dramatically. Initially, subtypes of 5-HT receptor were identified by pharmacological 
tools but the use of radioligand binding techniques, the development of more selective 
ligands and molecular biological techniques have assisted in subcharacterisation. Indeed 
functional correlates now lag behind molecular identification in that RNA has been 
identified for receptors that have no known functional significance (eg .5 -h tiE , 5-htiF , 
5-hts).
An important early distinction between 5-HT receptors was made by Peroutka and Snyder 
who described 5-HTi and 5-HT2 subtypes using the serotonergic ligands, [3H] 5-HT,
[3H] LSD (lysergic acid diethylamide) and [3H] spiperone. [3H] 5-HT had high affinity for 
5-HTi receptors and [3H] spiperone had high affinity for 5-HT2 receptors (Peroutka 
1988). Many other radioligands have been introduced since, initially leading to 
subdivision of 5-HTi into 5-HTiAto id and the identification of 5 -HT3 receptors (Bradley 
et al. 1986). More recent molecular biological techniques have identified the protein 
structure of 5-HT receptors, enabled cloning and expression in cell lines, clarified known 
groups, expanded subtypes, identified further groups and allowed further pharmacological 
and functional classification. Identification of receptor DNA sequences has enabled 
antibody and antisense techniques to further clarify individual receptor function.
To date, seven families of 5-HT receptor (5-HTi t0 7) and 14 structurally and
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pharmacologically distinct mammalian subtypes have been identified (TiPS Receptor and 
Ion Channel Nomenclature Supplement 2000). Some receptors still lack selective ligands. 
The families and subtypes of 5-HT receptors, their pharmacology, CNS distribution and 
function in human and animal models will be summarised. The physiological and 
behavioural function of 5-HT receptors has largely been localised to receptor groups so 
will be discussed under these headings. Receptors and their associated ligands are 
summarised in table 1.1.
5-HT! FAMILY
This family is characterised by high affinity binding of [3H] 5-HT (Peroutka 1988). 5-HTi 
receptors are negatively coupled to adenylate cyclase via G proteins. Subdivisions are 
classified 5-HTia to if, excluding 5-HTic which was reclassified as 5-HT2C (Pazos et al. 
1984). 5-HTi pharmacological effects are mimicked by 5-CT, blocked by methiothepin 
and not blocked by selective 5 -HT2 and 5 -HT3 antagonists (Bradley et al. 1986).
5-HT1A receptor
The 5-HTia receptor is the most investigated of the 5-HT receptors to date. The 
identification of this receptor subtype (Pedigo et al. 1981) and discovery of a selective 
5-HTi a ligand, 8-OH-DPAT (Hjorth et al. 1982), enabled rapid progress in 
pharmacological characterisation.
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As with other G protein linked receptors, this receptor has seven membrane spanning 
units. The 5-HTia receptor gene is located on chromosome 5 of the human genome and 
has a high sequence homology to the P2 adrenoceptor gene. Several P receptor ligands, 
for example pindolol, also have activity at 5-HTia receptors (see below).
The brain distribution of this receptor has been investigated in humans using several 
radioligands in both postmortem specimens using autoradiography (Hall et al. 1997), and 
in vivo in humans using PET (Pike et al. 1996). The most popular 5-HTia ligand 
currently used for distribution studies is radiolabelled WAY-100635, a silent and 
selective antagonist of 5-HTia receptors, the binding of which is antagonised by the 
addition of other 5-HTia receptor ligands, 5-HT, buspirone, pindolol and 8-OH-DPAT 
(Hall et al. 1997). A high density of 5-HTia receptors is observed in the hippocampus, 
raphe nuclei and neocortex. Brain regions such as the amygdala, septum and claustrum 
have a low density of sites, with fewer 5-HTia receptor sites demonstrated in the basal 
ganglia, cerebellum and brain stem structures (except the raphe nuclei). Localisation of 
the 5-HTia receptors at the cellular level has been possible using light and electron 
microscopic immunocytochemistry with specific antibodies (Riad et al. 2000). 5-HTia 
receptors are found presynaptically in the raphe nuclei, on serotonergic neuronal cell 
bodies, dendrites, and along extrasynaptic portions of their plasma membrane. They are 
present postsynaptically to serotonergic neurones throughout other brain regions. 5-HTia 
heteroreceptors are probably located in cholinergic neurones of the septum and 
glutamatergic neurones in cortex and hippocampus.
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5-HTia receptors are pharmacologically distinct from other 5-HTi receptors. Selective 
agonists include 8-OH-DPAT, dipropyl-5-CT, ipsapirone, gepirone and tandospirone. 
Buspirone is a weak, less selective, agonist but widely available and licensed as an 
anxiolytic. As above, the most useful experimental antagonist is WAY-100635, which is 
potent and has no intrinsic activity. P receptor antagonists, such as pindolol, penbutolol 
and tertatolol, are widely available for the treatment of hypertension, and may have 
5-HTia antagonist properties. Pindolol is likely to be a partial agonist, however (Gartside 
etal. 1999).
The function of the 5-HTia receptor is diverse. As animal experiments have contributed 
significantly to the elucidation of receptor function, these studies will be referred to 
alongside human studies. Using transfected cell lines, 5-HTia receptors have been shown 
to couple negatively with adenylate cyclase via G proteins, alter intracellular calcium ions 
and activate phospholipase C (reviewed by Boess and Martin 1994). Electrophysiology 
studies have demonstrated a K+ mediated neuronal hypeipolarisation resulting from 
5-HTia receptor stimulation (Nicoll et al. 1990). These studies have also revealed 
differential effects of some weaker agonists at dorsal raphe and forebrain regions (pre and 
postsynaptic), possibly relating to drugs such as buspirone acting as a partial agonist at 
areas of low receptor density (forebrain) and a full agonist at areas of high receptor 
density (raphe). This may also indicate further subdivision of 5-HTiA receptors (Barnes 
and Sharp 1999). Stimulation of 5-HTia receptors in the rat brain dorsal raphe by agonists 
such as 8-OH-DPAT and ipsapirone cause inhibition of serotonergic neurone cell firing 
(Sprouse and Aghajanian 1988). This effect is blocked by antagonists such as WAY-
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100635. Microdialysis studies in rats are consistent with this finding, in that 
5-HTia agonists reduce 5-HT release in forebrain areas (Sharp and Hjorth 1990). The 
dorsal raphe 5-HTia receptors are therefore acting as autoreceptors, modulating cell firing 
and subsequent 5-HT release. Studies of the effect of 5-HTia antagonists (e.g. WAY- 
100635) alone on cell firing rate and extracellular forebrain 5-HT are inconsistent (Sharp 
et al. 1996). This is probably due to an absence of basal tone at the 5-HTia receptor. In 
the presence of 5-HT reuptake inhibitors (e.g. paroxetine), cell firing is inhibited, but 
firing is restored when WAY-100635 is added (Gartside et al. 1997). The SSRI induced 
reduction in forebrain extracellular 5-HT in microdialysis studies is prevented by 
WAY-100635 (Gartside et al. 1995). This has been projected clinically to depressed 
patients with the use of pindolol augmentation of SSRIs, which in theory could induce a 
more rapid antidepressant response by diminishing the reduction of 5-HT release 
occurring when treatment with an SSRI alone is commenced (Artigas et al. 1994, as 
discussed above).
Cortical and hippocampal acetylcholine (ACh) and NA release is enhanced in the 
presence of 8-OH-DPAT in rats, and blocked by WAY-100635 (reviewed by Barnes and 
Sharp 1999). Both responses are likely to involve postsynaptic 5-HTia receptors. 5-HT 
may therefore play a part in modulation of responses known to involve both ACh and 
NA, such as attention, mood and cognition.
Many studies have examined behavioural and physiological responses in the rat using 
5-HTi a ligands (reviewed by Lucki 1992). 5-HTi a agonists cause hyperphagia,
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hypothermia, altered sexual behaviour, tail flick and the 5-HT behavioural syndrome 
(including hyperlocomotion, head weaving, flat body posture and forepaw treading). Only 
hyperphagia and hypothermia are likely to be mediated via presynaptic receptors.
Human studies have linked 5-HTia receptors with temperature control, anxiety and 
depression. In healthy volunteers, the azapirones buspirone, ipsapirone, aid  gepirone 
decrease body temperature (Cowen et al. 1990). The hypothermic effect of buspirone is 
reduced by pindolol (Anderson and Cowen 1992), but pindolol alone also has a 
hypothermic effect (probably due to its partial agonist effects), (Meltzer and Maes 1996). 
Stahl (1998) proposed that presynaptic 5-HTia receptor hypofunction is linked with 
anxiety (downregulation of receptors due to an excess of 5-HT) and hyperfunction 
(upregulation of receptors due to a lack of 5-HT) with depression. Buspirone has proven 
benefit in the treatment of generalised anxiety disorder, and, similar to the time of onset 
of effect with antidepressant drugs, takes from two weeks to have therapeutic effect, 
suggesting a need for receptor adaptation for its anxiolytic effects (Ninan 1999). 
Buspirone also possesses antidepressant effects in patients with major depression. In 
addition it is used to augment antidepressant medication in resistant depression, but the 
only randomised trial found no significant benefit (Landen et al. 1998). It has been 
speculated that buspirone may be effective in both anxiety and depression because of its 
partial agonist properties, enabling it to act as an antagonist (upregulating receptors) in 
anxiety, and an agonist in depression (desensitising receptors). This results in a net 
normalisation of 5-HT function in both conditions. This hypothesis seems rather 
implausible and in any case it is now increasingly recognised that antidepressant drugs 
such as SSRIs are also effective in a range of anxiety disorders. The neuroendocrine
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studies of human 5-HTia receptor function will be discussed in Chapter 2, particularly 
with reference to depressive disorders.
5-HTib receptor
Due to significant structural similarity between 5 - H T i b  and 5 - H T i d  receptors, and 
differing pharmacological properties between humans and animal models, much 
confusion has arisen in the classification and investigation of these receptors.
The 5 - H T i b  receptor was first characterised pharmacologically in the rat (Pedigo et al. 
1981). This receptor was subsequently identified in mouse and hamster. A further site, 
binding [ H] 5-HT was identified in bovine brain and subsequently in guinea pig, dog and 
human. This latter receptor was named 5 - H T i d .  Distribution of these 5 - H T i b  and 5 - H T i d  
receptors (in neuronal terminal regions) between species was identical, however, which 
brought about the suggestion that these were species equivalents of the same receptor 
(Hoyer and Middlemiss 1989). Human genomic investigation identified two related 
receptor genes, with high sequence homology, which when expressed had the 
pharmacological characteristics of the 5 - H T i D receptor (Hartig et al. 1992). These were 
labelled 5-HTioa and 5-HTmp receptors. Rat 5 - H T i b  receptors were later cloned and 
found to have high sequence homology (96%) with the human 5-HTiop gene (Jin et al. 
1992). The receptor nomenclature was subsequently reassessed, taking into account that, 
despite pharmacological differences, human 5 - H T i d p  receptors have the same function as 
rat 5 - H T i b  receptors. Human 5-HTiDp receptors were therefore relabelled as 5 - H T i b
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receptors and 5-HTiDa as 5-HTiD receptors (Hartig 1996). The gene encouing human 
5-HTib receptors is located on chromosome 9 (Saudou and Hen 1994).
In human studies, 5 - H T i b  receptors have been identified at highest densities in the 
substantia nigra and globus pallidus and moderate densities in the caudate nucleus, 
putamen, nucleus accumbens, central grey and hippocampal formation (Bonaventure et 
al. 1997). 5 - H T i b  receptors are located both presynaptically and postsynaptically on 
serotonergic neurones. Presynaptically they are found in the terminal regions, acting as 
autoreceptors. They are also found on non serotonergic neurones, suggesting action as 
heteroreceptors controlling neurotransmitter release (for review, Barnes and Sharp 1999). 
An association with GABAergic neurones in caudate and hippocampus has been 
identified (Boschert et al. 1994).
The 5 - H T i b  receptor is pharmacologically characterised by affinity for [ H] 5-HT and low 
affinity for spiperone and 8-OH-DPAT (in rats). Few selective ligands are available. 
Agonists include L-694247, RU 24969, 5-CT and CP 93129 and methiothepin is an 
antagonist. GR 127935 is a useful antagonist at 5 - H T i b / d  receptors, and more recently 
developed drugs, more potent at 5 - H T i B than 5 - H T i D receptors include SB-224289 and 
SB-216641. Problems have arisen in the past in differentiating the function of these 
receptors, but such specific antagonists will help clarify the picture. The 5 -HT2 receptor 
antagonists ketanserin and ritanserin also have a much greater affinity for 5 - H T i d  than 
5 - H T i b  receptors. Several ‘triptans’ such as sumatriptan, zolmitriptan, naratriptan and 
rizatriptan are agonists at 5 - H T i B/d  receptors, and are available for the treatment of
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migraine. A significant difference between human and rat 5 - H T i b  receptors is their 
affinity for beta blockers. Pindolol has significant affinity for both 5 - H T i a  and 5 - H T i b  
receptors in rats but just 5-HTi a receptors in humans (Parker et al. 1993), which has 
important implications in using animal data to help interpret findings with pindolol in 
humans.
Like other 5-HTi receptors, 5 - H T i b  receptors couple negatively with adenylate cyclase. 
Some 5 - H T i b  receptors are located presynaptically in nerve terminal regions where they 
act as autoreceptors, reducing the release of 5-HT. In vitro, 5-HT agonist induced 
reduction of 5-HT release is inhibited by the 5 - H T i b  selective antagonist SB-216641 
(Schlicker et al. 1997). 5 - H T i b  receptor antagonists alone may enhance 5-HT release, 
although this appears to vary between different brain regions, possibly depending on 
variations in neuronal tone (Barnes and Sharp 1999). Guinea pig 5-HTiB receptors appear 
to be a good pharmacological model of human 5 - H T i b  receptors (Pauwelj et al. 1998). 
5 - H T i b  receptors also appear to act as heteroceptors, being present in terminal regions of 
non serotonergic neurones, and influencing neurotransmitter release. 5 - H T i b  ligands have 
been shown to affect cholinergic (Cassel et al. 1995), dopaminergic (Iyer and Bradberry 
1996), glutamatergic (Boeijinga and Boddeka 1996) and GABAergic function (Johnson et 
al. 1992).
Behavioural and physiological effects of 5 - H T i b  ligands in animal models include 
stimulation of locomotion, hypophagia, hypothermia, penile erection, and corticosterone 
and PRL secretion (Middlemiss and Hutson 1990). A 5 - H T i b  knockout mouse has been
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developed (Saudou et al. 1994) which has increased aggression and an absent locomotor 
response to 5 - H T i B agonists. The greatest drive in the development of 5 - H T i b / d  ligands is 
currently for the treatment of migraine. The mechanism of action against migraine relates 
to controlling blood vessel dilation and protein extravasation. (Deleu and Hanssens 
2000).
5-HTiD receptor
The discovery and nomenclature problems of 5 - H T i d  receptors are described above. The 
5-HTiogene is located on chromosome 1.
The brain location of 5 - H T i d  receptors has been investigated by several groups. Castro et 
al. (1997) examined radiolabelled sumatriptan binding that is inhibited by ketanserin in 
human brains, indicating the presence of 5 - H T i d  receptors in globus pallidus, substantia 
nigra, periaqeductal grey and spinal cord. Bonaventure et al. 1997 and Vamas et al. 2001 
also examined 5 - H T i d  receptor distribution in human postmortem brain using 
radiolabelled 5 - H T i B/ i d  receptor antagonists (alniditan and GR 125743 respectively). 
They compared this 5 - H T i B/ i D binding in the presence and absence of ketanserin to more 
selectively inhibit 5-HT id binding and SB 224289 to inhibit 5 - H T i B binding (although 
these are not highly selective ligands). They concluded that the numbers of 5 - H T i d  
receptors in human brain were low (in comparison to 5 - H T i B receptors) and were 
localised primarily in the basal ganglia (more specifically in the ventral pallidum).
5 - H T i d  mRNA has been identified in rat brain at low levels in areas such as caudate,
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putamen, accumbens, dorsal raphe and locus coeruleus, but not in globus pallidus, or 
substantia nigra (Brunivels et al. 1994). This may indicate the presence of 5-HTiD 
receptors in non serotonergic neurones.
The pharmacology of 5-HTiD receptors is very similar to that of 5-HTiB receptors due to 
the high receptor structure homology. Several drugs have been developed with high 
specificity for 5-HTib/d receptors, such as GR 127935. The most useful distinguishing 
tools are ketanserin and ritanserin which both have a greater affinity for 5-HTid receptors 
(Pauwels et al. 1996).
Concerning function, it is possible that 5-HTid receptors have a role as autoreceptors on 
serotonergic and non serotonergic neurones, as implicated by their location (see above). 
Pineyro et al. (1995) demonstrated that 5-HTid receptor stimulation in rat dorsal raphe, in 
vitro and in vivo, negatively modulated the somatodendritic release of 5-HT.
Other 5 - H T i d  receptors are located postsynaptically and may act as heteroreceptors, 
controlling, for example, the release of glutamate. This thesis will comment further on 
5 - H T i d  function in Part 2.
5-htiE receptor
This receptor was originally defined pharmacologically, with significant affinity for 
[ H] 5-HT, no affinity for other known 5-HTi subtype antagonists and low affinity for 
5-CT (Leonhardt et al. 1989), although we now know that 5-htiF and 5-ht6 receptor
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subtypes share these properties. The human gene encoding the 5-htm receptor was 
subsequently identified (Zgombick et al. 1992) and is located on chromosome 6 (Levy et 
al. 1992).
No selective 5-htiE receptor ligands are available, so location of these receptors is unclear. 
5-htiEmRNA is present predominately in cortical areas, caudate and putamen and 
detectable in amygdala and hypothalamus (Bruinvels et al. 1994).
Pharmacologically, 5 - h t m  receptors have most in common with 5-HTm, 5 - H T i d  and 5-htm 
receptors. 5-htm are distinguished from 5 - h t m  by the latter having a greater affinity for 
sumatriptan. The function of this receptor is not yet known.
5-htm receptor
The 5-htm receptor was discovered following identification of a mouse gene sequence 
with homology to the 5-HTm/D receptor genes. Identification of the human gene followed 
soon after (Adham et al. 1993). This gene is located on chromosome 3 (Saudou and Hen
1994).
The location of 5-htm mRNA is clearly different to 5-htm mRNA. Using in situ 
hybridisation, 5 - h t m  mRNA is found in guinea pig cortex, hippocampus and to a lesser 
extent in the dorsal raphe nucleus (Brunivels et al. 1994). Autoradiography using radio 
labelled sumatriptan and 5-CT in the human brain has shown 5-htm receptor sites (with
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no displaced sumatriptan binding) that correlate highly with guinea pig 5-htip mRNA 
location (Pascual et al. 1996).
Pharmacologically, 5-htiF receptors have high affinity for 5-HT and sumatriptan, but low 
affinity for 5-CT. Selective ligands are being developed, including LY344864 (Phebus et 
al. 1997) and LY334370 (Johnson et al. 1997).
The function of 5-htiF receptors is unclear. From their location, it could be suggested that 
they may be involved as 5 - H T  autoreceptors and in visual and cognitive function. The 
selective agonist LY334370 does not evoke behavioural changes but does influence dural 
protein extravasation, possibly having a role in migraine treatment (Johnson et al. 1997). 
Several of the triptans used as acute antimigraine treatments have a high affinity for both 
the 5 - H T i d  and the 5 - h t iF  receptor
5-HT2 FAMILY
The 5-HT2 receptor family now has 3 members, 5-HT2A, 5-HT2B and 5-HT2C, which have 
a high degree of structural homology, are coupled positively to inositol phosphate and 
mobilise intracellular calcium. The 5 -HT2 receptor described by Peroutka and Snyder 
with a high affinity for spiperone is now known as the 5-HT2A receptor. The 5-HTic 
receptor was renamed the 5-HT2c receptor and the 5-HT2-iike receptor (located in the 
stomach) as 5-HT2B- Pharmacologically, this family have a relatively low affinity for
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5-HT, and a high affinity for the 5 -HT2 agonists DOI, DOB and DOM and antagonists 
such as ritanserin. mCPP and TFMPP are non selective, less potent 5 -HT2 agonists.
5 -HT2 receptors mediate several behavioural and physiological responses, such as 
increased motor activity, hyperthermia, head twitches and ‘wet dog shakes’ (for review 
see Koek et al. 1992). The mediation of certain neuropsychological processes is also 
likely and is discussed.
5-HT2a receptor
The human 5-HT2A receptor gene is located on chromosome 13. The CNS distribution 
has been identified as predominately cortical areas, caudate nucleus, nucleus accumbens, 
olfactory tubercle, hippocampus and forebrain (Pazos et al. 1985). 5-HT2A receptors are 
located postsynaptically to serotonergic neurones. The distribution of these postsynaptic 
sites is identical to the brain innervations of neurones from the dorsal raphe nucleus (Blue 
et al. 1988), although electrophysiological stimulation of the median raphe nucleus also 
induces 5-HT2A receptor mediated responses (Godbout et al. 1991). 5-HT2A receptors are 
also located extraneuronally in glial cells. Other neurotransmitter systems, such as 
GABAergic, glutamatergic and cholinergic neurones have been confirmed to contain 
5 -HT2A heteroreceptors (reviewed by Barnes and Sharp 1999).
Pharmacologically, there have been problems distinguishing 5 -HT2 receptor subtypes, 
until the recent introduction of more selective antagonists. Ketanserin and spiperone have 
a greater affinity for 5-HT2AOver 5-HT2B and 5 -HT2 0  Antagonists such as MDL100907
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distinguish 5-HT2A, but no selective agonists are available.
Functionally, 5-HT2A stimulation has been shown to activate specific gene expression 
including brain derived neurotrophic factor (BDNF) (Vaidya et al. 1997). There may be 
an association between the increased expression of BDNF seen during antidepressant 
treatment, 5-HT2A activity, and antidepressant efficacy (further discussed in chapter 8). 
Using electrophysiology techniques in rats, 5-HT2A receptors have been shown to mediate 
cortical excitation (Marek and Aghajanian 1994). Electrophysiology has also 
demonstrated that 5-HT2A stimulation inhibits noradrenergic neurotransmission at the 
level of the locus coeruleus; this has been confirmed by microdialysis (Done and Sharp 
1992). Behaviourally, ‘head twitches’ and ‘wet dog shakes’ in rats induced by non 
specific 5-HT2 ligands, 5-HT releasing drugs and 5-HT precursors, are mediated by 5- 
HT2A receptors (blocked by selective antagonists, such as MDL 100907, Schreiber et al.
1995). Hyperthermia induced by 5 -HT2 ligands is probably mediated by 5-HT2a receptors 
(Gudelsky et al. 1986).
Drugs acting via serotonergic systems to induce hallucinations have a mechanism of 
action probably involving activation of 5-HT2 receptors (reviewed by Glennon 1990).
This is likely to be mediated predominantly by 5-HT2A receptors, as mCPP (acting 
predominately at 5-HT2C receptors) is not hallucinogenic in humans. Several 
antipsychotic medications (such as clozapine and risperidone) have a Ugh affinity for 
5 -HT2Areceptors (reviewed by Leysen et al. 1993). There has obviously teen much 
interest in developing more selective 5-HT2A receptor ligands for the treatment of
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schizophrenia.
5-HT2b receptor
The 5 - H T 2b  receptor (as it is now known) was originally identified in the rat stomach 
fundus. The human 5 - H T 2b  receptor gene is located on chromosome 2, with DNA and 
receptor structure very similar to the other 5-HT2 receptors. Low levels of 5 - H T 2b  mRNA 
have been found in human brain (Bonhaus et al. 1995), with no clear localisation.
Drugs such as spiperone and ketanserin have a lower affinity and yohimbine a higher 
affinity for 5-HT2b receptors in comparison to other 5-HT2 receptors. SB204 741 has been 
described as a selective 5-HT2b receptor antagonist.
Functionally, 5-HT2b receptors have been shown to mediate the action of 5-HT on 
embryonic neuronal morphogenesis in mice, by using 5-HT2b antagonists in early stages 
of cell division (Choi et al. 1997). 5-HT2B receptors may also mediate anxiety, as shown 
by anxiogenesis in response to the 5-HT2b agonist BW 723C86 (Kennet et al. 1996) and 
anxiolysis in response to the 5-HT2B/2c antagonist SB200646A (Kennet et al. 1995), in 
rats.
5-HT2c receptor
This receptor was initially grouped with the 5-HTi receptors due to its high affinity for 
[3H] 5-HT but following cloning, and further investigation, a reclassification as 5-HT2c
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was necessary (Humphrey et al. 1993). The 5-HT2C receptor is X linked and is a 
G protein coupled receptor. A splice variant of this receptor has been identified but the 
resulting protein does not possess a 5-HT binding site. Several receptor isoforms have 
been identified, created by post transcriptional editing of receptor mRNA, with different 
brain distributions (Bums et al. 1997). This may indicate further functional subdivision of 
the 5-HT2C receptor.
5 -HT2C receptors have high density in the choroid plexus and are found widely in the 
cortex, limbic system and basal ganglia (reviewed by Barnes and Sharp 1999). 5-HT2C 
receptors do not appear to exist outside the CNS. There is good concordance between 
5-HT2c receptor mRNA distribution and 5-HT2C binding sites (Mengod et al. 1990).
The 5-HT2C receptor can be labelled with [3H] 5-HT, [3H] mesulergine, [3H] LSD but not 
[3H] ketanserin. Other 5 -HT2 agonists such as DOI and mCPP and antagonists such as 
ritanserin, LY 53857 and mianserin, non specifically bind to 5-HT2C receptors. Two 
ligands described by Martin et al. (1998), including
(S)-2-(chloro-5-fluoro-indol-l-yl)-l-methylethylamine 1:1 exhibit high affinity
for the 5-HT2c receptor, with much lower affinity for other 5-HT receptors. Antagonists 
such as SB242 084 also specifically distinguish 5-HT2C (reviewed by Barnes and Sharp 
1999).
Functionally, 5-HT2C receptors in the choroid plexus may regulate CSF production 
(Kaufman et al. 1995). In rats, 5-HT2C receptors appear to mediate hypolocomotion,
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hypophagia, anxiety, penile erection, and hyperthermia (Koek et al. 1992). In humans, 
regular administration of mCPP has been shown to reduce body weight (Sargent et al. 
1997a). Blockade of 5-HT2C receptors appears to increase slow wave sleep (Sharpley et 
al. 1994). The PRL response to mCPP administration appears to be mediated by 5-HT2C 
receptors (see below, Cowen et al. 1996). In several animal models, 5-HT2C receptor 
agonists have activity in models of compulsive behaviour (Martin et al. 1998), and 
antagonists have anxiolytic properties (Kennet et al. 1997). 5-HT2C antagonists have been 
shown to increase cortical NA and DA in animal models, suggesting 5-HT2C receptors 
tonically inhibit neuronal firing in these systems (Di Mateo et al. 1998; Millan et al.
1998).
Several polymorphisms of the human 5-HT2C receptor have been identified. Reynolds et 
al. (2002) identified an association between a polymorphism in the promotor region of the 
5-HT2C receptor gene and atypical antipsychotic induced weight gain. An association 
between 5-HT2C polymorphic variation and response to clozapine in schizophrenic 
subjects has also been described (Sodhi et al. 1995).
5-HT3 FAMILY
5 - H T 3 receptors are the only serotonergic receptors that are not G protein linked. Instead, 
this receptor is a ligand gated ion channel. The 5 - H T 3 receptor gene has been identified 
on chromosome 11. Two 5 - H T 3 receptor subunits have been identified (nominally 
5 -HT3A and 5-HT3b), with receptors having the structure 5 -HT3A alone or 5 -HT3A/ 5 -HT3B
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combined. The 5 -HT3B subunit expressed alone does not form a functional receptor 
(Davies et al. 1999).
5 -HT3 receptors have their greatest density in the dorsal vagal complex of the brainstem, 
but have been located in human forebrain areas such as the hippocampus, amygdala, 
caudate, putamen and superficial cortex. In the rat cortex and hippocampus, 5 -HT3 
receptors are associated with GABAergic neurones. In humans, 5 -HT3 receptors in the 
basal ganglia are also probably located on GABAergic neurones as opposed to 
dopaminergic neurones (reviewed by Barnes and Sharp 1999).
Several 5 -HT3 selective ligands are now available enabling the pharmacology of 5 -HT3 
receptors to be more clearly defined. Selective antagonists include ondansetron, 
granisetron and topisetron. Substances that act at other ligand gated ion channel receptors, 
such as alcohol, barbiturates and steroids, also act at the 5 -HT3 receptor.
The most important psychiatric functional attributions of the 5 -HT3 receptor are 
mediation of anxiety, cognition, and possibly psychotic symptoms. Ondansetron is 
licensed for use as an antiemetic following chemotherapy, radiotherapy or post 
operatively, an effect probably mediated via the dorsal vagal complex. In animal models, 
5 -HT3 antagonists (such as ondansetron) have been shown to reduce and 5 -HT3 agonists 
to enhance anxiety associated behaviours. The amygdala is thought to mediate this 
response (Higgins et al. 1991). 5 -HT3 receptor stimulation also enhances release of 5-HT 
(Martin et al. 1992), which may explain the association with anxiety. Cholecystokinin
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(CCK) release is also modulated by 5 -HT3 receptors (Raiteri et al. 1993), which may be a 
further association of 5 -HT3 with anxiety, as raised CCK induces anxiety in humans. No 
clinical studies have shown anxiolytic effects of ondansetron to date. 5 -HT3 antagonists 
have been shown to enhance cognitive function in animal models (for review, Bentley 
and Barnes 1995). This effect could be explained by enhanced cortical ACh function, an 
effect indirectly mediated by 5 -HT3 receptors expressed on GABAergic neurones 
(reviewed by Barnes and Sharp 1999). In animal models using behavioural, 
neurochemical and electrophysiological paradigms, the 5 -HT3 receptor modulates 
dopaminergic activity. For example, 5 -HT3 agonists induce release of DA in rat 
accumbens and striatum in vitro (Blandina et al. 1989). This underpins the excitement 
about 5 -HT3 antagonists having antipsychotic properties. However, initial randomised 
trials with ondansetron in schizophrenia were inconclusive. More recent randomised 
studies have indicated a possible role for ondansetron in decreasing alcohol use in alcohol 
dependent humans (Sellers et al. 1994); this could be attributable to a link between 5 -HT3 
receptors and DA mediated reinforcement processes.
5 -HT4 FAMILY
The 5 -HT4 receptor was identified initially using a functional assay of adenylate cyclase 
activity in animal brain tissue (Dumuis et al. 1988). 5 -HT4 receptor cDNA was discovered 
by scanning sequences using polymerase chain reaction (PCR) primers based on the 
structure of other G protein coupled 5-HT receptors with the characteristic 7 putative 
transmembrane domain. Four isoforms of the 5 -HT4 receptor have now been identified,
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nominated the 5-HT4(a), 5-HT4(b), 5-HT4(C) and 5-HT4(d) receptors, resulting from variations 
in splicing of 5 -HT4 mRNA (with 387,406, 380 and 360 aminoacids per isoform 
respectively), (reviewed by Barnes and Sharp 1999). The 5 -HT4 gene is located on 
chromosome 5.
Brain distribution of 5 -HT4 receptors has been investigated using available selective 
5 -HT4 radioligands, indicating high densities in human nigrostriatal and mesolimbic 
areas. Information concerning distribution of specific isoforms is not available.
The pharmacology of the 5 -HT4 receptor isoforms is very similar. The only known 
difference is that renazapride acts as a partial agonist at the 5-HT4(C) receptor and a full 
agonist at the other receptors. Highly selective antagonists, such as GR113808 and 
SB204070 are available.
Functionally, 5 -HT4 receptors are coupled positively with adenylate cyclase. 5 -HT4 
receptors have been shown to modulate the activity of cholinergic, dopaminergic and 
serotonergic systems. Using microdialysis in rats, frontal cortex acetylcholine release has 
been shown to increase following administration of selective 5 -HT4 agonists (BIMU1 and 
BIMU8), and the response is blocked by selective antagonists such as GR113808 
(Consolo et al. 1994). DA release in the striatum and substantia nigra is similarly 
increased by 5 -HT4 agonists and the response is blocked by selective antagonists 
(Steward et al. 1996; Thorre et al. 1998). 5 -HT4 receptors do not; however, appear to be 
located on dopaminergic neurones in humans and the changes in DA release are likely to
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be mediated by 5 -HT4 receptors located on the terminals of GABAergic neurones. 5-HT 
release is also enhanced by selective 5 -HT4 receptor agonists (and blocked by 
antagonists) in hippocampus and substantia nigra (Ge and Barnes 1996; Thorre et al. 
1998).
5 -HT4 ligands do not affect overt behaviour in rats, which is surprising in view of their 
DA releasing properties. Cognition enhancing properties of 5 -HT4 agonists have been 
demonstrated in rat and primate models. A notable performance improvement in the 
delayed matching task was demonstrated in older macaque monkeys on RSI7017 (Terry 
et al. 1998). This effect may be attributable to enhanced cortical ACh release.
5 -HT4 receptor agonists may therefore offer a novel means of boosting central cholinergic 
function and could thereby ameliorate the cholinergic deficit seen in some memory 
disorders. There are no reports to date on the central effects of cisapride (a brain 
penetrating 5-HT4 receptor agonist licensed for use in gastric motility disorders) (Barnes 
and Sharp 1999). The use of these ligands in humans may be restricted, however, due to 
peripheral side effects such as abdominal cramps, diarrhoea and ventricular arrhythmias. 
Several groups have suggested a role of 5 -HT4 receptors in anxiety having found in 
animal models that selective antagonists (eg. GR113808) block the anxiolytic effects of 
diazepam (Costall and Naylor 1997) and paradoxically that selective antagonists (eg.
GR113808 at higher doses) alone have anxiolytic effects in certain experimental 
paradigms (Silvestre at al. 1996). This effect may be mediated via 5-HT modulation in 
the dorsal hippocampus, an area suggested being involved with rat social anxiety 
(Andrews et al. 1994).
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5-hts FAMILY
The 5 - h t s  receptor was identified from DNA sequence screening, with two subtypes 
identified in rat brain (5-htsA and 5-htsB) (reviewed by Barnes and Sharp 1999). To date, 
only 5-htsA expression has been identified in humans, and there is no evidence of 
functional 5 - h t 5 receptors in vivo. The structure of 5 - h t s  receptors is unclear. The 5-htsA 
gene is on human chromosome 7 and 5-htsB on chromosome 2. The receptors are probably 
G protein linked.
The brain distribution of 5-htsA receptor mRNA is widespread. Focal areas of 5-htsA 
mRNA in human forebrain and cerebellum have been described. No 5-htsB mRNA has 
been found in human brains.
Pharmacologically, 5 - h t s  receptors behave similarly to 5 - H T i d  receptors, with relatively 
high affinity for 5-CT, LSD, ergotamine, methiothepin and sumatriptau. The transduction 
system associated with 5 - h t s  receptors is unclear and their functional significance 
unknown.
5-HT6 FAMILY
The 5-HT6 receptor was identified from DNA sequence screening (reviewed by Barnes 
and Sharp 1999). No functional gene variants (receptor subtypes) have been identified.
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This is similarly a G protein coupled receptor with 440 amino acids and 7 membrane 
spanning regions. The 5-HT6 receptor gene is located on chromosome 1.
5-HT6 receptor mRNA is found in the human striatum, olfactory tubercles, nucleus 
accumbens and hippocampus. Studies with radioligands for the 5-HT6 receptor have not 
been fruitful due to diffuse, non specific, low levels of binding. Using radiolabelled 
receptor antibodies, receptors have been found in the same distribution as 5-HT6 mRNA. 
Electron microscopy studies indicate that hippocampal and striatal 5-HT6 receptors are 
postsynaptic to 5-HT neurones. 5-HT6 receptors have also been identified on dendritic 
processes of GABAergic neurones terminating in the basal ganglia.
The pharmacology of 5-HT6 receptors is in its infancy, with only recently the 
identification of two selective antagonists (Sleight et al. 1998). Interestingly, several 
antidepressant and antipsychotic drugs (including clozapine) interact with this receptor, 
and may have therapeutic actions or adverse effects mediated by 5-HT6 (Roth et al. 1994). 
Functionally, 5-HT6 receptors are positively coupled to adenylate cyclase. Due to a lack of 
selective ligands, 5-HT6 mediated responses have not been clearly characterised. An 
interaction between 5-HT6 receptors and ACh systems has been demonstrated in rats 
(Bourson et al. 1998). Yau et al. (1997) demonstrated that 5-HT6mRNA expression 
(along with 5-HTi mRNA and 5 -HT7 mRNA) is increased in specific hippocampal areas 
(CA1) following pharmacological adrenalectomy. This may imply an inhibitory influence 
of corticosteroids on 5-HT6,5-HTi and 5 -HT7 expression, which may be enhanced in 
depressive disorder with associated hypercortisolaemia (as described above). This is a
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further interesting insight into the associations between CORT and monoamine changes 
observed in depressive disorders.
5 -HT7 FAMILY
The 5 -HT7 receptor is the most recent 5-HT receptor to be identified (reviewed by Bames 
and Sharp 1999). The 5-HT7 gene resides on chromosome 10 and contains two introns. 
Although 4 gene variants have been identified in total, only three appear to be expressed 
in human tissue: 5-HT7a, 5-HT7b and 5-HT7d. This G protein coupled receptor group 
predictably has amino acid sequences with seven membrane spanning regions. In the rat 
and guinea pig, 5 -HT7 receptors are located predominately in the thalamus, hypothalamus 
and hippocampus. Lower densities are found in cortex and amygdala. Receptor 
subgroups do not appear to have different distributions.
The pharmacology of this receptor is still to be explicitly defined but one selective 
antagonist has recently been reported. 8-OH-DPAT at high concentrations is a 5 -HT7 
agonist, which has caused some confusion about whether some of the effects previously 
attributed to 5-HTi a receptor activation are in fact due to stimulation of 5 -HT7 receptors. 
Several psychotropic drugs, such as antidepressants (fluoxetine) and antipsychotics 
(including clozapine) appear to bind to 5 -HT7 receptors (Roth et al. 1994), highlighting 
the need for further investigation into this receptor group. No pharmacological differences 
have been found between subtypes.
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Functionally, 5 -HT7 receptors are positively linked with adenyl cyclase, and appear to 
induce an increase in intracellular Ca2+. Several authors have described a role of 5 -HT7 
receptors in the regulation of circadian rhythms (agonists inducing phase shifts), and 
suprachiasmatic nucleus activity (Lovenberg et al. 1993). Indeed 5 -HT7111RNA is found 
in the suprachiasmatic nucleus. Bourson et al. (1997) have suggested a role of 5-HT7 
ligands in seizure control.
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Table 1.1 5-HT receptors and selective agonists / antagonists
RECEPTOR SELECTIVE AGONIST SELECTIVE ANTAGONIST
5 - H T i A Ipsapirone Gepirone WAY-100635 Pindolol
Tandospirone Penbutolol Tertatolol
5 - H T ib / id Methiothepin 
Sumatriptan Naratriptan 
Rizatriptan Zolmitriptan
GR127935 SB224289
5 - h t iE - -
5 - h t iF LY344864 LY344370 -
5-HT2A - SB200646A
5 - H T 2b - SB204741
5-HT2C (S)-2-(chloro-5-fluoro-indol-1 - 
yl)-l-methylethylamine 1 :1  - 
C4H4O4
SB242084
5 -HT3 “ Ondansetron Granisetron 
Topisetron
5 -HT4 Renazepride 
BIMU1 BIMU8
GR113808 SB204070
5-ht5 - -
5-HT6 - -
5 -HT7 - -
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5-HT FUNCTION AND DEPRESSION
Following the detection of 5-HT in brain extracts in 1953 (Twarong 1988), the interest in 
the involvement of 5-HT in brain disorders has flourished. Several drugs with established 
effects on mood and behaviour were later found to influence serotonergic 
neurotransmission, such as LSD, psilocybin, and bufotenine (McBride 2000).
At an early stage of investigation, the main breakdown product of 5-HT, 5-HIAA was 
found to be reduced in the CSF of depressed subjects (Ashcroft 1966). In the presence of 
probenecid, which blocks transport from the CSF, the rate of CSF 5-HIAA accumulation 
was also reduced in this group (van Praag 1977). Overall, more recent studies have not 
supported a difference in CSF 5-HIAA between depressed subjects and controls (Asberg 
1984, Gjerris et al. 1987). Potential biases in the early studies included concurrent 
antidepressant use, amount of CSF drawn and the control group (Asberg 1984). 5-HIAA 
produced from spinal cord as opposed to brain tissue may also bias these findings. A 
consistent finding however has been that of reduced CSF 5-HIAA in suicide attempters. 
Asberg et al. (1976) studied CSF 5-HIAA in a group of depressed patients, finding a 
bimodal distribution of 5-HIAA levels, with subjects in the lower mode attempting 
suicide significantly more often than those in the high mode, and using more violent 
means. A further study of suicide attempters by violent means suggested that the lower 
CSF 5-HIAA levels in this group were associated entirely with high in.pulsivity scores 
(Cremniter et al. 1999).
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Several early studies reported reduced 5-HT uptake sites, labelled with [ H] imipramine, 
on blood platelets in untreated depressed patients (as reviewed by Elliott 1991). More 
recent, larger studies however have not shown such differences between depressed 
patients and controls (eg Healy et al. 1990; Mellerup and Langer 1991). This between 
study variation may be due to patient selection and biochemical methods and is further 
complicated by [3H] imipramine not solely binding to 5-HT uptake sites (Hrdina 1984). 
Lawrence et al. (1994) examined platelet binding of [3H] paroxetine, which appears to 
only bind to 5-HT uptake sites, also finding no difference between depressed subjects and 
controls. Many studies have examined the platelet 5-HT2A receptor which mediates 5-HT 
activation of the platelet (reviewed by Mendelson 2000). Although study findings are 
inconsistent, 5-HT2A receptor density appears to increase in depressive disorders with the 
clearest increase in those attempting suicide. Studies have examined platelet 5-HT2A 
receptor density pre and post SSRI treatment, overall with no difference observed (eg. 
Hrdina et al. 1997). It remains unclear whether these platelet sites have functional 
similarities to brain uptake sites.
Postmortem studies initially demonstrated low brainstem 5-HT and diminished
-i
[ H] imipramine binding in the brains of non psychiatrically defined suicide victims 
(Stanley 1982). Subsequent studies in postmortem brains of previously depressed suicides 
have shown a wide variation of results, with decreases, increases and no difference in 
[ H] imipramine binding reported. Lawrence et al. (1998) demonstrated no overall 
difference in [3H] imipramine binding between retrospectively diagnosed depressed 
brains and controls, but the group of subjects who undertook non violent suicide had
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significantly less binding in the putamen than matched controls. This finding remained 
consistent when specific 5-HT uptake was examined (ie. Na+ dependent
-j
[ H] imipramine binding). Most studies examining [ H] paroxetine binding in this 
previously depressed group have also shown no difference from controls. One group, 
primarily investigating schizophrenia, found significantly less [ H] paroxetine binding in 
the prefrontal cortex of non psychotic suicides (Laurelle et al. 1993).
Investigation of 5-HT receptor subtype binding in previously depressed postmortem 
samples has also been undertaken. Lowther et al. (1997a) examined 5 - H T i a  receptor 
binding with [3H] 8-OH-DPAT, finding no difference between depressed suicides and 
controls (and no significant findings in sub analysis of method of suicide or treatment). 
This group also examined 5 - H T 2a  binding using [3H] ketanserin, similarly with no 
difference between diagnosed groups (Lowther et al. 1994), a finding replicated by 
Stockmeier et al. (1997). Some previous studies of 5-HT2 binding suggested higher 
binding in frontal and prefrontal cortex of depressed suicides, although subject numbers 
were smaller (eg. Arora and Meltzer 1989). Studies comparing treated with untreated 
depressed subjects showed a reduced 5-HT2 binding in the treated group (equal to control 
levels); suggesting treatment may decrease 5-HT2 receptor density in depressed subjects 
(eg. Yates et al. 1990). Prefrontal 5 - H T 2a  binding does appear higher in suicide victims 
irrespective of diagnosis, consistent with the platelet findings (eg Turecki et al. 1999). 
Lowther et al. (1997b) used [3H] 5-HT with specific antagonists to examine 5 - H T i B/d  and 
5 - H T i e / f  binding in suicides with retrospective depression diagnoses. The significant 
finding was of greater 5 - H T i b / d  binding sites in the globus pallidus of antidepressant free
86
depressed suicides in comparison to controls. This gives further potential evidence to the 
importance of 5 -H T ib /d  receptors in the aetiology of depression, which will be explored, 
further in chapters 4 and 5.
More recently, techniques to investigate the influence of 5-HT in depression using 
imaging technology have been developed. Progress has been restricted by the availability 
of appropriate radiotracers for use in vivo, but reports using ligands that bind to 5-HTia 
receptors, 5-HT2 receptors and the 5-HTT are growing.
5-HTia binding using PET has largely been examined with the ligand [n C] WAY 
100635. Sargent et al. (2000) measured [n C] WAY 100635 binding in treated and 
untreated depressed subjects and healthy controls. Binding was reduced across many 
brain regions, including frontal, temporal, and limbic cortex in all depressed patients 
compared with healthy volunteers. This finding replicated that of Drevets et al. 1999, 
which is significant in such a field of conflicting findings. Binding potential values in the 
Sargent study were similar in treated and untreated subjects suggesting no change in 
5-HTi a binding with SSRI treatment. This group further examined the ability of pindolol 
to bind to 5-HTia receptors in depressed subjects (used therapeutically as described 
above), finding that the commonly used dose of pindolol 2.5mg three times daily did not 
achieve significant 5-HTi a binding but the higher dose of 5mg three times daily did 
(Rabiner et al. 2001). Pindolol appeared to bind preferentially to the presynaptic 5-HTia 
receptor. This is a good example of how PET can inform clinical practice.
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The first studies looking at 5 -HT2 binding in depressed subjects used unspecific ligands 
and SPECT so findings such as higher parietal binding (D’Haenen et al. 1992) must be 
treated with caution. [18F] altanserin, a more specific (but rapidly metabolised) 5 -HT2 
ligand and PET was used by Biver et al. (1997) in unipolar drug free depressed subjects 
showing decreased binding in right posterolateral, orbitofrontal and anterior insular cortex 
in comparison to controls. Setoperone has been the most widely used 5 -HT2 ligand as it 
has high affinity and specificity for cortical 5-HT2A receptors, with 100 fold preference 
over 5-HT2C receptors and 10 to 50 times preference over D2 receptors (which have 
minimal presence in the cortex) (Meyer et al. 2001a). Massou et al. (1997) using PET 
demonstrated an increase in [18F] setoperone binding in the frontal cortex when 
comparing chronic SSRI treated depressed patients to untreated patients (not a within 
subject design), suggesting chronic treatment causes 5 -HT2 receptor up regulation, which 
may contribute to the therapeutic effect. Yatham et al. (1999) examined the effects of 
desipramine on 5 -HT2 receptors in depressed subjects using PET and [18F] setoperone, 
finding a significant decrease in 5 -HT2 receptor binding following treatment in several 
brain areas, particularly frontal cortex. This is consistent with other studies indicating 
postsynaptic 5-HT receptor downregulation following treatment as elaborated later in this
|  o
thesis. Meyer et al. (2001a) examined [ F] setoperone binding in depressed subjects pre 
and post SSRI treatment, a within subjects design, in comparison to matched controls. No 
difference in binding was observed between depressed subjects and controls but they 
found decreased binding in cortical regions of depressed subjects post treatment only in 
younger subjects, with no association with treatment response. The results of this study 
may be more valid than the Massou et al. study due to more rigid design. Messa et al.
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(2003) examined 5-HT2A receptor binding in depressed subjects and controls using 
[18F] fluoroethylspiperone, also a D2 antagonist, by examining the ratio of binding in 
cortex and basal ganglia. They found a significant reduction in binding ratio in pretreated 
patients in comparison to controls in several areas including frontal, temporal and 
cingulate cortices but not the striatum. No difference in binding ratio was observed in 
another group of successfully treated euthymic patients from controls, suggesting reduced 
5 -HT2A receptor binding may be a state dependant marker of depression that resolves with 
treatment. This would need to be clarified in a within subjects design. Yatham et al.
(2001) also examined the effects of TRP depletion (as described below) on 
[18F] setoperone binding in healthy subjects. TRP depletion induced a significant 
reduction in 5 -HT2 binding in several cortical regions, independent of mood effects in this 
group, which the authors argue is akin to the adaptive downregulation seen following 
antidepressant treatment.
Malison et al. (1998) first studied the 5-HTT in vivo in drug free depressed subjects using 
SPECT imaging of [123I] P-CIT binding, a cocaine derivative which binds to the 5-HTT 
molecule exclusively in the brainstem (but the DA transporter in other brain areas). They 
showed reduced brainstem binding in depressed subjects in comparison to controls, 
suggesting that depressed subjects have a reduced density of the 5-HTT at least in the 
brainstem. It remains unclear whether this is a state or trait phenomenon. Meyer et al. 
(2001b) examined 5-HTT binding potential in depressed subjects pre and post SSRI 
treatment using [n C] DASB binding measured with PET. They found a significant 
decrease in striatal 5-HTT binding following treatment, indicating approximately 80% of
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these receptors are occupied by the SSRI.
The methodologies and specificity of ligands involved in these scanning experiments are 
still being developed, which may explain the conflicting results found so far. The 
variation of findings between postmortem and in vivo scanning studies could be 
explained by many factors including problems with retrospective diagnosis of depression 
in postmortem samples and that the neurochemical aetiology of suicide may be different 
from depression. Further clarification of the findings discussed is required and may only 
happen with improving technology.
The use of serotonergic drugs as effective antidepressants is discussed above.
L-TRP and 5-hydroxytryptophan (5-HTP) are both precursors to 5-HT. As the brain 
capacity to produce 5-HT is limited by precursor availability (see above), the addition of 
these precursors induces a greater synthesis of 5-HT, with associated antidepressant effect 
in milder depressive states (Thompson et al. 1982; Meyers 2000). As brain 5-HT 
concentration is dependent on plasma levels of TRP, experimentally reducing TRP has 
been used to examine the effects of reduced serotonergic function. Rapid depletion of 
plasma TRP is achieved by consuming a protein drink lacking in TRP. This intervention 
briefly reverses antidepressant response in 67% of recently remitted depressed patients on 
medication (Delgado et al. 1990). This is only observed in subjects on serotonergic 
antidepressants, however. Those subjects treated with predominately noradrenergic drugs 
such as desipramine are largely not affected by TRP depletion (Delgado 1999). This 
demonstrates the importance of the serotonergic system in maintaining a euthymic mood
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in recovered subjects treated with serotonergic drugs. TRP depletion also precipitated 
clinical depressive symptoms in well, untreated women, vulnerable to major depressive 
disorder (Smith et al. 1997). The findings support a key role for deficient 5-HT function 
in the aetiology of depression in this group. Mood response induced by TRP depletion 
reliably predicted a further major depressive episode in drug free remitted patients during 
the subsequent year, in a small randomised controlled trial (Moreno et al. 2000). Other 
factors predisposing to depressive relapse after TRP depletion were more than one 
previous episode, female gender, and history of suicidal behaviour.
In summary, the best evidence that 5-HT is involved in depressive disorder comes from 
evidence that drugs that selectively increase 5-HT are antidepressant. However, this is not 
direct evidence for a role of 5-HT in the pathophysiology of depression. Evidence that 
5-HT function is abnormal in untreated patients in the studies so far described is 
inconsistent, probably because most study paradigms are indirect and models such as 
postmortem are beset with methodological difficulties. Developments in brain imaging 
offer promise and the consistent reduction in 5-HTia binding in depression appears to be 
an important finding. The extent to which this contributes to the psychopathology of 
depressive syndrome however is uncertain. This thesis will go on to describe more 
dynamic tests of 5-HT function which in general yield more consistent changes in 
depressed patients.
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CHAPTER 2
NEUROENDOCRINE STUDIES AND FINDINGS IN 
DEPRESSED SUBJECTS
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INTRODUCTION
Neuroendocrine techniques are a useful method to examine central amine 
neurotransmission. This experimental paradigm can be used to study differences in 
neurotransmission in disorders of brain function and the mechanisms of action of 
centrally active drugs.
The investigation of neuroendocrine abnormalities in depressive disorders followed from 
the identification of higher rates of depression in endocrine disorders, such as Cushing’s 
disease and thyroid disorders (Sachar 1973). Pituitary hormones were subsequently 
investigated in basal and stimulated states in depressive disorders and the regulation of 
pituitary hormones by central amines was more explicitly defined (Wurtman 1970). 
Neuroendocrine challenge tests rely on this influence of monoamines on the release of 
anterior pituitary hormones. Serotonergic neurones from the raphe nucleus have direct 
synaptic contact with cell bodies of secretory neurones in the hypothalamus (Tork 1990). 
These include cell bodies in the arcuate, infundibular, paraventricular, suprachiasmatic 
and ventromedial nuclei. Stimulation of these neurones leads to secretion of anterior 
pituitary releasing hormones, and other substances, from these hypothalamic secretory 
neurones into the capillaries of the hypothalamic-pituitary portal system to which they 
project. These releasing hormones and substances pass to the pituitary through the portal 
vessels and act on secretory cells in the pituitary to influence the release of PRL, GH and 
ACTH into the blood stream. Drugs which activate the serotonergic system can be used to 
measure the function of this hypothalamic mediated system by measuring the specific
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pattern of hormone release following their administration (Sachar 1973; Wurtman 1970). 
There are many factors that influence the secretion of these hormones however, that must 
be taken into account before a direct link can be made between the action of the drug and 
the subsequent hormone release. The specific mediators of and influences on the release 
of these hormones will be discussed individually.
Prolactin
The nature of PRL and its regulation is reviewed by Freeman et al. (2000). PRL is 
released from the pituitary lactotrophs which are widely distributed throughout the pars 
distalis of the pituitary gland. The normal pituitary holds 100 micrograms of PRL, 50 
times less content than GH. Lactotrophs have spontaneously high secretory activity which 
is regulated by hypothalamic DA and other factors. PRL is the only pituitary hormone to 
have release inhibited by the hypothalamus, which is mediated by DA produced from 
tuberoinfundibular DA neurones. These neurones have cell bodies in the ircuate nucleus 
of the hypothalamus and their short axons end in the median eminence where DA is 
secreted into the portal capillaries. The subsequent action of DA on the lactotroph is a 
tonic inhibitory influence, via D2 receptors. Other inhibitory factors of PRL release 
include somatostatin and GABA, and stimulatory factors include thyrotrophin releasing 
hormone (TRH), vasoactive intestinal peptide, oxytocin and neurotensin, all released 
from the hypothalamus into the portal system. Lactotrophs are also influenced by 
stimulatory and inhibitory factors from neighbouring cells (paracrine regulation) or from 
the lactotrophs themselves (autocrine regulation). Normal PRL plasma levels are less than 
20 micrograms per litre. PRL is released in pulses, with lowest circulating levels at mid
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day, a rapid increase at the onset of sleep and peak levels from the middle to the end of 
the night. PRL has an inhibiting action on its own secretion, via increasing hypothalamic 
secretion of DA, so subjects with high baseline PRL should be excluded from 
neuroendocrine tests as their subsequent PRL release will be inhibited and not reflect a 
true influence of the drug probe. Release is enhanced by stress, suckling, other nipple 
stimulation and orgasm.
DA antagonists increase the release of PRL by reducing the tonic inhibitory control at the 
level of the pituitary. Adrenergic 012 agonists may inhibit PRL release. In vitro, 5-HT does 
not cause PRL release from the lactotrophs, suggesting 5-HT purely mediates PRL release 
via the raphe-hypothalamic neurones. Histaminergic drugs enhance PRL secretion at the 
level of the hypothalamus, likely via H2 receptors and subsequent influence on portal DA 
levels. Opioids, both endogenous and administered, also enhance PRL release. 
Hyperprolactinaemia is seen in primary hypothyroidism due to raised TRH. Oestrogen 
enhances PRL release at the levels of both the hypothalamus and pituitary. The least time 
of oestrogen influence on PRL release is in the early stages of the menstrual cycle 
(O'Keane et al. 1991) hence neuroendocrine tests should ideally be carried out during this 
period of the cycle. For within subject comparisons, test days need to be at the same stage 
of the menstrual cycle. PRL acts on many organs including the liver, ovary, testis and 
prostate, but has its main role in initiating and maintaining lactation.
Growth hormone
The nature of GH and its regulation is reviewed by Muller et al. (1999). GH is secreted in
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a pulsatile maimer from the somatotrophs, which occupy the lateral wings of the pituitary 
gland. GH synthesis and release is stimulated by GH releasing hormone (GHRH), 
released into the portal circulation. GHRH secreting neurones have cell bodies in the 
infundibular nucleus which project to the median eminence, in close contact with portal 
vessels. GHRH neurone cell bodies are also present in other medial nuclei and project to 
other parts of the hypothalamus and sparsely to other brain regions. Other endogenous 
GH releasing peptides include TRH and gonadotrophin releasing hormone (GnRH). 
Somatostatin inhibits GH release, and is particularly important in the timing and 
magnitude of GH pulses, but has no effect on synthesis. Cell bodies of somatostatin 
secreting neurones are present in the ventromedial nucleus of the hypothalamus. GH 
inhibits its own release by action at the level of the hypothalamus, so as for PRL, subjects 
with high baseline GH should be excluded from neuroendocrine tests. GH release is also 
inhibited at the level of the pituitary by insulin like growth factor. The amount of GH 
secreted is greatest during adolescence and decreases with age. Females on the whole 
have greater GH secretion than males.
GH secretion is enhanced by slow wave sleep, chronic hyperglycaemia (diabetes), 
hypoglycaemia (starvation or anorexia), hepatic cirrhosis, exercise and stress. Certain 
amino acids, particularly arginine and leucine enhance release. Clonidine (and other a 
adrenergic agonists), DA agonists, ACh agonists and glucagon also stimulate release. 
Adrenergic P receptor antagonists augment GH stimulation, but have no effect alone. 
Many of these GH responses are blocked by muscarinic antagonists. GH release is
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reduced by acute hyperglycaemia, acute increase in plasma free fatty acids, obesity and 
emotional deprivation in children. All of these influencing factors appear to act at the 
level of the hypothalamus. Opioids, both endogenous and administered, do not appear to 
influence GH release. Oestrogen augments GH responses, and as for PRL, 
neuroendocrine tests in females should be undertaken in the early stages of the menstrual 
cycle (O'Keane et al. 1992). CORT inhibits the release of GH, so particularly when 
measuring GH release in depressed subjects it is important to concurrently measure 
baseline CORT levels, because depressed patients may have hypercortisolaemia. In rats 
5-HT has a stimulatory effect on GH release but in humans, 5-HT altering drug probes 
have a more varied influence, as covered later in this chapter. Histamine antagonists 
overall have an inhibitory influence over stimulated GH secretion. Depressive disorder 
itself does not appear to influence GH secretion as the GH response to GnRH 
(Amsterdam et al. 1982) and buspirone in melancholic subjects (Cowcn et al. 1994) is not 
different from healthy controls. Physiologically GH enhances cell growth and influences 
carbohydrate and lipid utilisation in the body.
Adrenocorticotrophic hormone and cortisol
The nature of ACTH and CORT and their release is reviewed by Holsboer and Barden
(1996). ACTH is released in a pulsatile manner from the pituitary coticotrophs into the 
blood stream. The synthesis and release of ACTH is controlled by corticotrophin 
releasing hormone (CRH), released into the portal system by hypothalamic neurones with 
cell bodies in the paraventricular nucleus. 5-HT neurones from the raphe have been 
shown to synapse directly onto these CRH containing cells. At least 2 rhythms of ACTH
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release operate with pulses of secretion every 1-3 hours and at meal times, superimposed 
on a 24 hour pattern with lowest levels following sleep onset and highest levels just 
before waking. Physical or mental stress will also initiate ACTH secretion. ACTH 
released into the blood stream subsequently acts on the adrenal gland to release CORT 
(particularly from the adrenal zona fasciculata) into the blood stream. Plasma CORT 
levels therefore follow the pattern of ACTH secretion. CORT is partially bound in plasma 
to a specific binding protein and only the unbound fraction is active. CORT inhibits 
release of ACTH at the levels of the hypothalamus and pituitary and also via the 
hippocampus.
Release of ACTH is stimulated by hypoglycaemia. Histamine, NA and ACh enhance and 
GABA inhibits ACTH release. Serotonergic drugs enhance ACTH release which is 
reviewed below. ACTH levels vary throughout the menstrual cycle (Genazzani et al. 
1975). As discussed above, in some depressed subjects the HPA appears hypersensitised 
and ACTH and CORT levels are increased. Replicated studies have shown an 
enlargement of adrenal glands in depressive disorders which resolves on treatment (Rubin 
et al. 1995). Plasma CORT is easier to measure than ACTH, so many studies use CORT 
as an endocrine measure of central 5-HT activity although this may not be as accurate, as 
peripheral 5-HT may directly influence the adrenal gland to release CORT. 
Physiologically ACTH acutely enhances the conversion of cholesterol to pregnenolone, it 
enhances synthesis and release of CORT, and maintains adrenal growth. ACTH also 
stimulates skin melanocytes. CORT has a wide ranging influence, including a catabolic 
effect, promotion of gluconeogenesis, control of water metabolism and modulation of
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responses to injury and stress.
The posterior pituitary hormones, oxytocin and vasopressin are synthesised in the cell 
bodies of neurones in the supraoptic and paraventricular nuclei of the hypothalamus.
They are directly transported along axons for release from the pituitary. Investigators have 
examined oxytocin in neuroendocrine paradigms but on the whole the response is less 
reliable than those of the anterior pituitary hormones. For example Cleare et al. (1998a) 
found the oxytocin response to ipsapirone was not robust and had significant baseline 
variation.
Weight loss has a significant influence on neuroendocrine responses, and is obviously a 
common feature of depressive disorders, particularly with melancholia (see appendix). 
Goodwin et al. (1987) demonstrated that recent weight loss enhanced the PRL response to 
L-TRP. In a group of low calorie dieters, Anderson et al. (1990b) also demonstrated an 
enhanced PRL response to L-TRP but only in female subjects, despite a similar 
percentage weight loss in both sexes. Female subjects showed a greater reduction in 
plasma TRP in this study.
Physical illness and pregnancy also influence hormone secretion. Aside from the stressful 
influence of physical disorders, other direct action on neuroendocrine systems may occur. 
Recently Muldoon et al. (2004) found a reduced PRL response to fenfluramine in a
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sample of patients with metabolic syndrome. A low PRL response was associated with 
greater body mass index, higher concentrations of triglycerides, glucose, and insulin, 
higher systolic and diastolic blood pressure, greater insulin resistance, and less physical 
activity.
Recent psychoactive drug exposure also has an important influence on neuroendocrine 
challenge outcome. Ensuring a long enough time period for any drug to be totally cleared 
from the subject’s system is essential to exclude any effect. The influence of drugs on 
system reactivity may last for longer than the drug is present in the plasma however. 
Gilmore et al. (1993) demonstrated that if healthy subjects are rechallenged with 
clomipramine following 2 weeks, a blunting of the PRL response is observed, which does 
not occur if the rechallenge is at 4 weeks, indicating that rechallenges should be at least 4 
weeks apart.
Season of the year may affect responses. Cappiello et al. (1996) demonstrated a seasonal 
variation in the PRL response to L-TRP in depressed subjects, particularly females. 
Rechallenging subjects several months after the first test may therefore give skewed 
findings.
To validly interpret the hormonal response to a neuroendocrine probe as due to its activity 
on that system, it is therefore important to minimise any other influence on hormone 
release. Hence combining the factors discussed above, subjects should be rested, not 
stressed, not sleeping or eating, not taking any medications or smoking during the trials,
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be physically well and not had recent weight loss. Females should be tested in the early 
phase of their menstrual cycle. These findings also highlight the importance of matching 
control subjects for age, sex and weight.
The other problematic issue is the selectivity of the neuroendocrine probe for the 5-HT 
system, to exclude influence of activity at other receptors. Many available drugs do not 
have such selectivity. As new, more specifically acting drugs are developed, more 
effective drug probes will become available. At present, it is often unclear exactly how, 
and at what anatomical level, drugs influence the release of hormones. When comparing 
neuroendocrine responses between different groups (as opposed to within subject 
comparisons), pharmacokinetic variables become important, again highlighting the need 
for accurate control matching for age, weight and sex at the very least. Some patient 
groups could also have reduced absorption rates of the drug used following oral 
administration (overcome by using an IV preparation), and could also theoretically have 
reduced brain uptake. Whilst stress can be minimised through environmental 
manipulations, the influence of the drug itself maybe stress inducing for he subject, for 
example by causing nausea and dizziness, further biasing hormonal responses. Probes 
should therefore be well tolerated (Cowen 1998).
An ideal neuroendocrine probe of 5-HT function therefore has the following 
characteristics (Yatham and Steiner 1993):
1. A large, robust and consistent hormone response.
2. A dose dependent relationship between the drug and the hormone response
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3. Hormone responses are due to a direct effect of the drug on the 5-HT system
4. Hormone responses due to other influences are abolished
5. The probe is well tolerated and does not lead to stressful side effects
The striking benefits of this method of investigation are that it is a functional, dynamic 
analysis of aminergic activity, minimally invasive, relatively easy to carry out and as well 
tolerated as the probe used (Delgado and Chamey 1991). The most important limitation 
in human studies is extrapolating changes in neuroendocrine function to changes in 
aminergic function at other parts of the brain outside the hypothalamus. It must also be 
acknowledged that the system being tested has many levels and interpretation must take 
into account possible abnormalities at any one of these levels. There is also a large 
variability of hormone responses between subjects and small changes in responses could 
be overlooked. This highlights the importance of ensuring adequate power and statistical 
interpretation of these studies and replication of results between studies.
Several pharmacological probes have been used to date to examine 5-HT activity in 
depression, including precursors of 5-HT (L-TRP, 5-HTP), 5-HT releasers 
(fenfluramine), 5-HT reuptake inhibitors (clomipramine) and direct acting 5-HT receptor 
agonists (mCPP, gepirone, ipsapirone) and antagonists (ritanserin, ketanserin, 
metergoline). Not all fulfil the criteria above. These groups of neuroendocrine challenge 
tests are dealt with specifically in this thesis and are summarised in table 2 . 1  (on page 
115).
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Probes of noradrenergic function (clonidine and desipramine) and dopaminergic function 
(apomorphine and haloperidol) are available, but are not covered in this thesis (see 
Cowen 1998 for review).
PRECURSORS OF 5-HT
L-Tryptophan
Administration of L-TRP intravenously, in doses above 5g, produces dose related 
increases in plasma PRL and GH (Cowen et al. 1985). These responses are blocked by 
pindolol (Smith et al. 1991), which has 5-HTia antagonist properties (rs well as being a 
P-adrenoreceptor antagonist) (Guan et al. 1992). Selective 5-HT2 and 5 -HT3 antagonists 
do not influence these hormonal changes (Cowen et al. 1985). Pretreatment with 
clomipramine (a 5-HT reuptake inhibitor) further enhances the PRL and GH response to 
LTP (Anderson and Cowen 1986). These findings imply that although L-TRP would 
theoretically enhance overall serotonergic function, the endocrine responses are mediated 
by indirect activation of postsynaptic 5-HTia receptors.
Dieting has been shown to reduce plasma TRP in women and enhances the plasma PRL 
response following intravenous L-TRP (Anderson et al. 1990b). It is therefore important 
to exclude such subjects with recent weight loss when examining neuroendocrine 
responses to L-TRP.
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Several studies have shown a blunting of PRL and GH following TRP infusion in drug 
free depressed subjects in comparison to normal controls (Cappiello et al. 1996; Cowen 
and Charig 1987; Deakin et al. 1990; Heninger 1984; Price et al. 1985; Price et al. 1991). 
PRL secretion does not appear to be otherwise impaired in depression as the PRL 
response to thyrotropin releasing hormone (a direct lactotroph stimulant) (Rubin et al. 
1989) and metoclopramide (a DA antagonist) (Anderson and Cowen 1991), are 
unimpaired. This blunted response to L-TRP in depression appears to be a state 
dependant abnormality, improving alongside the recovery of depressive symptoms 
(Upadhyaya et al. 1991). These findings imply a dysfunction of postsynaptic 5-HTia 
receptors during the process of a major depressive episode. Whether melancholic subjects 
have a greater blunting of hormonal response in comparison to non melancholic is unclear 
(Price etal. 1991).
Such blunting of responses to L-TRP have not been demonstrated in other psychiatric 
disorders (panic disorder (Chamey and Heninger 1986), obsessive compulsive disorder 
(Fineberg et al. 1994) and bulimia nervosa without depressive symptoms (Brewerton et 
al. 1992)), so reduced postsynaptic 5-HTia receptor function maybe solely associated 
with depressive disorders.
Studies to examine the influence of antidepressant medication on the PRL and GH 
response to L-TRP have also been undertaken. Chronic treatment with desipramine, 
amitriptyline, clomipramine, fluvoxamine, tranylcypromine, carbamazepine or lithium 
(reviewed by Price et al 1990b) all enhance the PRL response to L-TRP. This supports the
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hypothesis that 5-HTia receptor function mediates depressive disorders and their 
resolution. Bupropion, mianserin, trazodone (reviewed by Delgado and Chamey 1991), 
and mirtazepine (Whale et al. 2000) do not appear to alter these hormonal responses, 
suggesting that these drugs do not enhance serotonergic function (or at least 5-HTia 
neurotransmission). These drugs do however have antidepressant properties, suggesting 
mechanisms involving other 5-HT receptor subtypes or other aminergic mechanisms. 
Studies with TRP depletion and AMPT would help clarify the influence of these chugs on 
5-HT and NA function. Indeed, Delgado et al. (2002) demonstrated that in a group of 
depressed patients receiving mirtazapine, a partial return of depression in most was seen 
following tryptophan depletion and AMPT administration (undertaken 1 week apart), 
implying that both systems are involved in mirtazapine’s action.
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5-Hydroxytryptophan
5-HTP is the immediate metabolic precursor of 5-HT. The neuroendocrir e response to 
oral 5-HTP has been seen as unreliable and independent of dose (Westenberg et al. 1982). 
This may be explained by metabolism of 5-HTP into 5-HT both in and outside the CNS 
and a possible direct adrenal influence of 5-HTP to release CORT (reviewed by Delgado 
and Chamey 1991). Oral 5-HTP has been observed to increase CORT, which is 
attenuated by the 5 -HT2 antagonist ritanserin (Lee et al. 1991). The unreliable increase of 
PRL following 5-HTP has been shown to be attenuated by both ritanserin and pindolol 
(Meltzer and Maes 1994), but pindolol has no effect on CORT. The CORT response 
therefore appears to be mediated by 5 -HT2 receptors and the PRL response by 5-HTia 
receptors and 5 -HT2 receptors.
In untreated depressed subjects, the CORT response to oral 5-HTP is enhanced in 
comparison to controls (Meltzer et al.1984), which appears to correlate positively with 
the severity of depression (Meltzer et al. 1984b, Maes et al. 1987a). The enhanced CORT 
response correlated negatively with CSF 5-HIAA levels, and not with other monoamine 
metabolites, suggesting that this CORT response is CNS mediated (Koyama et al. 1987).
The CORT response to 5-HTP has been shown to be elevated following treatment with 
the serotonergic antidepressants fluoxetine, clomipramine and paroxetine in depressed 
patients (Meltzer et al. 1997, Sargent et al. 1998 a and b). This suggests enhanced 5 -HT2 
receptor function following these antidepressant treatments. This is unlikely to explain 
the therapeutic effect of all antidepressants, as TCAs do not demonstrate such effects
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(Meltzer et al. 1984c), but may relate to benefits seen in the treatment of other conditions 
(such as obsessive compulsive disorder) and observed side effects (such as sexual 
dysfunction).
5-HT RELEASERS 
Fenfluramine
Fenfluramine is an amphetamine derivative that reliably induces an increase in PRL, 
ACTH, and CORT but not GH (Lewis and Sherman 1984; Quattrone et al. 1983). The 
isomer, d-fenfluramine has specific action as a 5-HT releaser and a 5-HT uptake blocker 
(unlike the racemic mixture, which also has dopaminergic activity). The PRL response to 
fenfluramine is dose dependent and blocked by ritanserin and amysergide, but not by 
pindolol (reviewed by Newman et al. 1998), suggesting this response is mediated by 
postsynaptic 5-HT2A or 5-HT2C receptors. The active metabolite of fenfluramine, 
norfenfluramine, may have direct activity at 5 -HT2 receptors in rats and guinea pigs 
(Mennini et al. 1991), possibly explaining the influence of ritanserin.
Several studies have found a blunted PRL and GH response to fenfluramine in 
medication free depressed subjects in comparison to normal controls, suggesting an 
impairment of 5-HT2 receptor function (eg. Stahl et al. 1993; for review see Power and 
Cowen 1992). A minority of studies however have not replicated these findings.
The CORT response to fenfluramine appears unaltered in most studies (Newman et al. 
1998).
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The PRL response to fenfluramine is enhanced after TRP infusion (Price et al. 1990b), 
chronic treatment with lithium (Muhlbauer 1984) and imipramine (Shapira et al. 1989) 
and possibly after ECT treatment (Shapira et al. 1992). This suggests increased 
postsynaptic 5 -HT2 receptor function following these antidepressant interventions, and 
the possibility that specific 5 -HT2 receptor ligands may have antidepressant activity. The 
PRL response following SSRI treatment in depressed subjects does not appear enhanced 
however (Kavoussi et al 1999). Fenfluramine has been a very useful neuroendocrine 
probe, but was withdrawn from use in 1997 due to cardiotoxicity (Newman et al. 1998). 
This has left a poverty of reliable, available probes.
5-HT REUPTAKE INHIBITORS
Clomipramine
Clomipramine administered intravenously has been widely used as a neuroendocrine 
challenge. It acts as a potent and selective inhibitor of 5-HT reuptake, but is metabolised 
to desmethylclomipramine, which significantly blocks NA reuptake. During the period of 
an intravenous neuroendocrine challenge, however, levels of this metabofite are 
negligible, giving apparent selectivity to testing the serotonergic system (Golden et al.
1989). Clomipramine increases PRL, ACTH and CORT in healthy subjects and there is 
no consistent GH response (Golden et al. 1989,1990). The PRL response is blocked by 
the non selective 5-HT antagonist methysergide (Laakmann et al. 1983), but further 
receptor specific mediation of this response has not been established. Clomipramine can
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induce nausea and vomiting at similar doses to those required to induce a PRL response 
(Anderson et al. 1992b), which may cause problems in interpretation of response as 
nausea can also increase PRL. Several studies have reported a blunted PRL response to 
clomipramine in depressed subjects in comparison with healthy subjects (Anderson et al. 
1992b; Golden et al. 1990; Lopez-Ibor et al. 1989). In healthy subjects, the PRL response 
to clomipramine is enhanced following 4 days of lithium treatment, with no change in 
CORT response (McCance et al. 1989), but no significant hormone response to 
clomipramine is seen after 2 weeks of lithium treatment (Manji et al. 1991). Clear 
interpretation of these findings has not been possible.
5-HT RECEPTOR AGONISTS
5-HTia Agonists
The neuroendocrine profile of several 5-HTia agonists has been examined, including 
buspirone, ipsapirone, gepirone and tandospirone.
Buspirone
Buspirone is the most widely available 5-HTia agonist, marketed for the treatment of 
anxiety disorders. Oral buspirone (up to 30mg) induces an acute increase in GH, PRL, 
ACTH and CORT, and a reduction in body temperature in healthy subjects (Cowen et al. 
1990; Meltzer et al. 1983). Buspirone however has some DA antagonist activity that 
confounds the interpretation of these responses, and is likely to explain the PRL response
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(Meltzer et al. 1982).
Hypothermic responses to buspirone have been found to be blunted in drug free depressed 
subjects, particularly in subjects with melancholia, however the GH response was 
unchanged (Cowen et al. 1994). This implies an abnormality in presynaptic but not 
postsynaptic 5-HTia receptor activity (see below), and suggests that the blunted L-TRP 
induced GH release in depressed subjects is likely to be related to a presynaptic 
abnormality.
Ipsapirone
Ipsapirone has less intrinsic activity for DA receptors than buspirone (Peroutka 1988) and 
therefore is likely to be a more reliable probe of 5-HTia receptors. Ipsapirone (up to 
3mg/kg) induces an increase in CORT in healthy subjects, but has no effect on PRL or 
GH (Lesch et al. 1989). Ipsapirone also causes a reduction in body temperature in healthy 
subjects.
The hypothermic response to ipsapirone is blunted in depressed subjects (Lesch et al.
1990). Chronic antidepressant treatment of depressed subjects (with fluoxetine) further 
blunted this hypothermic effect (Lerer et al. 1999). These findings suggest a functional 
reduction in presynaptic 5-HTia activity in depressed subjects (see below), which is 
further reduced in the presence of SSRIs, consistent with preclinical findings (Blier and 
de Montigny 1990). Blunted CORT responses following ipsapirone have also been found 
in depressed subjects (Lesch et al. 1990), conflicting with the buspirone findings,
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however this may reflect dysregulation of the HPA axis in depression rather than 5-HTia 
function. The study by Lerer et al. (1999) found ACTH, CORT and GH responses were 
significantly blunted by fluoxetine treatment in depressed subjects, suggesting a 
functional down regulation of postsynaptic 5-HTia receptors following this intervention.
Gepirone and tandospirone
Gepirone and tandospirone are also relatively selective 5-HTia agonists without 
significant intrinsic dopaminergic activity. Their neuroendocrine profiles differ, however, 
as gepirone (up to 20mg) causes robust increases in ACTH, CORT, PRL, GH and 
reduced temperature (Anderson et al. 1990a) and tandospirone (60mg) only appears to 
increase GH and decrease temperature (Nakayama et al. 2002).
SSRI treatment has been shown to blunt the hypothermic, CORT and GH responses to 
gepirone (Sargent et al. 1997b), consistent with the effect of fluoxetine on ipsapirone 
response.
These differences in the responses to 5-HTia ligands many relate to differing intrinsic 
activity, receptor selectivity, and activity of metabolites. Pindolol (which exhibits 5-HTia 
antagonist activity) has been demonstrated to block the ACTH, GH and hypothermic 
responses to 5-HTi a ligands (Cowen 1993), suggesting it is these neuroendocrine 
responses that are most reliable indicators of 5-HTi a function. The hormonal responses to 
5-HTia agonists are hypothesised to be mediated by activity at postsynaptic 5-HTia 
receptors, as these findings are replicated in animal models by directly injecting the
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5 - H T ia  agonist 8-OH-DPAT into the hypothalamus. The hypothermic response appears 
to be mediated through presynaptic 5 - H T ia  receptors as this is replicated by injecting 
8-OH-DPAT into the dorsal raphe (Cowen 1993). However, in the rat (but not the mouse) 
a component of the hypothermic response may be mediated via activation of postsynaptic 
5 - H T i a  receptors.
5-HTib and 5-HTiD Agonists
A number of drugs (collectively known as ‘triptans’) recently introduced for the acute 
treatment of migraine have a high affinity for human 5 - H T ib  and 5-HT id receptors 
(Johnson et al. 1997), and have been used as neuroendocrine probes. The triptans include 
sumatriptan, naratriptan, rizatriptan and, more recently, zolmitriptan. The development of 
zolmitriptan as a neuroendocrine probe will be detailed in Chapters 5 and 6.
The triptans
Several investigators have found that acute administration of sumatriptan increases 
plasma GH in healthy men and women (Herdman et al. 1994; Boeles et al. 1997; 
Facchinetti et al. 1994; Franceschini et al. 1994). However the magnitude of this response 
is small and inconsistent (only 25 of 49 subjects pooled from different studies showed a 
GH response to sumatriptan greater than 5 mIU/1, Whale and Cowen 1998b).
Sumatriptan can also lower plasma PRL, although this effect is even less consistent 
(Herdman et al. 1994; Whale and Cowen 1998a). Recently it has been noted that 
rizatriptan can increase plasma GH (Sciberras et al. 1997). Animal studies suggest that
112
5-HTib receptor agonists can cause hypothermia (Hagan et al. 1997) although such an 
effect has been documented only rarely in humans (Wing et al. 1996).
Two studies have reported blunted GH responses to sumatriptan in patients with major 
depression (Cleare et al. 1998b; Yatham et al. 1997a), although these results are difficult 
to interpret because of the number of healthy subjects who fail to produce useful GH 
responses. Wing et al. (1996) investigated the effect of repeated SSRI administration in 
healthy subjects, finding no change in plasma PRL responses post treatment. These 
findings will be explored further in Chapter 5.
5-HT2 Agonists
5 -HT2 receptor ligands, such as mCPP have also been used in neuroendocrine studies. 
mCPP
mCPP is a metabolite of the antidepressant drug trazodone, and acts as a rather non 
selective 5-HT agonist, with greatest affinity for 5 -HT2C receptors. It also binds to the 
5 -HT2A receptor but acts there as an antagonist. It has been shown to elevate plasma PRL, 
ACTH and CORT and have a hyperthermic effect (Kahn and Wetzler 1991). This 
response is more reliable if mCPP is administered intravenously. IV mCPP (but not oral) 
inconsistently elevates plasma GH levels (Kahn and Wetzler 1991). The PRL and CORT 
responses (but not GH) are blocked by metergoline and ritanserin, implying these 
responses are mediated by postsynaptic 5-HT2C receptors (Seibyl et al. 1991).
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The CORT and PRL responses to mCPP in unmedicated depressed subjects did not differ 
from those of controls (Anand et al. 1994; Kahn et al. 1990). This conflicts with findings 
with the fenfluramine challenge (see above), and suggests that any abnormality in 
5 -HT2A/2C mediated PRL release may be due to a defect in presynaptic 5-HT neurones 
rather than at postsynaptic 5-HT2C receptors. mCPP has been also used to examine the 
effect of SSRI treatment on 5 -HT2C receptor function in healthy subjects. Quested et al.
(1997) found blunted PRL and hyperthermic responses to mCPP following SSRI 
administration, suggesting that SSRIs lower the sensitivity of post synaptic 5 -HT2 
receptors in healthy subjects.
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Table 2.1 Neuroendocrine challenges of serotonergic neurotransmission
DRUG HORM ONE RESPONSE E F F E C T IN EFFECT
RESPONSE MEDIATED BY DEPRESSION* O F SSRI **
L-TRP t  PRL GH post synaptic 5-HT1A blunted PRL GH enhanced PRL
5-HTP t  CORT (fP R L ) post synaptic 5-HT2 enhanced CORT enhanced CORT
Fenfluram ine t  PRL ACTH CORT post synaptic 5-HT2 blunted PRL PRL->
Clom ipram ine t  PRL ACTH CORT ? blunted PRL
Buspirone t  PRL GH ACTH CORT post synaptic 5-H T jA G H->
Temp pre synaptic 5-HT iA blunted Temp
Ipsapirone t  CORT post synaptic 5-HT1A blunted CORT blunted CORT
4 Temp pre synaptic 5-HT1A blunted Temp blunted Temp
Gepirone T PRL GH ACTH CORT post synaptic 5-H T iA blunted CORT GH
4- Temp pre synaptic 5-HT1A blunted Temp
Tandospirone t  GH post synaptic 5-HT2A
4 Temp pre synaptic 5-HT1A
Sum atriptan 4 PRL pre synaptic 5-HT1B PRL->
T GH post synaptic 5- H T1B/id blunted GH
m-CPP T PRL ACTH CORT post synaptic 5- HT2C C O R T-» blunted PRL
(tG H ) t  Temp PR L-* blunted Temp
Inconsistent hormone responses are in brackets
* Effect on hormone response in a depressed group in comparison to healthy controls 
** Further effect on the hormone response following SSRI treatment
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AIMS OF THE THESIS
Use of 5-HT neuroendocrine challenge tests has begun to give investigators insight into 
the function of 5-HT systems, the impact of illness states on these systems and the effect 
of drug treatments. The tests described are summarised in table 2.1 above. There are a 
number of areas where improvements would help develop neuroendocrine research.
This thesis describes the development of two new neuroendocrine challenges and their 
use in investigating depressive disorder:
I. Zolmitriptan as a probe of 5-HTi B/ i d  receptors.
n. Low dose citalopram as a probe of presynaptic 5-HT function
Aims of the zolmitriptan studies
Previous studies, as indicated above, have used sumatriptan to investigate 5 - H T ib / id  
receptor function. This receptor group is of particular interest in depressive disorders due 
to acting both as presynaptic autoreceptors and post synaptic receptors on 5-HT neurones 
(Barnes and Sharp 1999). The 5 - H T ia  receptor has been investigated extensively due to 
its autoreceptor function and ligands acting at this receptor have potential benefits in 
antidepressant treatment. It has been suggested that the 5 - H T ia  autoreceptor is 
hypersensitised in depressive disorders, leading to a reduction in synaptic 5-HT, reduced 
5-HT neurotransmission and changes in mood (Blier et al. 1990). If th“ temperature
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reduction to 5 - H T ia  neuroendocrine probes is a measure of presynaptic receptor function 
as proposed, then the findings in depressed subjects of a blunted temperature response is 
not consistent with this hypothesis. SSRIs have been shown to desensitise the 5 - H T ia  
autoreceptor in rats (Blier et al.1990) and enhance synaptic 5-HT levels and 
neurotransmission, with likely associated antidepressant effects. The addition of 5 - H T i A 
antagonists to SSRI treatment in humans does not appear to have as dramatic an effect as 
expected, however (Whale et al. in preparation). This maybe because 5 - I ! T ib / id  
autoreceptors further modulate the synaptic availability of 5-HT counteracting any 
benefits of 5 - H T ia  autoreceptor antagonism. Indeed, Roberts et al. (1999) demonstrated 
that to increase extracellular 5-HT in guinea pig frontal cortex, antagonism at both 5- 
H T i A a n d  5 - H T ib / id  receptors is required, but in the dorsal hippocampus a 5 - H T ib  
antagonist alone is enough to increase 5-HT. Sharpe et al. (1997) also demonstrated in 
rats that enhanced frontal cortex 5-HT was seen with an SSRI plus a 5 - H T ia  and a 5 - H T ib  
antagonist, an SSRI plus a 5 - H T ib  antagonist, but not with a 5 - H T i a  or 5 - H T ib  antagonist 
alone. 5 - H T ib / id  autoreceptors could also be hypersensitised in depressive disorders, 
contributing to the pathology. If neuroendocrine findings have not shown 5 - H T ia  
hypersensitivity, it could be that 5 - H T ib / i d  autoreceptors alone have this enhanced 
activity in depression. It is therefore of significant interest to examine this 5 - H T ib / id  
autoreceptor function in depression, and examine the influence of antidepressant 
treatment on this function.
The postsynaptic function of 5 - H T ib / id  receptors could also play a role in the 
development of depression and its treatment and similarly would be useful to examine.
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TCAs and ECT have been shown to hypersensitise postsynaptic 5 - H T i a  receptors in rats 
(Blier et al. 1990), theoretically enhancing neurotransmission and giving a potential 
mechanism for their action. As described above, studies with sumatriptan in healthy 
human subjects have shown a reduction in PRL and temperature (suggested to be 
presynaptic mediated responses) and increased GH (suggested to be a postsynaptic 
mediated response) following its administration (Whale and Cowen 1998a). These 
responses are inconsistent in subjects however, likely due to the pharmacokinetics of 
sumatriptan. In depressed subjects the proposed presynaptic responses (PRL and 
temperature) have not been described so no conclusions have been drawn. The GH 
response has been shown to be blunted in depression however (Cleare et al. 1998b, 
Yatham et al. 1997a), suggesting reduced postsynaptic 5 - H T ib / id  receptor function, and 
consistent with the hypothesis of reduced 5 - H T  neurotransmission in depression. SSRI 
treatment for 16 days in healthy subjects did not change the PRL and temperature 
response to sumatriptan (Wing et al. 1996), suggesting no change in presynaptic 
5 - H T i b / id  receptor function with treatment. It is therefore of significant interest to use a 
5 - H T ib / i d  receptor probe with better brain penetration than sumatriptan, to examine 
whether the findings with sumatriptan can be more reliably replicated and examine the 
function of this receptor group at both pre and postsynaptic levels in depressed subjects 
and following antidepressant treatment. The introduction of zolmitriptan following 
sumatriptan offered an ideal opportunity to explore this area.
I also proposed to examine if the neuroendocrine responses to zolmitriptan could be 
isolated to either 5-HTiBor 5-HTid receptors. This is of potential importance if just one
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of these receptor groups is dysfunctional in depression, and could influence selective 
ligand testing for therapeutic benefits with potentially less side effects of dually acting 
ligands.
Aims of the citalopram studies
The withdrawal of fenfluramine for use in neuroendocrine challenges was a great loss, 
particularly since its neuroendocrine responses were reasonably reliable and it had been 
worked up to a high level, with good information on the mechanism of the endocrine 
responses (Newman et al. 1998). The other hypothesised tests of presynaptic function, or 
possible net 5-HT activity, are L-TRP, 5-HTP and clomipramine, as discussed above. 
L-TRP has some differing neuroendocrine responses to fenfluramine which may represent 
the difference between their receptor mediated effects (5-HTia and 5 -HT2 respectively), 
the responses to 5-HTP are inconsistent and clomipramine is not always well tolerated. 
There was therefore much interest in using other drugs as potential presynaptic probes. 
Citalopram would appear to have such potential as it acts presynaptically, is available for 
IV administration, and SSRIs are in general better tolerated than TCAs. Preliminary 
studies with citalopram 20mg IV did not indicate that it was well tolerated however 
(Seiffitz et al. 1996). I therefore set out to examine lower doses of citalopram to see if 
these had utility as a neuroendocrine probe with good tolerability and reliable hormonal 
responses. I then proposed to examine which receptors had influence in mediating the 
hormonal responses to citalopram and examine these responses in depressive disorder. As 
table 2.1 demonstrates, the responses to probes with similar actions on the 5-HT system 
or similar receptor mediated responses (direct or indirect), are not fully consistent. There
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is therefore much benefit to be gained by the introduction of further neuroendocrine 
probes to clarify which are common responses to these probes and further validate their 
interpretation.
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PART 2 
EXPERIMENTAL STUDIES
CHAPTER 3 
GENERAL METHODS
SELECTION AND RECRUITMENT OF SUBJECTS
Normal volunteers
Normal volunteers were selected from a volunteer register that had been compiled 
through newspaper advertisement and recruitment from blood transfusion donor sessions. 
They underwent a brief telephone screening to exclude those with any history of 
psychiatric disorder, or significant medical disorder. They were invited to the laboratory 
and a more detailed examination was undertaken. They received a Structured Clinical 
Interview for DSM-IV (SCID) to ensure that none met criteria for any Axis I psychiatric 
disorder on DSM-IV. A physical examination, routine blood tests (full blood count, urea 
and electrolytes, liver and thyroid function tests) and electrocardiogram were undertaken. 
Subjects were excluded if they had any abnormalities on these investigations, substance 
misuse, or used psychotropic medication within the last 3 months. All subjects were in 
the age range 18 to 65 years.
Depressed subjects
Patients were recruited from clinics set up in the primary care setting and secondary care 
outpatient clinics at the Wameford Hospital, Oxford. Patients were incorporated into 
studies if they met criteria for Major Depression on the basis of the SCID. It was noted 
whether they also fulfilled criteria for Major Depression with Melancholia (DSM-IV) (see
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appendix). Severity of depression was assessed using the HAMD (Hamilton, 1967) (rated 
by the investigator or a research nurse) and the self rated Beck Depression Inventory 
(BDI) (Beck et al. 1961). Patients were accepted whether they had recurrent depressive 
episodes or not. A period of being free from psychotropic medication for at least 2 weeks 
(6 weeks if they had been on fluoxetine) was ensured prior to starting the studies. They 
underwent physical examination and exclusion as appropriate, as described for normal 
volunteers.
Patients who received treatment as part of the studies were prescribed an SSRI (including 
venlafaxine at lower dose) for at least four weeks before rechallenging with the 
neuroendocrine probe. During the treatment, patients were monitored as in usual clinical 
care, at most on a weekly basis, with sessions lasting up to 30 minutes. If psychological 
treatment was necessary then this was restricted to supportive psychotherapy 
incorporating problem solving (Hawton 1989).
Controls for depressed subjects
Controls were taken from the group of normal volunteers and matched individually to 
depressed subjects for gender, menstrual status (stage of the menstrual cycle or 
postmenopausal), age (+/- 5 years), weight (+/- 5kg) and hormonal medication (eg. oral 
contraceptives, hormone replacement therapy).
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Consent
All subjects gave written informed consent to the studies that could be withdrawn at any 
stage throughout the investigation. These studies were approved by the local ethics 
committee.
GENERAL PROCEDURE FOR NEUROENDOCRINE STUDIES
Subjects were brought to the laboratory having fasted for at least four hours. An 
indwelling venous cannula was inserted and maintained with heparinised saline. Subjects 
rested for a period of 30 minutes before drug administration to allow any stress effects of 
getting to the laboratory and cannulation on the baseline hormone levels to be minimised. 
Blood samples were removed before and at regular intervals following drug 
administration at time ‘O’. Subjects remained at rest throughout the test procedure and 
were not allowed to eat or smoke. If thirsty they were given sips of water. It was ensured 
that subjects remained awake throughout the procedure as sleep influences hormonal 
secretion. Female subjects underwent neuroendocrine challenge only in the early 
follicular phase of their menstrual cycle (if they were menstruating). The follicular stage 
starts on the first day of menstrual bleeding and continues for 15 days. Oestrogen levels 
remain low up to around day 10. The results of a rechallenge with drug at a later occasion 
were therefore comparable to the first, with minimised influence of oestrogen on hormone 
levels (O’Keane et al. 1991).
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Study design
Subjects were recruited to double blind, randomised, balanced order, placebo controlled, 
cross over designed trials. Randomisation was carried out by an independent researcher 
by coin toss. This researcher dispensed drug or placebo into sealed envelopes, labelled 
with the trial day and subject code. This method of randomisation is criticised firstly due 
to problems with full concealment from the investigators. This was attained in these 
studies in terms of the randomisation code but investigators could obviously try to predict 
which arm the subjects were in from side effects experienced with the probes. Proving the 
validity of the coin toss as purely random, completely excluding human influence, is 
more difficult and ideally random number generators should have been used. To ensure 
reproducibility at the end of the trial and following publication, the randomisation code 
was recorded in a permanent document and stored in a sealed envelope in a filing cabinet.
Zolmitriptan test
The nature and use of zolmitriptan and reasons for the dose chosen in these experiments 
is described in detail in Chapter 4. Zolmitriptan tablets (Astra Zeneca) 5 mg or placebo 
were encapsulated and administered at time 0. Blood samples (10ml up to 20ml (if a 
plasma drug analysis was taken at that time point)) were removed from the cannula at 15 
minute intervals from 30 minutes before, up to 180 minutes after drug administration.
126
Citalopram test
The nature and use of citalopram is described in detail in Chapter 6. Intravenous 
citalopram (Lundbeck), 5mg or lOmg, was made up to 10ml with saline. Citalopram or 
placebo (10ml saline) were infused over a 30 minute period using a syringe driver. Blood 
samples (10ml to 20ml) were taken at 15 minute intervals from 30 minutes before, up to 
180 minutes after drug administration.
Monitoring of vital signs and side effects
The subjects’ well being was monitored closely throughout the tests. The intention at the 
start of the studies was to give subjects 100mm visual analogue scales (VAS) to rate the 
subjective experiences of dizziness, drowsiness and nausea at 30 minute intervals 
throughout the testing, anchoring 0 as the least and 100 as the most they have ever 
experienced these effects. Oral temperature was measured in some studies, at 30 minute 
intervals, with a glass mercury clinical thermometer that remained in situ for ten minutes.
If subjects reacted to drug administration in a manner that would skew hormonal results 
(such as extreme nausea or vomiting) they were excluded from further analysis.
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Plasma samples
Following removal from the cannula, blood samples were labelled and stored in lithium 
heparin bottles on ice until the end of the individual test period. Plasma was separated 
from the blood samples by centrifugation at 200g for 10 minutes at 4°C. Plasma samples 
were then frozen at -20 °C and stored until assay.
Biochemical assays
All assays were carried out by the laboratory staff of the Neuroscience Department, 
Wameford Hospital. Plasma PRL and GH were measured using standard 
immunoradiometric assays (reagents provided by Netria, London). The inter and intra 
assay coefficients of variation of the PRL assays over the range encompassed by the 
standard curve were 4.8% and 2.4%. The corresponding values for GH were 4.1% and 
2.6%. Because GH can inhibit its own secretion, we excluded subjects whose tests 
demonstrated elevated baseline GH secretion (>10 mIU/1) at time ‘O’.
Plasma CORT was determined by direct specific radioimmunoassay (RIA). The intra and 
inter assay coefficients of variation over the range encompassed by the standard curve 
were 4.3% and 5.8%.
ACTH was not measured during these studies as the laboratory did not have the necessary 
reagents available, although this would ideally have been undertaken as a more direct
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measure of hypothalamic / pituitary function than CORT.
Plasma drug levels were measured by a high performance liquid chromatography (HPLC) 
procedure that utilised coulometric end point detection, and solid phase extraction 
(Clement and Franklin 2002).
Analysis of samples from each individual at each time point was always carried out in 
the same assay to remove intra assay variation as a confounding variable from within 
subject analyses. Assays were carried out blind to subject diagnosis and treatment.
Analysis of results
All statistical analyses were carried out using SPSS for Windows (version 11). Hormone 
and temperature responses are shown graphically, plotted against time. Hormone change 
data following neuroendocrine challenge are displayed as area under the plasma 
concentration versus time curve (AUC), calculated by the trapezoid method using plasma 
hormone values with baseline scores subtracted. Hormonal responses and drug levels 
were also measured as peak change from baseline where appropriate and correlations 
between peak change and AUC examined. AUC is a useful, sensitive measure of 
hormonal response to a challenge which takes into account the magnitude and duration of 
the response, and reflects individual pharmacokinetic variation. Peak hormone response is 
less useful as it just measures magnitude. The AUC is less worthwhile using if responses 
are absent (as can occur with GH) and gives erroneous values for responses that vary
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above and below the baseline. Change in hormone response AUC (AAUC) between 
active drug and placebo challenges was calculated to give simpler statistics in studies 
with placebo arms comparing patients and controls.
Data was examined for normal distribution using the one sample Kolmogorov Smirnov 
test, before using parametric analyses. The results will only be shown for this test if data 
do not conform to normal distribution.
Comparison of data using raw, AUC and AAUC values was undertaken as appropriate 
using analysis of variance (ANOVA) both within subjects for repeated challenges (active 
drug vs placebo or active drug vs active drug if rechallenged after a period of time) and 
between subjects for comparison between different subject groups (depressed subjects vs 
controls). ANOVA assesses whether the means of results on different test days or 
between subjects are from the same normal distribution and have equal variances. 
ANOVA is a powerful statistical tool to test this but if data are correlated (termed 
‘sphericity is violated’) then the critical value of F is too low and therefore biases the 
result. This can occur in ANOVAs with 3 or more levels. Thus the Huyhn-Feldt 
correction was used in all calculations to remove this potential bias. ANOVAs on raw 
values were omitted if there were too many levels within the calculation that would bias 
the result. Post hoc testing following significant ANOVA results used Student’s paired 
and unpaired t tests (2 tailed). Graphically, Fisher’s test of least significant difference was 
used to show significant differences in data at different time points.
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Exploratory ANOVAs were used to examine main or interactive effects of order of 
administration of drug or placebo, or gender on the hormone responses.
Correlations between variables were assessed by Pearson’s product moment correlation 
(r). Post hoc power analyses were conducted as necessary using the statistical program 
NCSS (Hintze 2004).
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CHAPTER 4
THE ZOLMITRIPTAN CHAT J,ENGE IN NORMAL
SUBJECTS
132
THE NEUROENDOCRINE EFFECTS OF ZOLMITRIPTAN IN
NORMAL SUBJECTS 
INTRODUCTION
The release of various anterior pituitary hormones is under the control of 5-HT neurones 
and hormonal responses to selective 5-HT ligands provide a useful means of determining 
the sensitivity of distinct 5-HT receptor subtypes in humans (Cowen 1993), as discussed 
in Chapter 2. The triptan group of drugs (including sumatriptan, rizatriptan, naratriptan 
and zolmitriptan) have a high affinity for human 5 - H T ib  and 5 - H T id  receptors (Johnson 
et al. 1997) and have potential use as probes of the function of these receptors (as 
discussed in Chapter 2). Measurement of the sensitivity of 5 - H T ib  and 5 - H T id  receptors 
is of interest because they may be involved in the pathophysiology of major depression as 
well as mediation of the effects of antidepressant drug treatment (Briley and Moret 1998) 
(see aims of the thesis, chapter 2). For example, desensitisation of presynaptic 5 - H T ib  
receptors on 5-HT nerve terminals may be involved in the ability of SSRIs to increase 
5-HT neurotransmission (Moret and Briley 1990). In addition, administration of the 
selective 5 - H T i B receptor antagonist SB-224289 increased 5-HT release in the guinea pig 
dentate gyrus, which would be explained by antagonism of the presynaptic 5 - H T ib  
autoreceptor, suggesting possible antidepressant activity as a sole agent (Roberts et al. 
1998). Administration of a 5 - H T ib / id  receptor agonist such as sumatriptan or zolmitriptan 
could either reduce 5-HT secretion from the presynaptic area by agonism of the
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presynaptic autoreceptor or stimulate 5-HT neurotransmission by agonism of the 
postsynaptic membrane receptors. This would be reflected in a neuroendocrine paradigm 
by a reduction or increase in resultant hormonal secretion respectively.
The use of sumatriptan as a neuroendocrine probe is reviewed in Chapter 2. In summary, 
sumatriptan increases plasma GH in healthy men and women and can also lower plasma 
PRL, although this effect is less consistent (Herdman et al. 1994; Whale and Cowen 
1998a). A hypothermic effect of sumatriptan can occasionally be seen in humans (Wing 
et al. 1996). This suggests a potential ability to measure both pre and postsynaptic 
5 - H T ib / i d  mediated responses.
The purpose of the present study was to assess the effects of the more recently developed 
5-HTi b / i d  receptor agonist, zolmitriptan (Martin 1997), on plasma GH and PRL and on 
oral temperature in healthy volunteers. Zolmitriptan is of particular interest to study 
because it has greater brain penetration than sumatriptan (Martin 1997; Sleight et al. 
1990) and its neuroendocrine effects might therefore be expected to be elicited more 
reliably.
Zolmitriptan’s chemical structure is shown in figure 4.1. Zolmitriptan is indicated for the 
acute treatment of migraine. The recommended dose to treat such an event is 2.5mg, 
which can be increased to 5mg with beneficial effect if a subsequent ndgraine occurs 
within 24 hours. It is well tolerated, with typically mild to moderate adve. se reactions 
occurring within 4 hours of administration, which resolve spontaneously. The most
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common adverse reactions are nausea, dizziness, somnolence, warm sensation, asthenia 
and dry mouth. Associated cardiovascular changes are minimal and not clinically 
significant (Seaber et al 1996).
NH
ch3
Fig 4.1 The chemical structure of zolmitriptan.
Zolmitriptan has high affinity and full agonist activity at transfected human 5 - H T ib  and 
5 - H T id  receptors, with some preference for 5 - H T i d . Other than moderate affinity for 
5 - H T ia  and 5 -h t iE /F  receptors, the drug has no or negligible affinity at other receptor types 
(including other 5-HT receptors) (Martin 1997). The 5-HTi binding profile of 
zolmitriptan in comparison to sumatriptan is shown in table 4.1 (on page 154).
The antimigraine effects of zolmitriptan appear to be mediated by constriction of specific 
blood vessels (including cranial arteries), and inhibition of excitability of cells in the 
trigeminal nucleus caudalis via a reduction of the neurogenic inflammatory response 
causing protein extravasation. This reduction of trigeminal excitability reduces sensitivity 
to mechanical and chemical stimuli that would normally be processed as pain by higher
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centres (as reviewed by Martin 1997).
Zolmitriptan has a higher oral bioavailability than sumatriptan (40% and 14% 
respectively) and studies with triptans have shown that this correlates with increased 
brain penetration (Martin 1997). Zolmitriptan is rapidly absorbed, with peak plasma 
levels occurring at 2 to 4 hours, and has high plasma clearance, with a half life of 2.5 to 3 
hours (Seaber et al. 1996). It is largely eliminated by hepatic biotransformation followed 
by urinary excretion. It has three main metabolites, the indole acetic acid, the N-oxide and 
the N-desmethyl analogues. The latter metabolite has 5 - H T ib / id  receptor activity and is 
likely to contribute to the clinical effect. This metabolite has peak levels up to 45 minutes 
following the parent drug, with similar half life (Seaber et al 1996).
This profile of good oral bioavailability, well tolerated, reasonably selective receptor 
activity, peak levels within 4 hours and fast elimination render zolmitriptan an attractive 
drug for potential use as a neuroendocrine probe.
METHODS
Subjects
Twelve healthy subjects were studied (6 men and 6 women, mean age 34, range 18 to 46), 
recruited as described in Chapter 3. On the basis of a semi structured clinical interview 
they were determined to have no personal history of psychiatric disorder. They had taken
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no psychotropic medication for at least 3 months. Two women were taking the 
contraceptive pill, and one was taking hormone replacement therapy.
Neuroendocrine tests
Procedures are described in chapter 3. Subjects were tested on two occasions receiving 
either zolmitriptan (5mg orally) or identical placebo in a double blind, placebo controlled, 
cross over, balanced order design. This dose of zolmitriptan was chosen as it is a well 
tolerated, clinically effective dose for the treatment of migraine and corresponded with 
the clinically effective dose (for migraine) of subcutaneous sumatriptan (6mg) which also 
demonstrated a reasonable neuroendocrine response (Whale and Cowen 1998a). Test 
days were separated by a mean of 11.6 days (range 2 to 29). Female subjects were tested 
within the follicular phase of their menstrual cycle. Subjects were studied at midday after 
a four hour fast when an indwelling venous cannula was inserted. After a 30 minute rest 
period, zolmitriptan or placebo were administered and blood samples removed at 15 
minute intervals for the following 180 minutes. Oral temperature was measured at 30 
minute intervals with a glass mercury clinical thermometer that remained in situ for ten 
minutes.
Biochemical measurements
Assay methods are described in Chapter 3. The plasma zolmitriptan level assay was 
unfortunately not available at the time of this study but would have beoi ideally 
undertaken to control for pharmacokinetic variation between subjects.
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Analysis of results
Hormone and temperature responses were analysed using a two way repeated measures 
ANOVA with ‘occasion* (zolmitriptan vs placebo) and ‘time’ as the main within subject 
factors. Plasma GH responses were also measured as AUC using the trapezoid method 
and analysed using a paired samples t test.
RESULTS
Zolmitriptan was well tolerated. The mean peak VAS scores (total possible score 100) for 
nausea, dizziness and drowsiness were 2, 5 and 9 on zolmitriptan test days and 0, 0 and 7 
on placebo test days respectively (ANOVAs of all measures between tests days were non 
significant with p values >0.2) . The number of subjects reporting no change in nausea, 
dizziness and drowsiness on the zolmitriptan challenge day was 10, 9 and 6 respectively. 
Three subjects were excluded from the GH analysis because at least ore of their baseline 
GH levels at time ‘0* was high. Following zolmitriptan, but not placebo, there was a 
marked increase in plasma GH (Fig 4.2). The two way ANOVA of individual GH data 
points showed a significant main effect of occasion (F= 14.27; df 1,8; p= 0.005) and time 
(F= 5.49; df 4, 29; p= 0.003) with a significant occasion by time interaction (F= 5.62; df 
3,25; p= 0.004). The peak GH response occurred between 60 and 120 minutes (Fig 4.2). 
Eight subjects had a clear GH response to zolmitriptan above 5mIU/l and the other 
subject had no response at all.
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Mean ± SEM GH AUC values on zolmitriptan and placebo test days were 24.8 ± 6.9 and 
-1.1 ± 1.5 mIUxHr/1 respectively (p=0.009). GH AUC values were highly correlated with 
peak GH change from baseline (r= 0.95; p= 0.001). Corresponding mean ± SEM peak 
GH positive change from baseline was 16.1 ± 6.0 mIU/1 and 0.4 ±1.0 mIU/1 respectively.
In contrast, zolmitriptan did not alter plasma PRL concentration relative to placebo (Fig 
4.3). The ANOVA showed no main effect of occasion (F= 0.14; df 1,11; p=0.72) but a 
significant effect of time (F= 9.19; df 3, 30; p< 0.001). However, there was no occasion 
by time interaction (F= 0.84; df 3, 38; p=0.49). Similarly there was no significant change 
in oral temperature following zolmitriptan, although from Fig 4.4 it is observed that mean 
temperature appeared lower on the zolmitriptan test days. This ANOVA showed no main 
effect of occasion (F= 2.71; df 1, 11; p= 0.13), or of time (F= 1.47; df 4,41; p= 0.23) and 
no occasion by time interaction (F= 1.39; df 5, 51; p= 0.25).
Sex of subject had no significant effect as a covariate in the two way ANOVA of 
hormone responses (for GH response, p=0.85). Mean peak ± SEM GH response on 
zolmitriptan test days for men and women was 22.4 ± 5.9 mIU/1 and 24.5 ± 11.7 mIU/1 
respectively. Order of administration of zolmitriptan or placebo similarly had no 
significant effect as a covariate in the two way ANOVA of hormone responses (for GH 
response, p=0.50).
These results are discussed following the next section on defining the mode of action of 
the GH response.
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Fig. 4.2 Mean ± SEM plasma GH concentrations in 9 healthy volunteers following 
administration of zolmitriptan (5mg orally) (open squares) and placebo (closed circles). 
Subjects were tested on two occasions in a double blind, cross over design. *p<0.05, 
**p<0.01 (Fisher’s test of least significant difference).
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Fig. 4.3 Mean ± SEM plasma PRL concentrations in 12 healthy volunteers following 
administration of zolmitriptan (5mg orally) (open squares) and placebo (closed circles). 
Subjects were tested on two occasions in a double blind, cross over design. No statistical 
difference between the two tests is observed (ANOVA).
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Fig 4.4 Mean ± SEM oral temperature in 12 healthy volunteers following administration 
of zolmitriptan (5mg orally) (open squares) and placebo (closed circles). Subjects were 
tested on two occasions in a double blind, cross over design. No statistical difference 
between the two tests is observed (ANOVA).
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DEFINING THE MODE OF ACTION OF THE NEUROENDOCRINE 
RESPONSE TO ZOLMITRIPTAN
INTRODUCTION
Having established the neuroendocrine properties of zolmitriptan, elucidating which 
receptor/s are involved in the mediation of the GH response is the next priority in 
developing a useful neuroendocrine probe. Zolmitriptan has highest affinity for 5 - H T ib  
and 5-HTm receptors, with moderate preference for 5 - H T i D (Martin 1 9 9 7 ,  Table 4 . 1 ) .  
These receptors have likely differing brain location and function (as described in Chapter 
1). Several antagonist drugs have activity which can be used to discriminate between 
5 - H T ib  and 5 - H T id  receptors, including the classical 5-H T 2 A  receptor antagonist and
ai adrenoceptor antagonist ketanserin, and the 5-HT2A/2C receptor antagonist ritanserin. 
Ritanserin was not available for use at the time of this experiment. In vitro and in vivo 
studies in animals show that ketanserin blocks the human 5 - H T id  receptor with some 
preference over the 5 - H T ib  receptor (Pauwels et al. 1996). With recombinant human
5 - H T id  and 5 - H T ib  receptors, ketanserin has moderate affinity for 5 - H T id  (pKi = 7.17) 
and 71 fold selectivity for recombinant human 5 - H T id  over 5 - H T ib  receptors (Zgombick 
et al. 1995). The affinity of ketanserin for 5 -HT2 receptors is 5 times greater than for NA 
and histamine receptors and 100 times greater than for DA receptors (Leysen et al. 1981).
Sharpley et al. (1994) used ketanserin 40mg orally in a study of the effect of blocking
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5 -HT2 receptors on slow wave sleep in humans, demonstrating that it does indeed 
enhance slow wave sleep (although not as effectively as ritanserin) and was well 
tolerated.
Ketanserin has been used for the treatment of arterial hypertension although is not 
currently licensed for such treatment in the UK (Electronic medicines compendium). The 
commonly used dose is 40mg twice daily. Following oral administration more than 98% 
is rapidly absorbed and peak plasma levels are reached within 0.5 to 2 hours. 
Bioavailability is around 50%. Due to a high level of plasma protein binding, the free 
fraction is 5%. Ketanserin is primarily metabolized by ketone reduction, and subsequently 
excreted in the urine. This metabolite does not add to ketanserin’s pharmacological effect. 
The terminal half life of oral ketanserin is 14.3 hours. Ketanserin’s pharmacokinetics are 
not influenced by age or sex. Plasma levels are higher in severe liver disease. There have 
besn no clear reports of influence on the metabolism of coadministered drugs. The only 
common side effects at usual therapeutic doses are sedation (mediated via histamine 
receptor antagonism) and reduced saliva production. Higher doses have been associated 
with cardiac QT interval prolongation (reviewed by Persson et al. 1991).
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METHODS
Subjects
Six healthy male subjects we recruited from the volunteer register (mean age 36, range 26 
to 44) as described in Chapter 3. One subject took part in both this study and the above 
zolmitriptan / placebo study. It was acknowledged that this was a small sample but such 
numbers were adequate in other studies which examined block of neuroendocrine 
responses (eg. Lewis and Sherman 1985) and it was predicted that if the large, robust GH 
response was purely mediated by 5 - H T id  receptors then even a small amount of receptor 
blockade would reflect a GH change that could be picked up with this sample.
Neuroendocrine tests
Subjects were brought to the laboratory at midday after a 4 hour fast. Each subject was 
studied on two occasions, receiving either zolmitriptan 5mg plus ketanserin 40mg, or 
zolmitriptan 5mg plus placebo, in a double blind, cross over, balanced order design. This 
dose of ketanserin was chosen due to the tolerability demonstrated by Sharpley et al. 
(1994), which produced near maximal blockade of brain 5-HT2A receptors. An indwelling 
venous cannula was inserted and ketanserin or placebo was given at -60 minutes to ensure 
optimum plasma ketanserin levels at the time of peak GH response to zolmitriptan. 
Zdmitriptan was administered at time ‘O’. Blood samples were removed at 15 minute 
intervals from -60 minutes to 180 minutes. Plasma samples for zolmitriptan levels were 
taken at 30 minute intervals, to examine any effect of ketanserin on zolmitriptan levels.
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Subjects remained at rest throughout the test procedure. Test days were separated by a 
mean of 28.5 days (range 14 to 61).
Biochemical Measurements and Analysis of Results
Plasma zolmitriptan levels were measured by HPLC (Clement et al. 2002).
Plasma GH and zolmitriptan levels were analysed using a two way repeated measures 
ANOVA with ‘occasion’ (ketanserin vs placebo) and ‘time’ as the main within subject 
factors. AUC values for GH and zolmitriptan levels were also calculated and analysed 
with paired t tests.
RESULTS
All subjects tolerated the drug challenges well with no associated significant adverse 
events. VAS scales were unfortunately not consistently used. Zolmitriptan induced GH 
responses were lower following ketanserin pretreatment (Fig 4.5). The two way ANOVA 
of GH responses showed a main effect of occasion (F= 11.07; df 1, 5; p= 0.021) and time 
(F= 5.89; df 3,16; p= 0.007) but only a trend to a significant occasion by time interaction 
(F= 2.61; d f 4 ,18; p= 0.074).
The mean ± SEM AUC GH response was 32.4 ± 9.9 mIUxHr/1 to zolmitriptan alone and 
13.3 ± 6.4 to zolmitriptan with ketanserin, for paired t test p= 0.013, (corresponding
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mean ± SEM peak GH response was 27.8 ±8.1 mIU/1 and 16.1 ± 7.3, p=0.015). The 
ANOVA of AUC GH response was significant between test days (F= 14.51; df 1, 5; 
p= 0.013), with a power of 0.86 (a being set at 0.05). Hence despite a small sample size, 
this comparison had sufficient statistical power to demonstrate a difference between test 
days.
Plasma zolmitriptan levels tended to be lower after ketanserin treatment although not 
significantly so (Fig 4.6). The two way ANOVA of zolmitriptan levels showed no main 
effect of occasion (F= 2.86; df 1, 5; p= 0.15) but a significant effect of time (F= 8.74; df 
3, 15; p= 0.001). However there was no occasion by time interaction (F= 1.26; df 4,19; 
p= 0.32).
Mean ± SEM AUC zolmitriptan levels following ketanserin were 6.2 ±1.8 pgxHr/ml 
compared to 10.1 ± 3.2 pgxHR/ml following placebo, p= 0.13, (corresponding mean ± 
SEM peak zolmitriptan levels were 4.35 ±1.1 pg/ml and 5.64 ±1.3 pg/ml, p= 0.35).
To account for the effect of the variance of zolmitriptan levels on the GH levels, 
zolmitriptan level AUC values were regressed on the GH AUC values for each treatment 
arm and the residualised scores for GH AUC were entered into an ANOVA. A significant 
effect of occasion (placebo vs ketanserin) was observed (F=46.61; df 1, 5; p=0.001). 
Hence, despite zolmitriptan levels being lower in the ketanserin arm of the study, the 
effect of ketanserin on the GH response remained significant.
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Fig. 4.5 Mean ± SEM plasma GH concentrations in 6 healthy men following 
administration of zolmitriptan (5mg orally) with placebo (open square) and zolmitriptan 
(5mg orally) with ketanserin (40mg) (solid square). Subjects were tested on two 
occasions in a double blind, cross over design. *p<0.05, **p<0.01 (Fisher’s test of least 
significant difference).
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Fig. 4.6 Mean ± SEM plasma zolmitriptan levels in 6 healthy men follov ing 
administration of zolmitriptan (5mg orally) with placebo (open square) and zolmitriptan 
(5mg orally) with ketanserin (40mg) (solid square). Subjects were tested on two 
occasions in a double blind, cross over design. No significant difference was observed 
(ANOVA).
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DISCUSSION OF ZOLMITRIPTAN STUDIES IN HEALTHY
SUBJECTS
Zolmitriptan increased plasma GH in healthy men and women but had no effect on 
plasma PRL or body temperature. The GH response to zolmitriptan was attenuated by 
ketanserin suggesting that it may be mediated by 5 - H T id  receptors (Pauwels et al. 1996).
The ability of zolmitriptan to increase plasma GH is also shared by sumatriptan and 
rizatriptan (Herdman et al. 1994; Sciberras et al. 1997). This suggests that the induction 
of GH release maybe a class property of 5 - H T ib / id  receptor agonists. Zolmitriptan has a 
better blood brain barrier penetration than sumatriptan (Martin 1997; Sleight et al. 1990), 
which raises the possibility that it may produce more reliable increases in plasma GH.
The neuroendocrine properties of sumatriptan and zolmitriptan are compared in table 4.1.
Comparison of zolmitriptan and sumatriptan in this respect is difficult because of the 
problems of comparing two drugs with somewhat differing receptor affinities as well as 
contrasting pharmacokinetic properties. With these reservations, the GH response to 
sumatriptan in healthy male and female volunteers from 6 earlier studies (where data was 
available) were examined (Herdman et al. 1994; Wing et al. 1996; Boeles et al. 1997; 
Yatham et al. 1997a; Cleare et al. 1998b, Whale and Cowen 1998a). When all these 
studies are taken together, 25 of 49 subjects showed a GH response to sumatriptan greater
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than 5mIU/l. In contrast, in the present study, 12 of 14 subjects had GH responses to 
zolmitriptan above this threshold (p=0.02, chi squared test). This provides tentative 
evidence that zolmitriptan may induce more reliable GH release than sumatriptan, at 
tolerated doses, and may be a more reliable neuroendocrine probe.
Gender did not influence the GH responses to zolmitriptan in these studies, unlike other 
studies examining 5-HT function including the sumatriptan challenge (Whale and Cowen 
1998), the fenfluramine challenge (Newman et al. 1998), L-TRP challenge following 
dieting (Anderson et al. 1990b) and TRP depletion (Smith et al. 1997a).
The GH response to zolmitriptan was significantly antagonised by pretreatment with the 
5-HT receptor antagonist, ketanserin. Ketanserin is primarily a 5-HT2A receptor 
antagonist that is also able to block the human 5 - H T id  receptor with some preference 
over the 5 - H T ib  receptor (Zgombick et al. 1 9 9 5 ;  Pauwels et al. 1 9 9 6 ) .  Our findings 
therefore tentatively suggest that the GH response to zolmitriptan is mediated by 5 - H T i D 
receptors.
The possibility, however, that some other pharmacological property of ketanserin may be 
responsible for the attenuation of zolmitriptan induced GH release cannot be excluded. 
Against this is the fact the zolmitriptan has no significant affinity for the 5-HT2A receptor 
(Martin 1996). In addition ketanserin did not antagonise the GH response to insulin 
hypoglycaemia suggesting that it does not produce a generalised reduction in stimulated 
GH release (Prescott et al. 1984). Ketanserin’s lesser activity as an a and histamine
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receptor antagonist would otherwise predict an inhibition of GH secretioi. (Muller et 
al.1999). Another relevant factor was that plasma levels of zolmitriptan tended to be 
lower in combination with ketanserin although allowing for this in a regression analysis 
did not remove the significant effect on GH responses. However, this possible 
pharmacokinetic effect of ketanserin as well as the small number of subjects studied 
means that conclusions concerning the role of 5 - H T i d  receptors in zolmitriptan induced 
GH release must remain tentative. The study was sufficiently powered to show a 
difference in the GH AUC analysis. Hopefully future studies will be able to employ more 
selective 5 - H T id  receptor antagonists to examine this question.
Despite its effective stimulation of GH release, no effect of zolmitriptan on plasma P R L  
was found. Administration of sumatriptan to healthy men and women at midday lowers 
plasma P R L  and this has been tentatively ascribed to the activation of 5 - H T ib  
autoreceptors on 5-HT nerve terminals (Herdman et al. 1994; Whale and Cowen 1998). 
The fact that zolmitriptan failed to produce this effect could suggest that an ability to 
lower plasma P R L  is a idiosyncrasy of sumatriptan rather than a property of 5 - H T i b / id  
receptor agonists in general. Another possibility, however, is the differential binding 
affinity of sumatriptan and zolmitriptan for 5 - H T i b  and 5 - H T id  receptors (Table 4.1). 
Whereas zolmitriptan has a moderate preference for 5 - H T i d  over 5 - H T ib  receptors, 
sumatriptan has a more equal binding affinity for the two receptor subtypes (Martin
1997). This raises the possibility that, at clinically used doses, zolmitriptan does not 
produce sufficient activation of presynaptic 5 - H T i b  receptors to lower plasma P R L .
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There have been few published reports on the effects of triptans on body temperature but 
there is evidence that activation of presynaptic 5 - H T ib  receptors causes hypothermia in 
guinea pigs (Hagan et al. 1997). In one study in humans, a modest lowering of oral 
temperature following sumatriptan administration was found (Wing et al. 1996). In the 
present study, graphically mean temperature responses appeared lower following 
zolmitriptan but this was not a statistically significant reduction, perhaps supporting the 
proposal that at doses used to treat migraine, zolmitriptan does not activate 5 - H T ib  
receptors in the human brain.
In conclusion this study supports the ability of 5 - H T ib / id  receptor agonists to increase 
plasma GH in humans and tentatively suggests that the pharmacological mechanism 
involves activation of 5 - H T id  receptors. 5 - H T id  receptors are located both 
postsynaptically (Bonaventure et al. 1997) and probably presynapticali /  in the raphe 
nucleus where they function as autoreceptors (Pineyro et al. 1995). Because increases in 
5-HT neurotransmission are associated with increased GH release in humans it suggests 
that the GH response to zolmitriptan and other triptans is mediated via activation of 
postsynaptic 5 - H T i D receptors probably located in the hypothalamus. Zolmitriptan does 
not appear to be a probe for presynaptic receptors. Overall it appears to be a useful 
neuroendocrine probe, increasing GH secretion most likely via postsynaptic 5-HTm 
receptor stimulation, and a more reliable inducer of GH release than sumatriptan which is 
the 5 - H T ib / id  receptor probe previously utilised in neuroendocrine challenge tests in 
depressed patients.
153
Teble 4.1 Comparisons of neuroendocrine effects and 5-HTi receptor affinity (adapted 
ffcm Martin 1997) for sumatriptan and zolmitriptan.
Neuroendocrine Response Sumatriptan Zolmitriptan
PRL i 0
GH t t t
TEMP i 0
Receptor affinity * Sumatriptan Zolmitriptan
5-HTia 7.0 6.5
5-HT1b 8.1 8.3
5-HTid 8.5 9.2
5-HT1e 5.6 <5.0
5-HT1f 7.6 7.1
* leceptor affinity figures are pKA at human receptors.
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CHAPTERS
THE ZOIMITRIPTAN CHALLENGE IN DEPRESSED 
PATIENTS AND THE EFFECT OF ANTIDEPRESSANT
TREATMENT
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INTRODUCTION
There is much evidence that impaired 5-HT neurotransmission contributes to the 
pathophysiology of major depression (see Chapter 1) but the precise nature of this 
abnormality, particularly in terms of the function of specific 5-HT receptor subtypes, is 
unclear. Current clinical data in this field are sparse because of the limited availability of 
selective probes for the various 5-HT receptors. Nevertheless, pharmacological challenge 
studies have suggested that the function of 5-HTia receptors is impaired in depressed 
patients (Cowen et al. 1994; Lesch 1992; Meltzer and Maes 1995; Sargent et al. 1997b), 
particularly in those whose symptoms meet criteria for melancholic depression.
As demonstrated in Chapter 4, the administration of zolmitriptan increases plasma GH, 
apparently mediated by activation of postsynaptic 5-HTm receptors. The aim of the 
present study was to use this GH response to zolmitriptan to assess the sensitivity of 
postsynaptic 5-HTm receptors in patients with major depression before and following 
treatment with SSRI antidepressants. On the basis of changes found in postsynaptic 
5 - H T ia  receptors in depression, I predicted that postsynaptic 5 - H T i d  receptor function 
would be decreased in depressed patients, especially those with melancholic symptoms, 
and would be further diminished by SSRI treatment (Cowen and Charig 1 9 8 7 ;  Lesch 
1 9 9 2 ) .  Following the findings of chapter 4, it did not appear possible to examine 
presynaptic 5 - H T ib / i d  function with zolmitriptan as discussed in the aims in chapter 2 .
156
METHODS
Subjects
Twenty six patients were recruited (10 men and 16 women) from clinics in primary care 
who on the basis of the SCID met criteria for Major Depression (as discussed in Chapter 
3). Their mean age was 37.9 years (range 21 to 54 years) and mean weight 70.0 kg (range 
51 to 96 kg). Fourteen subjects had never received psychotropic medication; the 
remainder had not received psychotropic medication for at least 2 weeks (mean 75 
weeks). One woman was taking the oral contraceptive pill, two were postmenopausal, and 
one was taking hormone replacement therapy. Depressed subjects had a mean score on 
the HAM-D scale of 24.9 (range 16 to 39). Ten subjects met DSM-IV criteria for major 
Depression with Melancholia (see appendix).
A group of 25 healthy controls were selected from the volunteer register, and matched to 
the patient group as described in Chapter 3. This group consisted of 9 men and 16 women 
with mean age 39.9 years (range 23 to 54 years) and mean weight 71.5kg (range 56 to 102 
kg). Controls had been free of psychotropic medication for at least 3 months.
Neuroendocrine tests
Methods are described in chapter 3. Subjects were brought to the laboratory in the 
morning having fasted for at least four hours. An indwelling venous cannula was inserted
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and a 30 minute rest period allowed to elapse before, zolmitriptan (5mg orally), was 
administered. Blood samples were then removed at 15 minute intervals for a further 180 
minutes. The placebo arm used in the studies described so far was omitted in this study 
due to the robust, reliable GH increase over placebo, as demonstrated above.
A sub group of 12 patients (3 men, 9 women) were rechallenged with zolmitriptan (5mg 
orally) following a trial of SSRI treatment of mean duration 33.9 days (range 27 to 76 
days). Of this group, 7 patients received fluoxetine (20mg daily, except one subject who 
took 20mg on alternate days), 3 paroxetine (20mg), 1 citalopram (20mg) and 1 
venlafaxine (150mg daily). At such a lower dose, venlafaxine appears to be 
predominately a 5-HT reuptake blocker (reviewed by Frazer 2001). Six healthy controls, 
similarly from the volunteer register, (4 men, 2 women) were also challenged twice with 
zolmitriptan (5mg orally), to examine the effect of repeated exposure to zolmitriptan on 
the GH response in untreated control subjects and ensure that rechallenge alone did not 
influence GH responses (as seen with the PRL response to rechallenge with clomipramine 
at 2 weeks; Gilmore et al. 1993). The mean interval between these two tests was 28.2 
days (range 23 to 35 days). In both these studies female subjects received the second 
zolmitriptan challenge at the same stage of the menstrual cycle as the first. It is 
acbiowledged that these two rechallenge groups were not matched for age and sex but a 
direct comparison was not the intention of this study. Sex was shown pot to influence the 
GH response to zolmitriptan in the previous studies.
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Biochemical measurements 
Assay methods are described in Chapter 3.
Analysis of results
GH responses and plasma zolmitriptan levels were analysed as AUC calculated using the 
trapezoid method. AUC GH was highly correlated with peak GH change from baseline 
(r=0.94, p<0.001). Baseline CORT and GH were measured as mean concentration from 
the 3 baseline sample levels.
Patient / control differences were analysed using repeated measures ANOVA with ‘time’ 
as the within subject factor and ‘depression’ (presence or absence) as a between subjects 
factor and a one way ANOVA of AUC data was conducted with ‘depression’ as the 
between subjects factor. Post hoc differences between patients and controls were 
examined with Student's unpaired t test (two tailed). Within group comparisons were 
made using Student’s paired t test (two tailed). Correlations were carried out using 
Pearson’s product moment. Data from subjects rechallenged with zolmitriptan were 
analysed using a two way repeated measures ANOVA.
RESULTS
All subjects tolerated zolmitriptan well. VAS for subjective effects were not consistently 
used. High baseline GH levels led to 3 patients (one with melancholia) and 2 controls
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being excluded. In the overall group of patients, mean ± SEM AUC GH did not 
significantly differ from those of controls, 5.9 ± 4.7 mIUxHr/1 compared to 15.8 ± 4.0 
mIUxHr/1, p= 0.12, (mean ± SEM peak GH responses 11.8 ± 3.4 compared to 16.3 ±3.4 
mIU/1, p= 0.36). The repeated measures ANOVA showed a main effect of time (F=l 1.69; 
df 14, 616; p<0.001) but no ‘depression’ by time interaction (F=0.62; df 14, 616; p=0.85). 
The one way ANOVA similarly showed no significant effect of ‘depression’ (F=2.58; df 
1,44; p= 0.12). Sex of subjects was not a significant covariate in the repeated measures 
ANOVA (p= 0.73). Three subjects described recent weight change: two weight gain (one 
of whom was melancholic) and one weight loss, with respective peak GH responses of 
16.3, 0.5 and 20.2 mIU/1. The influence of duration of illness, and previous treatment 
could not be examined as it was not systematically recorded.
When the patients were divided into those with and those without the melancholic 
syndrome, however, the GH responses of patients with melancholic depression were 
significantly less than controls (Table 5.1 and Figs 5.1, 5.2, 5.3). The mean ± SEM AUC 
GH response in the 9 melancholic patients was significantly less when they were directly 
compared with 9 controls matched for gender, age and weight, -1.2 ± 3.5 mIUxHr/1 
compared to 22.0 ± 7.3 mIUxHr/1, p=0.015 (mean ± SEM peak GH 4.5±1.3 compared to 
20,1± 5.9 mIU/1, p=0.03) (Fig 5.3). In figure 5.1, peak GH response is shown as opposed 
to AUC for visual clarity. The repeated measures ANOVA for this group showed a main 
effect of time (F=6.25; df 14, 224; p=0.002), a significant depression by time interaction 
(F=4.17; df 14, 224; p=0.014) and a significant effect of depression (F=6.63; df 1,16; 
p=3.02). The one way ANOVA also showed a significant effect of depression (F=8.20; df
160
1,16; p=0.011). As for the whole group, no influence of sex as a covariate in the repeated 
measures ANOVA of melancholic subjects was observed (p= 0.51).
Neither patient group differed from controls in baseline CORT concentration. Similarly, 
AUC of plasma zolmitriptan did not differ between patient groups and controls (Table 
5.1). In patients there was no significant correlation of AUC GH with AUC plasma 
zolmitriptan levels, baseline CORT concentration or HAM-D score, (r=0.17, p=0.45; 
r=0.12, p=0.58; r=-0.20, p=0.36 respectively). Similarly, there was no significant 
correlation of AUC GH with AUC zolmitriptan levels or baseline CORT concentration in 
controls (r=-0.25, p=0.26; r=0.32, p=0.14 respectively).
In the 12 patients who were rechallenged with zolmitriptan after SSRI treatment the AUC 
GH response was significantly attenuated: 11.2 ± 5.9 compared to -6.1 ± 2.9 mIUxHr/1, 
p=0.005, (mean ± SEM peak GH 14.2 ± 4.8 compared to 1.9 ± 0.7 mIU/1, p=0.024; Fig 
5.4). The repeated measures ANOVA showed no main effect of occasion (pre or post 
treatment) (F=4.37; df 1, 11; p=0.061), but a significant main effect of time (F=3.18; df 
14, 154; p<0.001) and a significant occasion by time interaction (F=5.32; df 14,154; 
p<0.001) (Fig 4.4). The mean ± SEM AUC of zolmitriptan levels was not significantly 
altered by SSRI treatment (9.8 ±1.4 ngxHr/ml compared to 10.8 ±1.4 ngxHr/ml, p=
0.45). The mean fall in HAM-D was 7.9. Five of the patients were responders as judged 
by a 50 per cent decline in HAM-D score. There was no correlation between fall in 
HAM-D and change in peak or AUC GH response to zolmitriptan (r=0.18, p=0.57 and 
r=-0.10, p=0.98 respectively).
161
Of this treated group, 5 subjects had major depression with melancholia, with responses 
similar to the whole group. Their mean ± SEM peak GH response fell from 6.6 ± 1.3 to 
0.8 ± 0.7 mIU/1 (p= 0.019 ), and HAM-D scores fell a mean of 5.2 points, although only 
one subject had at least 50% decline in HAM-D scores.
In the group of healthy controls who were tested on two occasions there was no 
significant difference between the AUC GH response to the first zolmitriptan challenge 
and the second: 15.7 ± 10.1 and 19.8 ± 14.2 mIUxHr/1, p=0.42 (mean ± SEM peak GH 
16.9 ± 7.6 compared to 17.3 ± 8.9 mIU/1, p=0.81). The repeated measures ANOVA 
showed no main effect of occasion (F=3.49; df 1, 5; p=0.12), no effect of time (F=1.06; 
df 14, 70; p=0.40) and no significant occasion by time interaction (F=0.64; df 14, 70; 
p=0.82) (Fig 5.5).
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Table 5.1 Mean ± SEM baseline CORT, peak and AUC GH, AUC plasma zolmitriptan 
level and HAM-D score in three groups of subjects undergoing zolmitriptan challenge.
Controls 
n = 23
Depressed 
Non melancholic 
n = 14
Depressed 
Melancholic 
n = 9
Baseline CORT 
(pg/lOOml)
23.8 ±2.5 23.8 ±2.0 20.8 ±2.6
Baseline GH 
(mIU/1)
3.1 ±0.9 4.7 ±1.1 4.3 ±1.1
AUC GH 
(mlUxHr/1)
15.8 ±4.0 10.5 ±7.3 -1.2 ±3.5*
A Peak GH 
(mlU/1)
16.3 ±3.4 16.5 ±5.2 4.5 ±1.3*
AUC Zolmitriptan 
level (ngx Hr/ml)
10.3 ±1.5 9.8 ±1.5 10.4 ±1.9
HAMD score 24 (± 1.3) 26 (±2.4)
* p < 0.05 (independent samples t test in comparison to individually matched 
control group).
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Figure 5.1 Peak GH response over baseline following zolmitriptan (5mg orally) in 
depressed patients and controls. The responses of the patients with melancholic syndrome 
are significantly less than the controls (p<0.05, unpaired t test).
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Figure 5.2 Mean ± SEM GH response following zolmitriptan 5mg at time ‘0’ in 14 non 
melancholic depressed patients (open inverted triangles) compared with matched controls 
(open squares). No significant difference is observed between the two groups (ANOVA).
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Figure 5.3 Mean ± SEM GH response following zolmitriptan (5mg) at time ‘O’ in 9 
melancholic depressed patients (closed inverted triangles) compared with matched 
controls (open squares). **p<0.01 (Fischer’s test of least significant difference).
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Figure 5.4 Mean ± SEM GH concentration in 12 depressed patients tested on two 
occasions, before (open inverted triangles) and after (closed inverted triangles) SSRI 
treatment (interval of mean 33.9 days). Patients received zolmitriptan (5mg orally) at time 
‘O’. *p<0.05, **p<0.01 (Fischer’s test of least significant difference).
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Figure 5.5 Mean ± SEM GH concentration in 6 healthy subjects teste*? on two occasions 
(mean 28.2 days interval), before (open squares) and after (closed squarer). Subjects 
received zolmitriptan (5mg orally) at time ‘O’. No significant difference between the two 
groups is observed (ANOVA).
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DISCUSSION
These findings indicate that the GH response to zolmitriptan is impaired in patients with 
major depression and melancholia. In patients treated with SSRIs, the GH response to 
zolmitriptan was markedly attenuated suggesting an adaptive desensitisation of the 5-HT 
mechanisms involved in zolmitriptan induced GH release. In normal subjects 
rechallenged with zolmitriptan (without SSRI administration), no such desensitisation 
was observed.
This blunted GH response to zolmitriptan in depressed subjects could be explained by 
high CORT levels, as seen in some depressed subjects (Carrol et al. 1981), inhibiting the 
secretion of GH (Goodwin et al. 1992). There was however, no significant difference 
between baseline CORT in patients and controls (including melancholic patients), 
excluding the possibility of this effect. GH responses in depressed subjects do not appear 
to be blunted in general, as the GH response to GnRH (Amsterdam et d . 1982) and 
buspirone in melancholic subjects (Cowen et al. 1994) is not different frc m healthy 
controls.
The finding of blunted GH responses to zolmitriptan in patients with melancholic 
depression are similar to those of challenge studies using 5-HTia receptor ligands where 
blunted endocrine and thermic responses are particularly apparent in melancholic subjects 
(Cowen et al. 1994; Lesch 1992). Two other studies have reported blunted GH responses 
to sumatriptan in patients with major depression (Cleare et al. 1998b; Yatham et al.
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1997a), giving greater confirmation that 5 - H T ib /d  receptor agonists have this effect, 
although results of sumatriptan challenge are difficult to interpret because of the number 
of healthy subjects who fail to produce useful GH responses (as discussed above). 
Yatham et al. (1997b) also found a blunted GH response to sumatriptan in patients with 
SAD in comparison to controls, implying that this disorder (and possible depressive 
disorder subtype) is also associated with impaired 5 - H T i b /d  receptor function.
These findings from challenge studies with directly acting 5-HT receptor agonists in 
depressed patients differ from those obtained with the 5-HT precursor, L-TRP, where 
endocrine responses are blunted in both melancholic and non melancholic subjects 
(Cowen and Charig 1987). This suggests that whereas depressed patients in general may 
have impaired presynaptic release of 5-HT, patients with melancholia may additionally 
exhibit impaired sensitivity of postsynaptic 5-HT receptors. This would be expected to 
result in a larger decrement in overall 5-HT neurotransmission. The findings of a reduced 
PRL response to clomipramine (Anderson et al. 1992b) and fenfluramine (Newman et al.
1998) in melancholia could also reflect such a further reduction in overall 5-HT 
neurotransmission. This could increase the severity of depressive symptoms or induce 
features particularly observed with the melancholic syndrome. Symptoms such as 
significant sleep disturbance, weight loss and psychomotor agitation (see appendix) are 
known to be particularly influenced by 5-HT (as discussed in chapter 1) which would fit 
wilh this hypothesis. The finding of a reduced placebo response in melancholic subjects 
(Pcselow et al. 1992) and some reports of a greater response rate to antidepressant 
treatment (eg. Heiligenstein et al. 1994) also appears consistent with a greater overall
170
reduction in 5-HT neurotransmission. Reduced plasma TRP has also been associated with 
melancholia (Maes et al. 1987b), potentially reducing brain TRP availability for 
subsequent 5-HT production, but reduced plasma TRP is also observed with weight loss 
(Anderson et al. 1990b), confounding this finding.
The possible contribution of impaired postsynaptic 5 - H T id  receptor sensitivity to the 
depressive syndrome is unclear because there are few known functional correlates of 
5 - H T id  receptor activation in animals or humans. High densities of postsynaptic 5 - H T id  
receptors are found in basal ganglia, which might indicate involvement in depression 
associated psychomotor changes, again more likely with melancholic severity (Barnes 
and Sharp 1999) and consistent with the above hypothesis. In addition, 5 - H T i D receptors 
in cortex modulate glutamate release, which might suggest a role in the memory 
impairments experienced by depressed patients (Maura et al. 1998).
Recent weight loss is a feature of the melancholic syndrome and can influence 
neuroendocrine challenge results as described in chapter 2. Only one subject reported 
weight loss in this study (who was non melancholic), and their peak GH response was 
greater than the mean, perhaps consistent with previous findings with the L-TRP 
challenge (Goodwin et al. 1987). To clarify the influence of weight loss on this challenge, 
the study would need to be repeated in a group with such attributes. Weight loss does not 
appear to be a significant confounding factor on the results of this study.
In patients treated with SSRIs the GH response to zolmitriptan was markedly decreased.
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This suggests that SSRIs produce a downregulation of postsynaptic 5 - H T i d  receptors. 
There is also evidence that repeated SSRI treatment can downregulate postsynaptic 
5 - H T i a  and 5 -HT2 receptors, in both healthy subjects and depressed patients (Lesch 
1992; Quested et al. 1997; Sargent et al. 1998a). The only other study to examine 
5-HTi b / i d  function following SSRI treatment was by Wing et al. (1996). This study 
examined the neuroendocrine response to acute sumatriptan in healthy subjects before 
and after 16 days of paroxetine treatment. Despite finding an initial reduction in PRL and 
temperature, there was no change in these responses following treatment. GH responses 
were not reported. If the PRL and temperature responses are mediated by presynaptic 
receptors, as discussed above, it implies that presynaptic 5 - H T i b / i d  function is not altered 
by SSRI treatment, whereas the blunted GH response to zolmitriptan following SSRIs 
possibly indicates reduced postsynaptic 5-HT function. Chronic SSRI treatment has been 
shown to enhance PRL levels in humans however (Sargent et al. 1998a) which may 
counteract any further blunting of the PRL response. The function of 5-HTi B/ i d  receptors 
may also vary between healthy and depressed groups, which would indicate a need to 
repeat this sumatriptan challenge post SSRI treatment in a depressed group to clearly 
examine any effect. Davidson and Stamford (2000) examined the sensitivity of 5 - H T i B 
and 5 - H T i d  autoreceptor function in rats following 21 days of paroxetine treatment, and 
found no change in sensitivity of 5 - H T i d  receptors, but densensitisation of 5 - H T i b  
receptors only when a 5 - H T i a  antagonist was added. This is consistent with the findings 
of Wing et al. and is also consistent with the possible beneficial effect of adding pindolol 
to an SSRI. Yatham et al. (1997b) examined the effects of light therapy on the GH 
response to sumatriptan in a group of patients with SAD, finding a resolution of the
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previously blunted GH response with treatment, implying that light therapy has a different 
mode of action (certainly as far as 5 - H T ib / i d  receptors are involved) than SSRIs.
Despite these effects of SSRIs on postsynaptic 5-HT receptors, it is likely that overall, 
SSRIs increase 5-HT neurotransmission because procedures such as TRP depletion, 
which lower synaptic 5-HT availability, reverse the antidepressant effects of SSRIs in 
recovered patients (Delgado et al. 1999). From this point of view the downregulation of 
postsynaptic receptors seen during SSRI treatment is presumably an adaptive response 
which limits, but does not remove, the increase in 5-HT neurotransmission produced by 
chronic 5-HT reuptake blockade and increased levels of synaptic 5-HT. This may explain 
the apparently paradoxical finding that some unmedicated patients with major depression 
have impaired postsynaptic 5-HTm receptor function, which is further diminished by 
effective treatment. This postsynaptic downregulation occurs at the time of onset of 
antidepressant effect so maybe crucial to this (Stahl 1998). It could however not be 
relevant to the therapeutic effect and just be a marker of some other intracellular activity.
It is also possible that the magnitude of postsynaptic downregulation is not equal between 
receptor groups and the relative neurotransmission at one receptor type may actually be 
increased due to a relatively greater downregulation of other receptors. Such increased 
specific receptor mediated neurotransmission despite downregulation, possibly most 
relevant at 5-HTia receptors (as implicated by an enhanced PRL response to TRP 
following SSRI treatment), could therefore equate with antidepressant activity. Consistent 
with this, impaired 5-HTia receptor function in depression appears to resolve following 
treatment as discussed later (Smith et al. 2000).
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CHAPTER 6 
THE CITALOPRAM CHALLENGE IN
HEATTHY SUBJECTS
THE NEUROENDOCRINE EFFECTS OF CITALOPRAM IN
HEALTHY SUBJECTS 
INTRODUCTION
Previous chapters have discussed the use of pharmacological probes to measure brain 
5-HT receptor function via changes in the plasma concentration of certain anterior 
pituitary hormones. Progress in this field was marred by the withdrawal of d-fenfluramine 
from the market in 1999, due to cardiotoxicity (Baumann et al. 2000). This further 
prompted the search for a neuroendocrine probe that can increase presynaptic 
serotonergic function in humans in a reliable and well tolerated manner, and has led to the 
examination of other available drugs that may act in this way, such as citalopram (Hyttel 
1982; Joubert et al. 2000).
Citalopram’s chemical structure is shown in figure 6.1. Citalopram is indicated for the 
treatment of depressive disorder in acute and maintenance phases and also for panic 
disorder. The recommended initiation dose for the treatment of depression is 20mg, 
increased to a maximum of 60mg. Adverse reactions are typically mild to moderate and 
usually occur within the first 2 weeks of treatment. The most common adverse reactions, 
above those seen at placebo rates, are nausea, somnolence, dry mouth, increased sweating 
and tremor (Electronic Medicines Compendium).
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Fig 6.1 The chemical structure of citalopram.
Citalopram, as with other SSRIs, preferentially inhibits 5-HT reuptake at the presynaptic 
membrane. In vitro animal studies have shown a 3400 fold preference for blocking 5-HT 
over NA uptake (with even greater preference over DA uptake) (Hyttel et al. 1995). It is 
the most selective of currently available SSRIs, lacking inhibition at any other receptor 
sites. The highest affinity at other receptors, but at micromolar levels is at ai and 
histamine Hi receptors (Hyttel et al. 1995).
Citalopram is a racemic mixture with pharmacological activity residing in the (+)- 
enantiomer with the 1-(S) absolute configuration (Hyttel et al 1995). This active 
enantiomer of citalopram has recently been released for clinical use (Owens et al. 2001).
Citalopram is highly lipophillic and is readily absorbed from the gastrointestinal tract 
when administered orally (time to peak levels is approximately 3 hours). The absolute
bioavailability of citalopram tablets is 80% of the intravenous dose (Baumann and Larsen 
1995). Citalopram shows a biphasic elimination following a single dose, with a terminal 
half life of approximately 36 hours (Kragh-Sorensen et al. 1981).
Citalopram is metabolised to demethylcitalopram, didemethylcitalopram, citalopram-N- 
oxide and the deaminated propionic acid derivative. Citalopram is the predominant 
compound in plasma after a single dose, with the metabolites appearing at much lower 
levels (Baumann and Larsen 1995). It is 75% excreted in urine. The metabolites are less 
potent SSRIs and enter the brain less readily, so do not contribute to the overall 
pharmacological effect (Hyttel and Larsen 1985).
Intravenous citalopram is preferable in a neuroendocrine paradigm to ensure greater 
bioavailability and a theoretically more rapid hormonal response in comparison to the oral 
preparation.
A pre\ious study by Seifiitz et al. (1996) in healthy humans showed that a 20mg dose of 
intraveious citalopram robustly increased plasma PRL and CORT concentrations as also 
observed in rats (Meltzer et al. 1981). Seifiitz et al. (1996) demonstrated that citalopram 
at this lose had no effect on body temperature or heart rate. There were draw backs in 
using atalopram as a neuroendocrine probe at this dose, however, as there were also 
signifhant increases in subjective ratings of distress, restlessness, sickness, nausea and 
dizzinss. These subjective experiences could themselves influence the neuroendocrine 
respone (Cowen 1998), and recruitment of subjects for such a drug challenge could be
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problematic, diminishing the usefulness of this test.
The following experiment aimed to assess the neuroendocrine effects of two lower doses 
of intravenous citalopram (5mg and lOmg) to examine whether these doses would be 
sufficient to elevate PRL and CORT relative to placebo, in the absence of such adverse 
effects.
METHODS
Subjects
Eleven healthy volunteers (6 male, 5 female) mean age 37.2 years (range 21 to 62 years) 
and mean weight 73.6kg (range 56.9kg to 93.4kg) were recruited as described in Chapter 
3. They had no significant physical illness and had been free of medication for at least 
three months.
Neixoendocrine tests
Subjects were tested on three occasions. They attended the laboratory at midday and 
received, over 30 minutes, an infusion of (a) citalopram 5mg, (b) citalopram lOmg, or (c) 
placebo, in a double blind, random order design. The infusion was prepared as discussed 
in Ciapter 3. Further blood sampling was carried out at the end of the infusion and at 15 
minite intervals thereafter for the next 150 minutes. The mean interval between the tests
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was 11 days (range 5 to 44 days). Female subjects were tested in the early follicular stage 
of the menstrual cycle. Subjects were monitored by nursing staff throughout the testing 
sessions and questioned every 30 minutes about adverse effects.
Biochemical measurements
Assay methods are described in Chapter 3. GH responses were not examined as similar 
pharmacological challenges, such as clomipramine and fenfluramine, have no effect on 
GH (Laakmann 1990). Plasma citalopram level assays were not undertaken but would 
have been ideally, to control for pharmacokinetic variation between subjects.
Analysis o f results
Hormone responses to citalopram and placebo were calculated as AUC using the 
trapezoid method with subtraction of baseline secretion extrapolated from time ‘O’. The 
AUC values were analysed with a one way ANOVA with ‘treatment’ (citalopram vs 
placebo) as the within subject factor. Post hoc comparisons between AUC values were 
conpared using t tests for different treatment arms. Individual time point data were 
analysed using a two way ANOVA with ‘occasion’ (citalopram at each dose vs placebo) 
and‘time’ as the main within subject factors.
RESULTS
Citalopram treatment elevated plasma PRL in a dose related manner (Table 6.1, Fig 6.2).
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The one way ANOVA for PRL AUC showed a significant effect of treatment (F= 7.62; df 
71, 17.09; p= 0.006). Post hoc testing showed significant differences in the AUC PRL 
response between placebo (mean AUC mIUxHr/1 ± SEM was -64.1 ± 36.9) and 
citalopram 5mg (37.1 ± 23.6) (comparison p=0.010) and between placebo and citalopram 
lOmg (62.4 ± 25.8) (p=0.014), but not between the 5mg and lOmg doses of citalopram 
(p= 0.36).
The: two way ANOVA for citalopram lOmg vs control showed a significant effect of 
occasion (F= 9.89; df 1, 10; p=0.010), a significant effect of time (F= 3.67; df 2.87,
28.74; p=0.025), and a significant occasion by time interaction (F= 4.35; df 3.75, 37.45; 
p=0.006). The ANOVA for citalopram 5mg vs control was not significant for occasion 
(F= 0.85; df 1, 10; p=0.38), but a significant effect of time (F= 3.17; df 2.94,29.37; 
p=0.04) and of the occasion by time interaction was observed (F= 5.09; df 7.35, 73.45;
p<0.001).
Citalopram treatment also elevated plasma CORT in a dose related manner (Table 6.1,
Fig 6.3). The one way ANOVA for CORT AUC showed a significant effect of treatment 
(F= 5.81; df 20.00,2.00; p= 0.010). Post hoc tests showed no significant difference in the 
AUC CORT response between placebo (with mean AUC mcgxHr/lOOml ± SEM of -11.6 
±3.0) and citalopram 5mg (-6.3 ± 3.5) (comparison p=0.21) but a significant difference 
between citalopram lOmg (3.1 ±4.9) and placebo (p=0.005). No significant difference 
between the 5mg and lOmg doses of citalopram was observed (p= 0.090).
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The two way ANOVA for citalopram lOmg vs control showed a significant effect of 
occasion (F= 5.96; df 1,10; p=0.035), of time (F=l 1.29; df 3.35, 33.48; p<0.001), and of 
the occasion by time interaction (F= 6.53; df 4.05,40.48; pO.OOl). The ANOVA for 
citalopram 5mg vs control was not significant for occasion (F= 0.2.19; df 1,10; p=0.17), 
but significant for time (F= 9.26; d f24.21,2.42; p=0.001) and not significant for the 
occasion by time interaction (F= 0.33; df 22.86,2.29; p=0.75).
Gender was not a significant covariate in the two way ANOVAs for citalopram lOmg vs 
control for either PRL (p=0.46) or CORT (p=0.83) data.
VAS scales for subjective ratings were unfortunately not completed for all subjects but it 
was noted when subjects felt significantly different during the challenge. Citalopram 
lOmg IV was well tolerated with no subjects vomiting throughout the &tudy. No adverse 
effects were reported after placebo but after 5mg of citalopram 4 subjects reported 
drowsiness and 1 nausea. After lOmg citalopram 8 subjects reported drowsiness, 4 nausea 
and 1 light headedness. These effects occurred within the first 60 minutes of the start of 
the infusion and were of brief duration (1 hour at the most) and not severe.
These results are discussed at the end of this chapter.
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Table 6.1
Mean ± SEM AUC responses for PRL and CORT following citalopram lOmg IV, 
citalopram 5mg IV and placebo infusion in 11 healthy subjects tested on 3 occasions.
Citalopram lOmg Citalopram 5mg Placebo
PRL AUC Response 62.4 ±25.8* 37.1 ±23.6** -64.1 ±36.9
mIUxHr/1
CORT AUC Response 3.1 ±4.9** -6.3 ± 3.5 -11.6 ±3.0
mcgxHr/lOOml
*p<0.05 ** p<0.01 for paired t tests in comparison with placebo values
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Figure 6.2 Mean ± SEM plasma PRL (measured as change from baseline) in 11 healthy 
subjects who were tested on 3 separate occasions receiving (a) placebo (open squares), (b) 
citalopram 5mg (closed triangles) and (c) citalopram lOmg (closed circles), infused 
intravenously over 30 minutes starting at time ‘O’.
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Figure 6.3 Mean ± SEM plasma CORT (measured as change from baseline) in 11 healthy 
subjects who were tested on 3 separate occasions receiving (a) placebo (open squares), (b) 
citalopram 5mg (closed triangles) and (c) citalopram lOmg (closed circle?), infused 
intravenously over 30 minutes starting at time ‘O’.
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DEFINING THE MODE OF ACTION OF THE NEUROENDOCRINE 
RESPONSE TO INTRAVENOUS CITALOPRAM 
THE EFFECT OF CYPROHEPTADINE ON THE 
NEUROENDOCRINE RESPONSE TO CITALOPRAM 
INTRODUCTION
Having established that citalopram enhances PRL and CORT release, the receptor 
mediated mode of action of this effect was investigated. As discussed in Chapter 1, 
d-fenfluramine reliably induces an increase in PRL, ACTH, and CORT which appears to 
be mediated mainly via activation of 5-HT2a/c receptors (Albinsson et al. 1994; Goodall 
et al. 1993; Park and Cowen 1995). D-fenfluramine has properties similar to citalopram 
in that it can block the presynaptic reuptake of 5-HT (although differs from SSRIs in 
causing 5-HT release). I therefore hypothesised that the PRL and CORT responses to 
citalopram were also mediated by 5 -HT2 receptors.
Cyproheptadine hydrochloride (Hoyer 1988) was the 5 -HT2 antagonist used for this study 
purely due to its availability. Cyproheptadine is licensed for use as an antiallergic- 
antipruritic and in the treatment of migraine and vascular type headache. The oral 
therapeutic dose range is from 4mg to 20mg a day for antipruritic effect and up to 8mg in
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a 6 hour period for migraine. Its antiallergic therapeutic action is mediate 1 through 
histamine receptors and antimigraine action via 5-HT receptors (Lehrer 2004). 
Cyproheptadine is contraindicated in asthma attacks, breast feeding, gut stenosis, urinary 
retention, glaucoma, with MAOIs, and in the elderly. It is well tolerated with the only 
common side effect being sedation. Peak plasma levels occur 6 hours following oral 
administration. Elimination is primarily in urine as a quaternary ammonium glucuronide 
conjugate, but it is also found in stools metabolised and unmetabolised (Electronic 
medicines compendium).
Cyproheptadine primarily acts as an antagonist at histamine and 5 -HT2 receptors (Stone et 
al.1961). It also has activity as an antagonist at ACh receptors, and much less so at DA 
and a  receptors (Stone et al. 1961; Williams and Martin 1982). Lewis and Sherman 
(1985) used cyproheptadine pretreatment (0.06 mg/kg orally every 6 hours for 2.5 days) 
to successfully blunt the PRL response to fenfluramine. Cyproheptadine did not influence 
basal PRL or GH levels in this study. Sharpley et al. (1990) also used cyproheptadine to 
examine the influence of 5 -HT2 receptor antagonism on slow wave sleep. They used 4mg 
orally, a dose equivalent to that used by Lewis and Sherman, which successfully 
increased slow wave sleep and reduced REM sleep in healthy volunteers. The dose of 
4mg was therefore chosen for this study as it appears to effectively block 5 -HT2 receptors, 
has no apparent influence on basal PRL levels (Lewis and Sherman 1985) and is likely to 
only have significant activity at 5-HT and histamine receptors (Stone et al.1961). 
Histamine antagonism alone does not appear to influence PRL secretion (Rivier and Vale 
1977), although histamine agonism can enhance PRL secretion (Freeman et al.2000).
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ACh is inhibitory to PRL release (Freeman et al. 2000) so cyproheptadine could 
theoretically enhance PRL secretion. Cyproheptadine can reduce ACTH secretion and 
plasma CORT levels (Electronic medicines compendium).
METHODS
Subjects
Six healthy subjects were recruited as described in Chapter 3, consisting 5 male and 1 
female of mean age 40.7 years (range 21 to 52 years) and mean weight 75.2kg (range 59 
to 88kg). This number of subjects is low although was adequate to show a clear effect of 
cyproheptadine on the PRL response to fenfluramine in the Lewis and Sherman (1985) 
study.
Neuroendocrine tests
Subjects were tested on two occasions, receiving intravenous citalopram (lOmg over 30 
minutes) on both occasions. Six hours prior to infusion subjects took either 
cyproheptadine, 4mg orally (as used by Sharpley et al. 1990), or placebo in a double 
blind, random, balanced order design. This ensured that on the cyproheptadine test day, 
plasma cyproheptadine was at peak level at the start of the citalopram infusion. Blood 
samples were taken as above. The mean interval between the tests was 7 days (range 5 to 
10 days). The female subject was tested in the early follicular stage of her menstrual 
cycle. Subjects were monitored by nursing staff throughout the testing sessions and
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questioned every 30 minutes about adverse effects.
Biochemical measurements 
Assay methods are described in Chapter 3.
Analysis of results
Hormone responses were analysed using a two way ANOVA with ‘occasion’ 
(cyproheptadine vs placebo) and ‘time’ as the main within subject factors. The AUC 
values for PRL and CORT (calculated as above) were also analysed with a one way 
ANOVA with ‘occasion’ (cyproheptadine vs placebo) as the within subject factor.
RESULTS
Administration of cyproheptadine significantly lowered baseline plasma PRL and CORT 
concentration. For PRL, the mean ± SEM value at time ‘0’ was 94 ± 9 mRJ/L for the 
cyproheptadine challenge day and 109 ± 11 mIU/1 for the placebo day (p=0.031). For 
CORT the corresponding values were 8.6 ± 2.1 mcg/lOOml and 13.1 ± 2.3 mcg/lOOml 
(p= 0.003). Despite this, cyproheptadine treatment failed to antagonise the PRL and 
CORT responses to citalopram, as shown in figures 6.4 and 6.5 respectively. To correct 
for the baseline influence on the cyproheptadine study arm, ANOVAs were undertaken on 
change from baseline data.
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The ANOVA for PRL change from baseline, cyproheptadine vs placebo, showed no 
effect of occasion (F=0.85; df 1, 5; p=0.40), or time (F=1.58; df 1.7, 8.4; p=0.26), or 
occasion by time interaction (F=0.62; df 6.3, 31.7; p=0.72). The mean AUC PRL ± SEM 
response for citalopram / placebo was -2.2 ±21.3 and for citalopram / cyproheptadine 
21.5 ± 23.1 mIUxHr/1. The ANOVA for PRL AUC showed no significant effect of 
cyproheptadine vs placebo (F=0.80; df 1, 5; p=0.41) but with a power of 0.11 (a being set 
at 0.05). This demonstrates that the sample size was not large enough to show any clear 
difference between treatment days. PRL responses tended to be greater following 
cyproheptadine.
The two way ANOVA for CORT change from baseline, cyproheptadine vs placebo, 
showed no significant effect of occasion (F=0.21; df 1, 5; p=0.67), time (F=2.55; df 4.3, 
21.7; p=0.06) or of occasion by time interaction (F=1.92; df 2.0, 9.9; p=0.20).
The mean AUC CORT ± SEM response for citalopram/placebo was 7.8 ± 5.7 mlU hr/1 
and for citalopram/cyproheptadine 8.5 ± 7.2 mlU hr/1 (one way ANOVA comparison, 
F=0.05; df 1, 5; p=0.84). The power of this AUC ANOVA was very low at 0.05 (a being 
set at 0.05), again demonstrating that the sample size was not large enough to show any 
cleai difference between treatment days
As vith the previous study, VAS scales for subjective ratings were unfortunately not 
completed for all subjects. No adverse experiences were reported however.
The results of this study are discussed at the end of this chapter.
189
Pr
ol
ac
tin
 
ch
an
ge
 
(m
lU
/l)
Fig 6.4 Mean ± SEM plasma PRL response in 6 healthy subjects challenged twice with 
citalopram lOmg IV in addition to placebo orally (closed circles) or cyproheptadine 4mg 
orally (closed stars). No significant difference is observed (ANOVA).
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Fig 6.5 Mean ± SEM plasma CORT response in 6 healthy subjects challenged twice with 
citalopram lOmg IV in addition to placebo (closed circles) or cyproheptadine (closed 
stars). No significant difference is observed (ANOVA).
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THE EFFECT OF PINDOLOL AND PENBUTOLOL ON THE 
NEUROENDOCRINE RESPONSE TO CITALOPRAM 
INTRODUCTION
The previous study using cyproheptadine was unable to clarify whether the increase in 
PRL and CORT following citalopram infusion is likely to be mediated by 5 -HT2 
receptors. Other neuroendocrine probes that influence presynaptic function (in common 
with citalopram) include L-TRP. The PRL increase following L-TRP infusion may be 
mediated via activation of postsynaptic 5-HTia receptors as it is antagonised by pindolol 
(Smith et al. 1991, as discussed in Chapter 2). It is therefore possible that the 
neuroendocrine effects of citalopram are also mediated by 5-HTia receptors.
The effects of pindolol and penbutolol on the hormone responses to citalopram were 
examined. Pindolol has classically been used to examine the involvement of 5-HTia 
receptors in neuroendocrine probe studies (eg. Smith et al. 1991), but this drug has partial 
agonist properties which therefore makes findings difficult to interpret (Hjorth and 
Carlsson 1986). Penbutolol was also used in this study as a potential antagonist of the 
neuroendocrine effects of citalopram, as it has clear 5-HTia receptor antagonist properties 
in animal models (Hjorth 1992), and functionally has acted more potently than pindolol at 
this receptor (Gartside 1999).
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Penbutolol is a noradrenergic Pi and P2 receptor antagonist (with 4 times greater potency 
than the commonly used propranolol) and a 5-HTia receptor antagonist. It is indicated for 
the treatment of arterial hypertension, with a dose range of 20 to 80mg daily. This effect 
is achieved through central and peripheral p receptor blockade and related reduction in 
renin secretion. Penbutolol is well tolerated up to 80mg with most common side effects of 
headache, dizziness, fatigue and nausea reported infrequently (in less than 8% of 
subjects). Contraindications are cardiogenic shock, sinus bradycardia, atrioventricular 
conduction block, obstructive pulmonary disease and asthma. Metabolism of penbutolol 
is through conjugation, oxidation and subsequent urinary excretion. The oxidative 
metabolite has some but much less affinity for p receptors than the parent compound. 
Following oral use, penbutolol is rapidly and completely absorbed. Peak blood levels 
occur 2 to 3 hours following ingestion. Plasma half life is approximately 5 hours 
(Schwarz Pharma 1995).
Pindolol is also a noradrenergic Pi, p2 and 5-HTia receptor antagonist, indicated for the 
treatment of arterial hypertension and the prophylactic treatment of angina pectoris. The 
dose range for both indications is between lOmg and 45mg per day in divided doses. 
Pindolol has intrinsic sympathomimetic activity which provides the heart with some basal 
stimulation, similar to normal resting sympathetic activity. Contraindications are as for 
penlutolol. Similarly, pindolol is well tolerated within therapeutic doses with most 
common but infrequent side effects as for penbutolol. Up to 40% of pindolol is excreted 
unclanged in the urine, while the rest is excreted by liver and kidney as inactive 
metibolites. Following oral use, pindolol is rapidly and more than 95% absorbed, with
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bioavailability of 87%. Peak blood levels occur within 1 hour of ingestion. Plasma half 
life is approximately 5.5 hours (Electronic medicines compendium). Anderson and 
Cowen (1992a) used a predosing regime of pindolol 80 mg over 3 days to successfully 
blunt the GH and hypothermic responses to buspirone, and Smith et al. (1991) used 40mg 
over 2 days to successfully blunt the PRL and GH responses to L-TRP.
In a PET scanning study, concurrent to this study, Rabiner et al. (2000) examined the 
binding of pindolol and penbutolol in human brain in vivo. Both drugs exhibited 
occupancy effects at 5-HTia receptors, with higher binding at higher drug plasma levels. 
Pindolol displayed a preferential occupancy of the presynaptic 5-HTia receptor following 
a single dose of lOmg (which disappeared at 20mg), whereas penbutolol did not show any 
preferential pre or post synaptic occupancy at any dose tested (upto 80mg). Both pindolol 
lOmg and penbutolol 80mg were well tolerated, and therefore were used in the current 
neuroendocrine challenge. Using these findings, I hypothesised that pindolol lOmg would 
enhance the PRL and CORT responses to citalopram, due to preferential autoreceptor 
binding, and penbutolol 80mg would diminish these responses, if postsynaptic 5-HTia 
receptors were involved in mediating the endocrine response to citalopram.
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METHODS
Subjects
Ten healthy subjects were recruited as described in Chapter 3, (5 male, 5 female) with 
mean age 36 years (range 22 to57 years), and mean weight 69.5kg (range 56.9 to 80.0kg). 
Two of the female subjects were postmenopausal, one of whom was taking constant dose 
hormone replacement therapy.
Neuroendocrine tests
Subjects were tested on three occasions, receiving intravenous citalopram (lOmg over 30 
minutes) on all occasions. On one of these occasions subjects received pindolol lOmg 
orally, on another penbutolol 80mg orally and on the other occasion, placebo in a double 
blind, randomised, balanced order design. Pindolol was given 2 hours before citalopram 
infusion and penbutolol was given 3 hours before infusion, to ensure peak plasma levels 
at time ‘O’ (tmax of pindolol and penbutolol in plasma being 1 to 2 hours and 1 to 3 hours 
respectively, Sweetman 2002). Giving pindolol or penbutolol at these differing times does 
influence blinding, but this was improved by administering the placebo at either 2 or 3 
hours before time ‘0* in a similarly random manner. Blood samples were taken as above. 
The mean interval between the tests was 11 days (range 3 to 22 days). Female subjects 
were tested in the early follicular stage of the menstrual cycle. Subjects were monitored 
by nursing staff throughout the testing sessions and questioned every 30 minutes about 
adverse effects.
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Biochemical measurements 
Assay methods are described in Chapter 3.
Analysis of results
PRL and CORT responses were initially analysed using a one way ANOVA on AUC data 
with ‘treatment’ (pindolol/penbutolol or placebo) as the within subject factor. Sub 
analyses of pindolol vs placebo and penbutolol vs placebo were undertaken using paired t 
tests;. Two way ANOVAs with ‘occasion’ (pindolol vs placebo or penbutolol vs placebo) 
and ‘time’ as the main within subject factors were also examined.
RESULTS
A female subject was excluded from further analysis due to vomiting ct 60 minutes 
following the start of citalopram infusion during one neuroendocrine challenge (later 
found to be the pindolol test day). No other adverse feelings were reported by subjects but 
ideally this should have been recorded with systematic VAS measures. A further female 
subject was excluded due to a large peak in PRL (>500mIU/l) during one session 
(placebo arm). For clarity, the results are summarised in Table 6.2 and shown in figures 
6.6 and 6.7.
Mean baseline (time ‘0’) PRL ± SEM on placebo, pindolol and penbutolol test days were 
158 mlU/L ± 20,123 mlU/L ± 14 and 121 mlU/L ± 17 respectively. Pindolol and
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penbutolol PRL baselines were significantly lower than placebo (for t tests, p= 0.02, and 
p=0.01 respectively) but were not significantly different from each other (p=0.81). Mean 
baseline CORT ± SEM on placebo, pindolol and penbutolol test days were 9.7 
mcg/lOOml ± 1.7,10.9 mcg/lOOml ±1.6 and 15.6 mcg/lOOml ±1.9 respectively. 
Penbutolol but not pindolol test day baseline CORT was significantly greater than 
placebo (for t tests, p=0.01 and p=0.46 respectively) and pindolol and penbutolol 
comparisons verged on significant difference (p=0.05). The following ANOVAs are 
undertaken using change from baseline data to take into account these bareline changes.
The one way ANOVA for PRL AUC clearly showed no effect of treatment in comparison 
to placebo (F=0.001; df 22, 1; p= 0.98). Mean PRL AUC in the pindolol and penbutolol 
treatment arms did not significantly differ from placebo, as shown in Table 6.2.
For pindolol vs placebo the two way ANOVA of PRL change from baseline response was 
not significant (for effect of occasion F=1.57; df 1,7; p=0.25; of time F=0.97; df 16.2, 
2.3;p=0.41, and the occasion by time interaction F=1.61; df 16.1,2.3; p=0.23).
For penbutolol vs placebo the two way ANOVA of PRL change from baseline response 
was similarly not significant (for effect of occasion F=1.55; df 1,7; p=0.25; of time 
F=1.36; df 2.7; 19.0; p=0.28, and the occasion by time interaction F=1.84; df 2.04, 
2.14.27; p=0.20).
The one way ANOVA for CORT AUC also showed no effect of treatment in comparison 
to placebo (F=0.17; df 1, 22; p=0.69). Mean CORT AUC in the pindolol and penbutolol
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treatment arms similarly did not significantly differ from placebo, as shown in Table 6.2.
For pindolol vs placebo the two way ANOVA of CORT change from baseline responses 
was not significant (for effect of occasion F=0.46; df 1,7; p=0.52; of time F=1.70; df 5.7, 
39.8; p=0.15, and for the occasion by time interaction F=2.21; df 34.6,4.9; p=0.0S).
For penbutolol vs placebo the ANOVA of CORT change from baseline responses was 
similarly not overall significant (for effect of occasion F=1.17; df 1,7; p=0.32; of time, 
significantly, F=9.32; df 7.4,51.8; pO.OOl, and for the occasion by time interaction 
F=1.31;df 3.1,21.5; p=0.30).
Comparisons of pindolol vs penbutolol test days were significantly different for PRL 
AUC: F= 7.36; df 1, 7; p=0.03, but not for CORT AUC: F= 1.60; df 1, 7; p=0.25.
These results are discussed below with the results from the other citalopram studies.
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Table 6.2
Mean ± SEM baseline (time ‘0’) and AUC responses for PRL and CORT following 
citalopram lOmg IV in 8 healthy subjects on 3 occasions pretreated with either, pindolol 
lOmg, penbutolol 80mg, or placebo.
Pindolol (lOmg) Penbutolol (80mg) Placebo
Baseline PRL ± SEM 123 ± 14 * 121 ±17* 158 ±20
mIU/1
Baseline CORT ± SEM 10.9 ±1.6 15.6 ±1.9* 9.7 ±1.7
mcg/lOOml
PRL AUC Response -30.5 ± 12.5 24.8 ±15.7 -3.6 ±22.3
mIUxHr/1
CORT AUC Response 1.8 ±2.4 -4.4 ±4.7 1.1 ±2.3
mcgxHr/lOOml
*pO.05 for paired t tests in comparison with placebo values
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Fig 6.6 Mean ± SEM plasma PRL response to citalopram lOmg IV in 9 healthy subjects 
on 3 occasions pretreated with either placebo (closed circles), pindolol lOmg (closed 
triangles) or penbutolol 80mg (closed diamonds) in a randomised manner.
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Fig 6.7 Mean ± SEM plasma CORT response to citalopram lOmg IV in 9 healthy 
subjects on 3 occasions pretreated with either placebo (closed circles), pindolol lOmg 
(closed triangles) or penbutolol 80mg (closed diamonds) in a randomised manner.
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DISCUSSION OF CITALOPRAM STUDIES IN 
HE ALTHY SUBJECTS
There is now much evidence that intravenous administration of SSRIs and other less 
specific drugs (such as clomipramine), in humans, increases plasma PRL and CORT 
(Laakmann 1990; Raap and Van de Kar 1999). Consistent with this, the citalopram dose 
response study shows that relatively modest doses of intravenous citalopram increase 
plasma PRL and CORT in healthy volunteers. These hormones were most robustly 
increased in comparison to placebo following lOmg intravenous citalopram, although 
direct comparisons between lOmg and 5mg showed numerical but not statistical 
difference. Blinded clinical observations indicated that both doses of citalopram were 
well tolerated but further studies with standardised subjective rating scales would be 
needed to confirm this impression, and exclude any potential bias of subjective effects. 
Optimal PRL responses to citalopram in larger studies are therefore likely to be attained 
at the dose of lOmg, as opposed to the apparently less well tolerated dose of 20mg 
(Seifritz et al. 1996). To confirm this finding, a within subject comparison between 
citalopram at lOmg and 20mg would need to be undertaken. Gender did not influence the 
hormonal responses to citalopram (as with zolmitriptan).
The release of PRL and CORT following SSRI administration is likely to reflect 
increased synaptic concentrations of 5-HT at the hypothalamic level, but the receptor 
mechanisms involved to influence these hormones have been difficult to establish clearly. 
Studies with selective 5-HT receptor antagonists in both humans and animals have
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suggested that a variety of postsynaptic 5-HT receptors (5-HTiA, 5-HT2A, 5-HT2c) are 
involved in 5-HT mediated PRL and ACTH release (Raap and Van de Kar 1999; Van de 
Kar 1991). For example, the PRL response to the 5-HT releasing agent, d-fenfluramine, is 
abolished by the 5 -HT2A/2C receptor antagonist, ritanserin (Goodall et al. 1993), but the 
abiliity of pindolol, a 5-HTia receptor antagonist, to block this response is equivocal (Park 
and Cowen 1995).
The initial hypothesis was that the PRL and CORT responses to citalopram are mediated 
by 5-HT2A/2c receptors. Ritanserin was not available for use, and therefore the less 
selective 5-HT2A/2C receptor antagonist, cyproheptadine (Hoyer 1988) was used. In this 
study, pretreatment with cyproheptadine at a dose sufficient to lower baseline plasma 
PRL and CORT, did not attenuate the endocrine responses to citalopram, but the study 
was underpowered to detect such a difference. Lewis and Sherman (1985) did not 
demonstrate this baseline change in PRL with cyproheptadine at an equivalent dose, but 
the baseline CORT reduction was predicted (Electronic medicines compendium). They 
did demonstrate that cypropheptadine blocked the PRL response to fenfluramine, 
however. These preliminary data therefore can not clarify whether citalopram induced 
endocrine responses are mediated predominantly by 5-HT2A/2C receptors, and the study 
would need to be repeated with cyproheptadine and a larger sample or another 5-HT2A/2C 
receptor antagonist with less activity at other receptors. Other receptor subtypes may also 
be sufficiently involved in the endocrine responses to citalopram to be able to overcome 
the effects of 5-HT2A/2C receptor blockade.
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The second hypothesis was that the PRL and CORT responses to citalopram are mediated 
by 5 - H T i a  receptors and that pindolol lOmg would enhance and penbutolol 80mg 
diminish the endocrine effects. Neither pindolol nor penbutolol demonstrated a 
significant effect on PRL and CORT responses to citalopram in this study (table 6.2).
This would initially suggest these responses are not mediated by 5-HTia receptors. If in 
this sample, pindolol bound preferentially to presynaptic receptors (as predicted, Rabiner 
et al. 2000) then its partial antagonistic activity (Hjorth and Carlsson 1986) at this site 
may have prevented any significant change in hormone secretion following citalopram in 
comparison to placebo. Some postsynaptic binding still occurs with pindolol lOmg 
(Rabiner et al. 2000) and this may have been enough to negate the postsynaptic effect of a 
rise in 5-HT release occurring with the influence of citalopram and presynaptic blockade, 
again with no net effect on hormone secretion. Similarly, if penbutolol has no preferential 
pre or postsynaptic binding (Rabiner et al. 2000) the net hormonal effects of citalopram 
could be negligible. In animal models, both pindolol and penbutolol have been shown to 
enhance serotonergic activity following acute SSRI infusion (Gartside et al. 1999; 
Gundlah et al. 1997) which may enhance the validity of the trend to an increase in PRL 
above placebo in the penbutolol arm at the end of the blood sampling period, as shown in 
Fig 6.5. This study would need to be repeated with a longer sampling period to examine 
whether penbutolol indeed had such an effect. This could indicate a potentially useful 
property of penbutolol, in the augmentation of the antidepressant effect of SSRIs. Overall, 
it is unlikely that postsynaptic 5-HTia receptors mediate the PRL response to citalopram.
Baseline PRL was significantly less for the pindolol and penbutolol test days in
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comparison to placebo. This raises the possibility that both drugs alone can reduce tonic 
brain 5-HT neurotransmission and highlights the importance of including a placebo arm 
in such a trial to gain a true impression of the impact of these drugs on the 
neuroendocrine responses to citalopram. The mechanism of this PRL reduction could be 
antagonism of postsynaptic 5 - H T ia  receptors or partial agonist activity at presynaptic 
5 - H T ia  receptors. The p  adrenoceptor antagonist effect of pindolol and penbutolol may 
also influence PRL secretion via changes in NA neurotransmission. Propranolol, similarly 
a p adrenoceptor antagonist, appears to enhance PRL secretion in some paradigms (the 
desimipramine challenge, Laakmann et al. 1986) but has no effect in others (the L-TRP 
challenge, Upadhyaya et al. 1990). In sheep, NA inhibits PRL secretion which is reversed 
in vitro by propranolol (Colthorpe et al. 2000). P adrenoceptor antagonist effects are 
therefore unlikely to inhibit PRL secretion. This reduction in baseline PRL could 
potentially influence the subsequent PRL response when citalopram is administered. To 
identify such an effect, again a full cross over design would need to be used so that the 
effect on PRL secretion of penbutolol alone without citalopram could be accurately 
defined.
At this stage it is therefore unclear which receptors mediate the neuroendocrine responses 
to citalopram but using currently available ligands, clarification of the involvement of 
postsynaptic 5-HTia or 5-HT2A/2C receptors has not been possible. More selective 
antagonists, acting only at postsynaptic areas would be required and this should be 
investigated as they become available. Recent studies from the laboratory of Dr Trevor 
Sharp have shown that PRL and CORT responses to citalopram in rats are not
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antagonised by either selective 5-HTia or selective 5 -HT2 receptor antagonists or by both 
antagonists given together (Sharp T, personal communication). Although this leaves open 
the question of which receptors mediate the endocrine responses to citalopram, it does 
suggest that the findings here are valid.
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CHAPTER 7
THE CITALOPRAM CHAT J.ENCE IN 
DEPRESSED SUBJECTS
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INTRODUCTION
Having shown the effects and tolerability of citalopram lOmg administered intravenously 
in healthy subjects, and attempted to define the mode of action of the neuroendocrine 
responses, the next stage was to apply this test to a sample of depressed patients.
I hypothesised that the PRL and CORT responses to citalopram would be blunted in a 
grouip of depressed subjects, in comparison to a healthy control sample, as observed with 
other presynaptic acting neuroendocrine probes such as fenfluramine (Stahl 1993). The 
subs equent study examines this hypothesis.
METHODS
Subjects
Fourteen depressed subjects were recruited as described in Chapter 3. All had DSM-IV 
Major Depressive disorder (see appendix I) identified through the SCID, and had been 
drug free for at least three months. Equal numbers of each sex were recruited, 7 men and 
7 women, of mean age 45 years (range 25 to 62) and mean weight 74.7 kg (range 55.0 to 
104.8). Mean HAM-D and BDI scores were 20 (range 9 to 33) and 25 (range 8 to 43) 
respectively. Only two subjects were identified as melancholic type depressive disorder, 
negating the usefulness of such a subanalysis. Fourteen controls were ^elected from a 
volunteer list, individually matched to the depressed group as described in the methods 
section. This group had a mean age of 41 years (range 21 to 57) and mean weight 71.1kg
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(range 56.0 to 94.8). One patient with a weight of 104.8 did not have a close match for 
this variable and hence a control with the nearest weight of 94.8kg was selected.
Neuroendocrine tests
All subjects were tested on two separate days in a double blind, balanced order, placebo 
controlled design. The mean ± SEM interval between the two tests was 10 ± 2 days with 
no significant difference between the groups. Subjects fasted after a light breakfast and 
came to the research unit at 12.00 hours. After a 30 minute rest period for removal of 
baseline venous samples for PRL and CORT estimation, citalopram lOmg (diluted in 5ml 
saline) or 5ml saline (placebo) were administered over 30 minutes. Blood sampling 
continued at 15 minute intervals for a further 150 minutes. All female subjects were 
tested in the first half of the menstrual cycle.
Biochemical measurements
Assay methods are described in Chapter 3. The inter and intra assay coefficients of 
variation of the PRL assays over the range encompassed by the standard curve were 5% 
and 1% respectively (as opposed to those stated in Chapter 3). CORT was analysed using 
RIA with inter and intra assay coefficients of variation over the range encompassed by the 
standard curve of 10% and 1% respectively.
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Analysis of results
Baseline plasma PRL and CORT levels between patient and control groups were 
analysed by unpaired t tests between means of the 3 baseline measures taken on the 
placebo test day (at time points -30, -15 and 0).
AUC PRL and CORT responses were examined in ANOVAs with citalopram and 
placebo test days as ‘occasion’ within subject factors and ‘depression’ presence or 
absence as a between subjects factor.
To more simply and accurately analyse this dataset, patient and control PRL and CORT 
responses are expressed as AAUC values, calculated by subtraction of the individual 
placebo challenge AUC values from their respective citalopram response AUC values. 
The difference between these values was investigated using univariate ANOVA of AAUC 
values with depression (presence or absence) as the between (fixed) subjects factor. The 
ANOVAs on raw values for PRL and CORT were not undertaken due to the large number 
of levels in this analysis, which would make interpretation of the results more difficult.
RESULTS
Due to a high baseline PRL, one depressed subject (and therefore their matched control) 
was excluded from the study. Mean ± SEM placebo test day baseline scores for PRL for 
patient and control groups were 164 ± 20 and 157 ±18 mIU/1 respectively, with no
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significant difference (unpaired t test t= -0.26; df 23.6; p= 0.80). Mean ± SEM placebo 
test day baseline scores for CORT for patient and control groups were also non 
significantly different at 18.4 ± 2.2 and 16.4 ± 2.7 mcg/lOOml respectively (unpaired t test 
t= 0.58, df24.7,p= 0.57).
For die ANOVA of PRL AUC values with the within subject factor of occasion 
(citalopram or placebo) and between subject factor of depression (patient or control), a 
highly significant effect of occasion (F=14.29; df 1,24; p=0.001) and a significant 
occasion by depression interaction (F=7.30, df 1,24; p=0.012) was observed.
Mean PRL AAUC ± SEM scores for depressed subjects and controls were 14.8 ± 19.9 
and 89.1 ± 19.0 mlU hr/1 respectively. The univariate ANOVA of PRL AAUC scores, 
with depression as fixed factor and AAUC as dependant variable showed a significant 
effect of depression (F=7.30, df 24,1; p=0.012). The post hoc independent samples 2 
tailed t test for PRL AAUC between depressed subjects and controls was similarly 
significant (t=2.70; df 24; p=0.012). Figures 7.1 and 7.2 demonstrate graphically the 
effect of depression on PRL responses to citalopram.
The ANOVA of CORT AUC values comparing citalopram and placebo test days with 
deprjssion as a between subjects factor showed a significant effect of occasion (F=l 1.21; 
df 1,26; p=0.002) but no significant occasion by depression interaction (F=2.45; df 1,26; 
p=0.l3). Mean CORT AAUC ± SEM scores for depressed subjects and controls were 5.7 
± 4.5 and 15.7 ± 4.0 mcgxHr/lOOml respectively. The univariate ANOVA of CORT 
AAUC values showed no effect of illness (F=2.45; df 26,1; p=0.13). Figures 7.3 and 7.4
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show these effects, suggesting a trend to blunting of the CORT response in the depressed 
group in comparison to healthy controls.
Gender was not a significant covariate in the ANOVAs of either PRL AUC (p=0.38) or 
CORT AUC (p=0.27) data. No correlations were observed between PRL AAUC and Beck 
(i=-Q.58; p=0.85) or Hamilton (r=0.048, p=0.88) depression rating scores or CORT 
AAUC and Beck (r=-0.16; p=0.60) or Hamilton scores (r=0.22; p=0.48) in the patient 
group. In individual subjects, PRL AAUC did not correlate with CORT AAUC (r=0.054; 
p=0.86, for the depressed group).
Although accurate comparative analysis of data between melancholic and non 
melancholic subjects is not possible, due to there only being two melancholic subjects, 
their individual PRL AAUC scores were 58.0 and 14.8 mlU hr/1, and their CORT AAUC 
scores were 6.4 and -10.7 mcgxHr/lOOml respectively. These do not appear to be 
markedly different from the spread of data from non melancholic subject? although 
obviously a larger number of melancholic subjects would be needed to test this 
hypothesis.
No depressed subjects described recent weight change, although excluding this as a 
confounding factor is not fully possible as these were subjective reports. The influence of 
duration of illness, and previous treatment could not be examined as it was not 
systematically recorded.
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As before, citalopram was well tolerated with no adverse effects reported by subjects. 
Ideally this should have been recorded systematically with VAS to more clearly exclude 
any bias due to subjective effects.
DISCUSSION
These findings indicate that the PRL response to citalopram is blunted in patients with 
Major Depressive disorder. The CORT response to citalopram in this group shows a trend 
to blunting. This is consistent with the reliable body of data that shows such PRL 
secretion reduction in depression with similar presynaptic acting ligands (Cowen 1998), 
specifically clomipramine (Anderson et al. 1992b; Golden et al. 1992). Another group has 
recently examined the influence of neuroendocrine responses to citalopram 20mg IV in 
depression, with very similar findings for PRL and CORT (Kapitany et al. 1999). Similar 
rates of side effects were observed in the Kapitany et al. study as with the Seiffitz et al. 
(1996) study with 20mg citalopram in healthy subjects. The lack of significant reduction 
in CORT, despite an observed trend in both studies, may indicate a need to test a larger 
number of subjects to clarify this finding.
Citalopram levels were not examined in this study but this would have been ideal to 
examine any difference in pharmacokinetic properties between these two subject groups. 
Sucli a difference would be unlikely but cannot be excluded.
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It is notable that baseline PRL and CORT did not vary between patient and control 
groups, which may otherwise have influenced the subsequent endocrine response to 
citalopram. Absolute CORT values have been shown to differ in some groups of 
depressed patients in comparison to healthy subjects (Dinan 1994), but this is not 
replicated in this sample and is discussed further in chapter 8.
As discussed in the previous chapter, the receptor mediated mechanism of the PRL 
response to citalopram has not been defined. These findings are likely however to 
represent disturbed presynaptic serotonergic functioning in depressed subjects. Brain 
imaging studies in patients with depressive disorders have identified decreased 
availability of 5-HT reuptake sites in midbrain and brain stem (Malison et al. 1998; 
Willeit et al. 2000) which are consistent with these neuroendocrine findings.
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Figure 7.1 Mean ± SEM PRL concentration change in 13 depressed patients (closed 
symbols) and matched controls (open symbols) tested on two occasions with citalopram 
lOmg IV (circles) and placebo (squares).
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Figure 7.2 Individual AAUC PRL responses of acutely depressed subjects (n= 13) and 
matched healthy controls. AAUC PRL was calculated by subtraction of the individual 
placebo challenge AUC PRL values from their respective citalopram lOmg AUC PRL 
response values.
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Figure 7.3 Mean ± SEM CORT concentration change in 13 depressed patients (closed 
symbols) and matched controls (open symbols) tested on two occasions with citalopram 
lOmg (circles) and placebo (squares).
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Figure 7.4 Individual AAUC CORT responses of acutely depressed subjects (n= 13) and 
matched healthy controls. AAUC CORT was calculated by subtraction of the individual 
placebo challenge AUC CORT values from their respective citalopram lOmg AUC 
CORT response values.
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PART 3 
CONCLUSIONS
CHAPTER 8 
CONCLUSIONS
5-HT FUNCTION IN DEPRESSION
The aetiology of depressive disorders remains unclear. The heterogeneity of clinical 
symptoms, apparent causative factors, levels of vulnerability and response to existing 
treatments is not fully explained by current knowledge of this disorder. The level of 
mortality and morbidity for the individual and society (Scott and Dickey 2003) drives 
active investigation into the biological substrates of depressive disorders and the 
development of more effective treatments.
Chapter 1 reviewed the complexity of depressive disorders and 5-HT function in the 
human brain. At this stage, we are still identifying the role of 5-HT in the normal brain, 
so it could be argued that examining 5-HT function in the disordered brain is premature. 
Overall the evidence suggests that changes in brain 5-HT function are associated both 
with the state of depression and its pharmacological treatment. The evidence for this view 
comes from numerous lines of enquiry, such as CSF studies, postmortem studies, TRP 
depletion, neuroendocrine tests, neuroimaging and the effective antidepressant action of 
5-HT promoting agents. The exact nature of the link with low brain 5-HT function and 
depression remains unclear however. Equally, how pharmacological potentiation of a 
single neurotransmitter leads to clinical antidepressant effect is unknown, although the 
complex interplay between monoamines and their resultant effect on intracellular events 
is starting to be elucidated.
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NEUROENDOCRINE STUDIES
Neuroendocrine studies primarily give the investigator information about hypothalamic 
and pituitary function, in which 5-HT systems play an important regulatory role. The 
development of these studies has been valuable in the further investigation of functional 
changes in depressive disorders, and investigating the effects of antidepressant treatments 
at the receptor level. While PET imaging provides information about receptor density it 
has not provided information about receptor function. The use of pharmacological 
functional MRI offers possibilities in this direction (Anderson et al. 2002) but at present 
neuroendocrine studies are the simplest and most accessible means of measuring brain 
neurotransmitter function in humans.
Neuroendocrine studies however have a number of methodological difficulties (see 
Chapter 2). For example, they rely on knowing the mechanism of action of the drug probe 
used, and controlling for parameters that may influence hormone secretion such as age, 
gender, weight, hormonal status and previous psychotropic drug treatment.
To date this field of investigation has been marred by the poor availability of selective 
receptor ligands, which are required to clearly define whether a specific receptor type 
mediates the changes in hormone secretion observed. The large number of partially 
selective ligands (such as ketanserin for the 5 - H T id  receptor or pindolol for the 5 - H T ia  
receptor) has helped to give a possible idea of which receptors are involved (eg. the
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5-HTia receptor possibly mediates the PRL response to L-TRP). Replication of some of 
the neuroendocrine findings using different probes with the same pharmacodynamic 
properties has also strengthened the evidence.
The main limitation of neuroendocrine studies is extrapolating changes in serotonergic 
activity influencing hormone secretion at the level of the pituitary to serotonergic activity 
in other parts of the brain. The results of neuroendocrine studies are therefore valuably 
combined with findings from other experimental paradigms such as functional imaging to 
give a wider view of what biological changes occur in depressive disorders.
This thesis set out to investigate two new potential neuroendocrine probes, zolmitriptan 
and low dose citalopram, which had hypothesised advantages over existing probes. In all 
of these studies, common confounding factors of neuroendocrine challenges of weight 
loss (despite including melancholic subjects), physical illness, recent psychoactive drug 
exposure, stage of menstrual cycle and external environmental stress were adequately 
excluded or controlled for.
THE ZOLMITRIPTAN CHALLENGE
Zolmitriptan, licensed for the treatment of migraine, markedly increased plasma GH in 
healthy subjects but had no effect on plasma PRL or body temperature. The GH response 
was blocked by ketanserin, in an adequately powered study, suggesting that it may be
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mediated by 5 - H T i D receptors (Pauwels et al. 1996). In patients with major depressive 
disorder with melancholia, this GH response to zolmitriptan is impaired. In patients 
treated with SSRIs, the GH response to zolmitriptan was markedly attenuated. Healthy 
subjects rechallenged with zolmitriptan (without SSRI administration) showed no such 
desensitisation. These findings suggest an impaired 5 - H T i D receptor function in 
melancholic subjects with antidepressant treatment causing a further adaptive 
desensitisation of the 5 - H T i d  receptor function. The hypothesis concerning 5 - H T ib  
autoreceptor dysfunction in depression could not be tested with this probe. It is not clear 
whether the blunted GH response to zolmitriptan is a depressive state dependent 
phenomenon or whether it may represent a vulnerability factor to depression (as discussed 
below). It would be useful to investigate this by challenging a group of recovered 
depressed subjects with zolmitriptan.
Zolmitriptan therefore appears to be a reliable, well tolerated neuroendocrine probe, 
possibly of postsynaptic 5 - H T id  receptor function. This mode of action will need to be 
clarified with the introduction of more selective ligands. It appears to enhance GH 
secretion more reliably than the existing 5 - H T ib / i d  receptor probe sumatriptan.
Concerning the criteria for a valid probe (Yatham and Steiner 1993), zolmitriptan has a 
large, robust and consistent hormone response, which appears to be due to a direct effect 
of the drug on the 5-HT system with the influence of other factors excluded, and is free 
from stressful side effects. A dose dependent relationship between the drug and the 
hormone response was not demonstrated in this study but is suggested when these GH 
results with 5mg are compared with the magnitude of GH responses from the more recent
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study by Moeller et al. (2000) who used 2.5mg (although a within subjects study would 
be necessary to prove this).
The specific functional relevance of 5-HTm receptors and their role in depressive 
disorders is as yet unknown. They appear in small numbers in the human basal ganglia, 
and could therefore have a role in movement and cognitive disturbances in depression. 
Despite low numbers, such receptors could have a dramatic regulatory influence over 
brain function. Disturbance of 5 - H T id  receptor function could equally be incidental to 
the aetiology of depressive disorders. Several studies have examined the role of 5 - H T ib /d  
receptors in obsessive compulsive disorder, with reports of sumatriptan, but not 
zokmtriptan, significantly enhancing the GH response in these subjects in comparison to 
controls (Boshuisen and den Boer 2 0 0 0 ) .  Acute challenge with sumatriptan has been 
shown to both enhance and diminish obsessive symptoms (Stein et al. 1 9 9 9 )  and longer 
treatment with sumatriptan does not appear to improve obsessive symptoms (Koran et al. 
2 0 0 1 ) .  Preliminary studies have also linked obsessive compulsive disorder with genetic 
variation of the 5 - H T i b  receptor gene (Camarena et al. 2 0 0 4 ) ,  which may explain the 
difference between the GH response to sumatriptan and zolmitriptan in this group, due to 
zolnitriptan having a greater affinity for 5 - H T id  than 5 - H T ib  receptors. There are no 
specific 5 - H T id  receptor ligands available in humans however, to clearly test potential 
therapeutic effects with either obsessive or depressive symptoms.
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THE CITALOPRAM CHALLENGE
Data from this thesis indicates that low dose intravenous administration of citalopram 
(lOnng) has potential value as a 5-HT neuroendocrine probe, with associated increased 
PRL and CORT secretion. As with zolmitriptan, the utility of the citalopram 
neuroendocrine test will be increased if the 5-HT receptor mechanisms underlying its 
effects are more clearly established. It could not be clearly concluded whether 5-HTiAor 
5 -HT2 receptors are involved in mediating these hormonal changes from these studies. 
Using the criteria for a valid neuroendocrine probe (Yatham and Steiner 1993), 
citalopram lOmg IV has a reasonably large, robust and consistent hormone response 
(confirmed recently by Lotrich et al. 2004), which appears to be due to a direct effect of 
the drug on the 5-HT system with the influence of other factors excluded, and few 
subjects report stressful side effects. A dose dependent relationship between the drug and 
the hormone response is demonstrated. Findings from these studies confirm that acute 
major depression is associated with blunted 5-HT mediated PRL release, most likely 
representing impaired presynaptic functioning. It was not possible to clearly examine the 
influence of melancholia on the responses to citalopram challenge in this study, but one 
could hypothesise that the neuroendocrine response may be more robust, as observed with 
fenfluramine (Newman et al. 1998).
Hennig and Netter (2002) recently showed that an acute challenge of citalopram 20mg 
orally increased CORT but not PRL in a sample of 48 male subjects and was apparently 
well tolerated (replicated by Nadeem et al. 2004). It is unclear why IV citalopram
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increases PRL and oral citalopram does not, but similarly, IV clomipramine increases 
PRL and oral clomipramine does not (Laakman et al. 1984). The PRL response may 
require higher plasma levels of citalopram or clomipramine than are produced by oral 
administration. Oral SSRIs can, however, elevate PRL after long term treatment (Cowen 
and Sargent 1997).
The recently developed active S- isomer of citalopram (Owens et al. 2001) may be even 
more effective at enhancing the reliability of such hormonal responses. However, 
Nadeem et al. (2004) examined the salivary CORT response to this isomer and the 
racemic mixture of isomers, finding no significant difference in change of salivary CORT 
between the two.
To examine whether 5-HT disturbance may be a vulnerability factor to depressive 
disorders, an extension to the citalopram study in Chapter 7 was undertaken (Bhagwager 
et al. 2002). A group of recovered depressed patients were recruited who had been 
euthymic for at least 6 months and had been off medication for at least 3 months. They 
underwent citalopram challenge as in Chapter 7. The control group was not individually 
matched to these patients however, as undertaken in the preceding studies, but mean age, 
weight and sex ratio was similar between groups. The PRL response to citalopram was 
also blunted in these subjects in comparison to controls, but not significantly different to 
the acute depressed group described above. Weight loss may complicate interpretation of 
these findings (as described above, Cowen 1998), but such changes were also not 
apparent in this recovered sample. Along with the finding that subjects who have had a
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previous episode of depression are at a high risk of future episodes (Kendler et al. 1993), 
these results suggest that a blunted PRL response to citalopram in comparison to healthy 
controls may be a trait marker indicating vulnerability to major depression, as discussed 
further below.
The studies in this thesis therefore support a dysfunction of 5-HT in depressive disorders, 
and offer the investigator two further tools for neuroendocrine investigations. At a time 
when neuroimaging is being developed to measure the activity of 5-HT systems, these 
probes are also a useful addition for associated activation of presynaptic 5-HT function 
(citalopram) and postsynaptic 5-HTm receptors (zolmitriptan).
INVESTIGATIONS OF 5-HT FUNCTION IN DEPRESSION
To bring together the findings of the preceding chapters concerning 5-HT function and 
depression in humans, firstly it is clear from TRP depletion studies that a significant 
proportion of subjects are vulnerable to depressive symptom relapse in response to a 
lowering of brain 5-HT synthesis (Smith et al. 1997a). This is particularly, but perhaps 
not surprisingly, evident in subjects who are treated with SSRIs. Importantly, in healthy 
subjects without this vulnerability, diminishing brain activity through TRP depletion is 
insufficient to cause depression. Post mortem studies in depressed subjects on the whole 
have provided inconsistent results although the increase of globus pallidus 5 - H T ib / id  
receptors may be an important finding. Platelet 5-HT studies have similarly shown
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inconsistent results but again the possible increase in 5-HT2A receptor density maybe 
important. The clearest neuroimaging findings in depressive disorder are a replicated 
reduction in 5 - H T i a  and 5-HT2A binding (the latter being inconsistent with the platelet 
results). Preliminary imaging studies also indicate a reduction in 5-HTT binding, 
consistent with downregulation following reduced stimulation due to reduced synaptic 
5-HT. Neuroendocrine studies have provided a greater body of replicated findings which 
may represent a more realistic measure of overall 5-HT function and 5-HT receptor 
function (as opposed to receptor density). In depression, these studies have shown a likely 
reduction in presynaptic 5 - H T ia  and postsynaptic 5-HTia function. The zolmitriptan 
studies in this thesis add to the existing data to indicate a reduction in postsynaptic 
5 - H T id  function in melancholic subjects. These studies do not appear to give information 
on presynaptic 5 - H T j b / id  function. The studies of postsynaptic 5 -HT2 receptors are 
difficult to interpret but possibly indicate an increased function (consistent with platelet 
findings). If L-TRP, fenfluramine and clomipramine are probes of overall presynaptic 
function (or possibly net 5-HT function) then this is diminished in depression, which is 
further confirmed by the results from this thesis with citalopram. It is unclear whether 
these findings are a primary dysfunction, causing depressive symptoms or a result of 
another primary abnormality. Reduced presynaptic function and downregulated 
postsynaptic receptors however, are consistent with reduced overall 5-HT 
neurotransmission and the associated emergence of depressive symptoms. Reduced 
presynaptic 5 - H T ia  autoreceptor function is an understandable adaptation to reduced 
overall presynaptic 5-HT output, and appears inconsistent with theories of autoreceptor 
hypersensitivity in depression. 5-HT receptor dysfunction and overall reduced 5-HT
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neurotransmission appears particularly likely in subjects with major depression with 
melancholic features.
Several investigators have examined whether these 5-HT system abnormalities found in 
depressive disorders change following illness resolution. Such a differentiation of trait 
from state markers could indicate persistent biological vulnerability factors to depressive 
disorder which may have been present before illness onset, but equally may represent a 
biological scar following a depressive episode that makes the subject more vulnerable to 
further episodes, as observed clinically. The PRL response to L-TRP resolves (Upadhyaya 
et al. 1991; Smith et al. 2000), but the PRL responses to fenfluramine (Coccaro et al 
1987; Shapira et al.1993; Flory et al 1998), clomipramine (Golden et al. 2002) and 
citalopram (Bhagwager et al. 2002, as above) remain blunted in recovered depressed 
subjects. The difference between L-TRP and the other probes is that the L-TRP response 
is blocked by pindolol and therefore possibly mediated by postsynaptic 5-HTiA receptors. 
5-HTia receptor function therefore appears impaired in depression and resolves following 
treatment. If fenfluramine, clomipramine and citalopram measure presynaptic 5-HT 
function, then presynaptic dysfunction appears to be a trait abnormality in depression. On 
its own, this dysfunction is not enough to cause depression. This finding is consistent 
with TRP depletion causing a reduction of presynaptic 5-HT and subsequent recurrence 
of depressive features. An attractive hypothesis is that hypercortisolaemia following 
stressful events reduces brain TRP availability, through induction of peripheral TRP 
pyrrolase (causing increased metabolism of peripheral TRP) and therefore precipitates a 
depressive episode in vulnerable subjects (Cowen 2002). Such a vulnerability in 5-HT
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function could be caused by genetic abnormalities, early environmental influence or as a 
consiequence of a previous episode of major depression.
INVESTIGATIONS OF THE EFFECT OF SSRIS
The clearest findings of the effects of SSRIs on the 5-HT system are reduced 
neuroendocrine function mediated via postsynaptic 5-HTia, 5-HTiD (shown in this thesis) 
and 5-HT2C receptors. 5-HTia receptors in one imaging study also remained reduced 
following treatment but were not reduced further than untreated subjects (Sargent et al. 
2000). Both postmortem and imaging studies have also indicated a reduction in 
postsynaptic 5 -HT2A receptor numbers with treatment. As discussed, this is consistent 
with an adaptive downregulation of postsynaptic receptors following enhanced 
presynaptic 5-HT output and appears at first sight to contradict the idea of an overall 
increase in 5-HT neurotransmission; however, if the increase in presynaptic 5-HT is 
sufficiently large, net 5-HT neurotransmission may still be enhanced. It is unclear 
whether this postsynaptic downregulation is necessary for antidepressant action. 
Presynaptic 5-HTia receptor function appears reduced following SSRI treatment (using 
temperature response as an index of function) which is consistent with theories of 
antidepressants having their action via autoreceptor desensitisation, as observed in rats, 
thereby enhancing levels of synaptic 5-HT. The function of presynaptic 5-HTm receptors 
(probed with sumatriptan) appeared unchanged following SSRI treatment in healthy 
subjects, again consistent with rat studies. The enhanced neuroendocrine response to 
L-TRP following SSRI treatment may indicate overall increased presynaptic 5-HT
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function which would be expected following these treatments. SSRIs alone can increase 
basal PRL secretion which is also consistent with overall increased 5-HT function. These 
changes associated with SSRI treatment assist in understanding the process by which they 
have therapeutic effect and may give investigators clues as how to develop more effective 
or better tolerated antidepressants.
FURTHER INVESTIGATIONS INTO DEPRESSIVE DISORDERS
The development and growth of brain imaging techniques has offered much hope for the 
future investigation of depressive disorders. For example, the reduced presynaptic 
function of 5-HT neurones in depression implied from the citalopram challenge could be 
further investigated by examining presynaptic 5-HT release with PET, as has been 
examined with DA release in schizophrenia (Laruelle 2000, Abi-Dargham et al. 2000). To 
date, however, such PET studies have not been successful, possibly relating to the nature 
of the 5-HT system rather than the ligands used (Rabiner et al. 2002). The ligand [n C] 
DASB has recently been developed for in vivo imaging of the 5-HTT and studies in 
depressed subjects are awaited (Ginovart et al. 2003). If such paradigms are worked out, 
it would be valuable to correlate PET findings with neuroendocrine findings within 
studies and examine whether these have any prognostic value (as with the DA studies, eg. 
Abi-Dargham et al. 2000).
It is clear that receptor function changes are just one of many events that occur in 
depressive disorders. Several authors have now examined the phenomenon of brain
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atrophy in affective disorders. Sheline et al. (1996) found smaller hippocampal volumes 
in recurrent depressed subjects compared to controls using MRI. Shah et al. (1998) found 
reduced left sided grey matter density (including hippocampus) in chronic depressed 
subjects using MRI, and Drevets et al. (1997) demonstrated decreased function of 
prefrontal cortical areas in familiar unipolar depressed subjects using PET. Mathew et al. 
(2003) recently demonstrated that macaques exposed to early adverse rearing 10 years 
previously demonstrated changes in magnetic resonance spectroscopic images of anterior 
cingulate brain regions in comparison to controls, indicating reduced neuronal integrity 
and metabolism.
One theory to explain such findings in depressive disorders is of raised CORT (as 
discussed in Chapter 1) having a toxic effect on susceptible neurone groups, such as the 
hippocampus, as demonstrated in controlled animal experiments (Hellsten et al. 2002). 
Studies have demonstrated this hypercortisolaemia in depressive disorders (Dinan 1994) 
but it is not a consistent finding in all subjects. The depressed subjects examined in this 
thesis (in Chapters 5 and 7) did not have baseline plasma CORT levels that differed from 
healthy controls, despite abnormalities in 5-HT function as demonstrated by zolmitriptan 
and citalopram challenges. This absence of a difference in plasma CORT persisted even 
when comparing melancholic subjects and controls. Strickland et al. (2002) examined 
salivary CORT in a large community sample of ICD-10 depressed subjects, which again 
did not differ from healthy controls, even in the sub sample of severely depressed 
subjects. Hypercortisolaemia therefore cannot be considered a ubiquitous phenomenon in 
depressive disorders and therefore is not likely to be a common route to the development
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of depression and associated findings such as focal brain atrophy. The theory that severe 
or melancholic depression is associated with hypercortisolaemia is also inconsistent with 
the above findings. Recent severe life events have been associated with 
hypercortisolaemia however (Strickland 2002), which appears to be the confounding 
factor in the association with depressive disorders.
Several studies have now shown the effect of antidepressant treatments on neuronal 
integrity and plasticity in animal models. Both electroconvulsive shock (ECS) treated rats 
(Scott 2000) and chronic lithium treated mice (Chen 2000) showed enhanced 
hippocampal cell generation in comparison to controls. Hellsten (2002) eloquently 
demonstrated how the neurotoxic effects of corticosterone can be reversed with ECS. In 
corticosterone treated rats, neurogenesis was decreased by 75%, which was counteracted 
by a single ECS. Multiple ECS further enhanced neurogenesis, with no d’fference from 
non corticosterone treated rats after 5 ECS. Czeh (2001) also demonstrated the effects of 
tianeptine, a modified TCA, in tree shrews subjected to chronic psychosocial stress. The 
untreated animals showed reduced hippocampal neuronal proliferation and cell loss 
which was prevented in the tianeptine treated group.
A further hypothesised mechanism for the enhancement of cellular growth following 
antidepressants involves nerve growth factors. BDNF is one of these nerve growth factors 
which collectively play a critical role in the development of neuronal systems and the 
survival and function of neurones throughout life (Thoenen 1995). BDNF is expressed in 
high levels in hippocampus and cortex of mature brain. The action of BDNF is mediated
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by binding to TrkB receptors which triggers a cascade of intracellular events which 
subsequently have a diverse effect on cellular function (Duman 1998). Chronic 
administration of antidepressants, including SSRIs, upregulates the cAMP pathway at 
several levels, including increased expression of the cAMP response element binding 
protein (CREB). CREB can subsequently increase the gene expression of BDNF (Nibuya 
et al. 1995). The time of chronic antidepressant administration in these studies is 
consistent with the time for therapeutic effect of antidepressants (Duman 1998). Other 
psychotropics do not appear to upregulate BDNF (Nibuya et al. 1995). Acute 
manipulation of 5-HT levels appears to have a paradoxical effect on BDNF expression in 
comparison to chronic manipulation. Acute elevation of rat brain 5-HT using p- 
chloroamphetamine (PCA) or paroxetine caused reduced hippocampal BDNF mRNA 
expression, whereas acute depletion using multiple injections of PCA caused increased 
hippocampal BDNF mRNA expression (Zetterstrom et al. 1999). Other research 
paradigms have supported the involvement of BDNF in the mode of action of 
antidepressants, including animal behavioural models: infused BDNF has antidepressant 
effects in the forced swim test and learned helplessness models (Siuciak U al. 1996). 
Stress also reduces expression of BDNF (Smith et al. 1995), which could influence cell 
death in vulnerable brain areas and could theoretically be reversed by antidepressant 
treatment.
This neurogenesis model for the action of antidepressants suggests new targets for 
potential antidepressant agents at many different levels including increasing expression of 
theBDNF-TrkB system and increasing cAMP pathway function. Several 5-HT receptors
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are coupled directly to the cAMP system (see Chapter 1) but only 5 -HT4 and 5 -HT7 are 
significantly expressed in hippocampus and limbic areas. Both 5 -HT4 (Bijak et al. 1997) 
and 5 -HT7 (Sleight et al. 1995) have altered function following chronic antidepressant 
treatment in animal models. Selective ligands for these receptors may have valuable 
antidepressant properties. Stimulating 5-HTiA receptors causes inhibition of cAMP 
pathways, which may explain the antidepressant benefits of pindolol, a 5-HTia receptor 
antagonist (Whale et al. in preparation). 5-HT2A receptors have influence on the 
phostphatidylinositol system and are present on GABA neurones in the hippocampus. 
Duman’s group have demonstrated that 5-HT2A receptors regulate BDNF expression in 
this area (Duman 1998), increasing interest in 5-HT2A ligands.
Combining these investigations and theoretical models of antidepressant activity will 
hopefully lead to the development of tolerable, more effective antidepressant agents and 
help lift the psychosocial burden that depressive disorders currently impose.
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Appendix
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) guidelines for 
diagnosis of Major Depressive Disorder
Criteria for Major Depressive Episode
A. Five (or more) of the following symptoms have been present during the same 2 week 
period and represent a change from previous functioning; at least one of the 
symptoms is either (1) depressed mood or (2) loss of interest or pleasure.
Note: Do not include symptoms that are clearly due to a general medical 
condition, or mood incongruent delusions or hallucinations.
(1) depressed mood most of the day, nearly every day, as indicated by either 
subjective report (eg. feels sad or empty) or observation made by others (e.g. 
appears tearful). Note: In children and adolescents, can be irritable mood.
(2) markedly diminished interest or pleasure in all, or almost all activities most of 
the day, nearly every day (as indicated by either subjective account or 
observation made by others)
(3) significant weight loss when not dieting or weight gain (eg. a change of more 
than 5% of body weight in a month), or decrease or increase in appetite nearly 
every day. Note: In children, consider failure to make expected weight gains.
(4) insomnia or hypersomnia nearly every day
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(5) psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down)
(6) fatigue or loss of energy nearly every day
(7) feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self reproach or guilt about being sick)
(8) diminished ability to think or concentrate, or indecisiveness, nezrly every day 
(either by subjective account or as observed by others)
(9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide
B. The symptoms do not meet criteria for a Mixed Episode
C. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning.
D. The symptoms are not due to the direct physiological effects of a substance (eg. a 
drug of abuse, a medication) or a general medical condition (eg. nypothyroidism).
E. The symptoms are not better accounted for by Bereavement, ie. after the loss of a 
loved one, the symptoms persist for longer than 2 months or are characterized by 
marked functional impairment, morbid preoccupation with worthlessness, suicidal 
ideation, psychotic symptoms, or psychomotor retardation.
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Criteria for Melancholic Features
A. Either of the following, occurring during the most severe period of the current 
episode:
1) loss of pleasure in all, or almost all, activities
(2) lack of reactivity to usually pleasurable stimuli (does not feel much 
better, even temporarily, when something good happens)
B. Three (or more) of the following:
1) distinct quality of depressed mood (ie. the depressed mood is experienced as 
distinctly different from the kind of feeling experienced after the death of a 
loved one)
(2) depression regularly worse in the morning
(3) early morning wakening (at least 2 hours before usual time of awakening)
(4) marked psychomotor retardation or agitation
(5) significant anorexia or weight loss
(6) excessive or inappropriate guilt
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Abbreviations
ACTH adrenocorticotrophic hormone
cAMP cyclic adenosine monophosphate
AMPT a-methyl-p-tyrosine
ANOVA analysis of variance
AUC area the under the curve method
BDI Beck depression inventory
BDNF brain derived neurotrophic factor
Ca2+ calcium ion
CBT cognitive behavioural therapy
CNS central nervous system
COMT catechol O-methyltransferase
CORT cortisol
CRH corticotrophin releasing hormone
CSF cerebrospinal fluid
DA dopamine
DSM-IV Diagnostic and Statistical Manual of Mental Disorders Edition 4
DST dexamethasone suppression test
ECS electroconvulsive shock
ECT electroconvulsive therapy
EEG electoencephalogram
GABA gamma aminobutyric acid
GH growth hormone
GHRH growth hormone releasing hormone
GnRH gonadotrophin releasing hormone
HAM-D Hamilton depression rating scale
HPA axis hypothalamic pituitary adrenal axis
HPLC high performance liquid chromatography
HVA homovanillic acid
IPT interpersonal therapy
IV intravenous
K+ potassium ion
L-Dopa L-Dihydroxyphenylalanine
LSD lysergic acid diethylamide
MAO monoamine oxidase
MAOI monoamine oxidase inhibitor
mCPP m-chlorophenyl piperazine
MHPG 3-methoxy-4-hydroxyphenylglycol
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
NA noradrenaline
NNT number needed to treat
PCA p-chloroamphetamine
PCR polymerase chain reaction
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PET positron emission tomography
PRL prolactin
RCT randomised controlled trials
REM rapid eye movement (sleep)
RIA radioimmunoassay
rTMS repetitive transcranial magnetic stimulation
SAD Seasonal affective disorder
SCID Structured Clinical Interview for DSM-IV
SEM standard error of the mean
SNRI selective noradrenaline reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
SPECT Single photon emission computerised tomography
TCA tricyclic antidepressant
TRH thyrotrophin releasing hormone
TRP tryptophan
TSH thyroid stimulating hormone
VAS visual analogue scale
WAY-100635 [N-(2-(4-(2-methoxyphenyl)-1 -piperazinyl)ethyl)-N- 
(2 -pyridyl)cyclohexanecarboxamide]
5-HIAA 5-hydroxyindoleacetic acid
5-HT 5 -hydroxytryptamine
5-HTT serotonin transporter protein
8-OH-DPAT 8-Hydroxy-2-(di-n-propylamino) tetralin
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